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Focal deposition o f lipids in the form of lipoproteins is an important step in the 
pathogenesis of the early, fatty streak and the later advanced atherosclerotic 
plaque. In this thesis, two mechanisms potentially leading to lipid accumulation 
are examined, namely the interaction of arterial wall proteoglycans with 
lipoproteins and LDL oxidative modification.
In study 1, chondi'oitin sulphate proteoglycan (CS-PG) was dissociatively 
extracted and purified fi-om human aorta in guanidine-HCl. This was incubated 
with LDL and the extent of complex formation was determined by measuring 
turbidity at 600nm. The interaction of total LDL (d L019-1.063g/ml) was 
examined in 59 angiographically positive coronary heart disease patients. The 
extent o f APG-LDL complex formation was positively correlated with the 
percentage o f small, dense LDL-III within total LDL and with plasma 
triglyceride level, while it was inversely related to the percentage of the large 
buoyant LDL-I within total LDL and plasma HDL cholesterol. In the second 
study the reactivity of apoB containing lipoproteins towards APG was examined 
in three groups of subjects whose LDL subJfraction profile consisted of mainly 
LDL-I, LDL-II or LDL-III. Two firactions fi'om each lipoprotein class were 
isolated by cumulative density gradient centrifugation (VLDLl Sf 60-400, 
VLDL2 Sf 20-60, IDLl Sf 16-20, IDL2 Sf 12-16, LDLA Sf 8-12 and LDLB Sf 
0-8. A similar' pattern o f reactivity was found in aU subjects in which IDL2 and 
LDLA were the most reactive species towards APG followed by LDLB and 
IDLl and the least reactivity was found in the VLDL fractions. The magnitude 
of the reactivity of the lipoproteins was highest in the CHD group of patients 
with a predominance of small, dense LDL, intermediate in the group who had 
an LDL-II dominated subfi-action profile and lowest in the group with the 
mainly high level o f LDL-I. Lipid lowering treatment with ciprofibrate 
(lOOmg/day for 8  weeks) decreased the reactivity of aU apoB containing 
lipoproteins towards APG, this was attributed to the triglyceride lowering effect 
of the drug.
Neutral carbohydrate and sialic acid concentration were determined in all the 
apoB containing lipoproteins in study 4. A higher concentration o f neutral
Ill
carbohydrate, as measured by the phenol sulphuric acid method, was found in 
LDL-I compared with the small, dense LDL-III sublfaction. Sialic acid 
concentration was highest in VLDLl and lowest in LDLB in all subjects. 
Neither the neutral carbohydrate nor sialic acid correlated significantly with the 
extent of APG-Lipoprotein complex formation. This was confirmed by 
subfiractionation of LDL into 3 subfiractions by affinity chromatography on Con- 
A on the basis of the high mannose structure of apoB. An unbound, a weakly 
bound and a strongly bound fraction were obtained. Each had similar' binding 
reactivity towards APG. Finally a series of LDL modifications were performed 
to explore the mechanism of APG-LDL interaction. Neuraminidase treatment 
of LDL increased its reactivity towards APG by 76% and addition o f GM3 
ganglioside fi'om plasma decreased it by 12%. Charge modification by 
cyclohexandione treatment and carbamylation blocked the interaction as did 
reductive méthylation which alters the apoB protein structure. LDL incubation 
with apoE2 and apoE3 also blocked its binding with APG while apoCIII 
addition had no effect. These findings suggested that although APG-LDL 
interaction is charge related, conformation o f apoB is critical in controlling the 
interaction process.
The second major study was determination of the effect o f Evening Primrose 
Oil (EPO) on plasma lipid levels and LDL sublfaction profile and LDL 
susceptibility to oxidative modification in a group of non-insulin dependant 
diabetics (NIDDM). At a dose o f 500mg/day no significant effect was found on 
lipid parameters. However the extent of in-vitro copper catalysed LDL 
oxidation measured by fluorescence at 430 was significantly increased after 
EPO treatment and was positively related to the percentage o f small deiKe LDL 
within total LDL and plasma triglyceride concentration.
In conclusion the main findings from the studies provide evidence that the 
heterogeneity of apoB containing lipoproteins as seen in an atherogenic 
lipoprotein phenotype (ALP) is an important determinant o f the atherogenic 
properties o f the lipoprotein. The potential atherogenicity o f small dense LDL 
is linked to its enhanced oxidative modification and its preferential association 
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1.1 Impact of CHD on population
Atherosclerosis is the underlying cause of most cardiovascular disease and 
cerebrovascular disorders in western populations. Coronary heart disease 
(CHD) is the largest single cause of death in the UK accounting for 
approximately 26% of all deaths in England in 1991 (OPCS 1990, HMSO 
1992) with even a higher rate in Scotland, Wales and Northern Ireland. It 
accounts for 2.5% of the total National Health Service expenditure. In the 
United States over half a million people die every year from this cause. Many 
contributory or risk factors associated with higher rates of CHD have been 
identified. Until the middle of the 20‘'* century age was considered to be the 
major determinant of atherosclerosis. However, the absence of the disease at 
autopsy in many individuals of all age groups is clear evidence that 
atherosclerosis should be regarded as a disease and not an inevitable 
consequence of ageing, even though the risk of CHD mortality increases with 
age. The macroscopic changes of atherosclerosis was first recognised by 
Leonardo da Vinci (1452-1519) (Keelê 1952) and it was Marchand who
coined the term “atherosclerosis” (Aschoff 1924). Several theories were 
proposed to explain the pathogenesis of atherosclerosis, The response to injury 
by Virchow (1856) and “the thrombogenic” theory by Rokitansky (1804-1878), 
both of which recognised lipid accumulation to be involved in the process of 
atherosclerosis development.
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The abundance o f cholesterol in human atherosclerotic lesions was well known 
after the turn of the century (Windaus 1910). Anitschkow propounded the 
“lipid hypothesis” theory and presented the first evidence associating dietary 
cholesterol with the development of atherosclerosis (Anitsckow & Chalatow 
1913). Following a series o f key studies indicated the importance o f cholesterol 
as a predictor of risk (Steiner & Domanski 1943, Gertler et al 1950). Another 
striking observation was the occurrence o f coronary artery occlusions in males 
more than in females (Master et al 1939). Framingham study and other 
prospective studies established the three major risk factors as liigh serum 
cholesterol, hypertension and smoking (Dawber et al 1959, Dawber 1980). 
This was further confirmed by extensive data from the Pooling project (Pooling 
project research group 1978), which added diabetes mellitus, and the MRFIT 
study (Stamler et al 1986). The high incidence of CHD in affluent societies 
indicates that diet and life style, e.g. unhealthy eating, drinking, smoking and 
lack of exercise (McKeown 1979) are of critical importance in the causation of 
CHD. It was first pointed out by Keys that variation in the frequency of CHD 
between countries, could be attributed to differences in the dietary fat intake 
(Keys 1957, 1970). In support of this, a higher incidence of CHD was found 
among Japanese migrants in Cahfornia who adopted the US diet compared to 
Japanese in Japan on a traditional fish and rice diet (Keys et al 1957). It was 
also shown that the type o f fat ingested was important in determining serum 
cholesterol (Kinsill et al 1952). Diets rich in vegetable oil were shown to lower 
serum cholesterol level (Kinsill et al 1952). A number o f intervention trails 
have demonstrated that lowering blood cholesterol on a population basis leads 
to lowering of the incidence o f ischemic heart disease (LRCP 1984a, 1984b, 
Frick et al 1987).
The incidence of CHD varies and changes constantly in different countries all 
over the world. Eastern European countries together with Scotland and 
Northern Ireland lead the international league table of CHD mortality rates 
(Marmot 1988). Japan has the lowest rate due to low blood cholesterol level in 
their population. It is noteworthy that a low CHD rate exists in Japan despite 
high rates of hypertension and smoking.
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1.2 Risk factors for CHD
One of the goals in the management of CHD is the identification o f patients at 
risk. This requires assessment of the different factors associated with the 
disease process. The aetiology of CHD is multifactorial and risk factors can be 
classified as modifiable or non-modifiable (Table 1.1).
Table 1. 1









Lack o f physical activity
During the last 15-20 years CHD mortality rates have fallen in England by 20% 
(HMSO1992), in Scotland by 10% (Marmot 1988) and in the USA CHD rates 
have halved in the last 20 years due to improved risk factor status (Stamler and 
Stamler 1984). In Japan the dramatic fall in hypertension seams to be the major 
cause behind the large change in CHD rates (Ushima et al 1987). In addition, 
understanding how non-modifiable risk factors influence the occurrence o f the 
disease may suggest other preventive strategies. The greater occurrence of 
coronary artery occlusion in males than females below the age of 40 ( MaGiQ & 
Stern 1979) and the decrease in the sex difference with increasing age is 
suggestive of a relationship to hormonal changes. Evidence from uncontrolled 
trials indicates that oestrogen replacement therapy in postmenopausal women 
reduces the incidence o f CHD (Barrett- Connor & Bush 1991).
Since CHD has a multifactorial aetiology the individual impact o f risk factors 
must be gauged by multivariate analysis. Further, in the process of managing 
individuals, the effect o f coexisting risk factors should be taken in to account.
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For example, a hypertensive man who has a mild elevated cholesterol carries a 
greater risk than a male with a normal or low blood pressure with a high 
cholesterol concentration due to the multiplicative effect of risk factors.
The initial observations of the association between high serum cholesterol level 
and increase risk of CHD was made on the basis of total cholesterol. With the 
development of analytical centrifugation (Lindgren et al 1951, Gofman et al 
1950) and paper electrophoresis (Less & Hatch 1963), it was shown that the 
distribution of cholesterol among lipoproteins, which are complex molecules 
responsible for the transport of lipids around the body in plasma, also predicted 
risk. There follows a description of the structure, heterogeneity and metabolism 
of lipoproteins, particularly of apoBlOO containing lipoproteins. Finally, the 
role of a specific lipid and lipoprotein abnormalities in the pathogenesis of 
atherosclerosis is discussed.
1.3 Lipoprotein structure
Five main classes of lipoproteins, chylomicrons (CM), very low density 
lipoprotein (VLDL), intermediate density lipoprotein (IDL), low density 
lipoprotein (LDL) and high density lipoprotein (HDL), are defined based on 
their hydrated density (g/ml), electrophoretic mobility, particle size and 
flotation rate (Mills et al 1984). The last property is determined in the 
analytical centrifuge at a background density of 1.063 or 1.21 g/ml. Flotation 
rates are given in Svedberg units (Sf), one unit Sf = 10"*^  cm/s/dyne/g. The 
physicochemical properties of apoBlOO containing lipoproteins are illustrated 
in Table 1.2.
While all lipoproteins have the same basic pseudomicellar structure each class 
has a distinct composition, function and metabolic behaviour. They all contain 
a core of neutral lipid consisting cholesteryl esters (CE) and triglyceride (TG) 
and a surface shell of polar lipid (unesterified cholesterol and phospholipids) 
and protein (apolipoprotein). The latter are required for the synthesis and 
secretion of specific lipoproteins and interact with specific cell surface 
receptors that are responsible for the removal of the lipoprotein from plasma.
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Table 1.2
Physicochemical properties of apoBioo containing lipoproteins.
Properties VLDL IDL LDL
Density range 0.94-1.006 1.006-1.019 1.019-1.063
g/ml
Flotation rate Sf 60-400 12-20 0-12
Particle diameter nm 30-80 25-35 18-27
EP-mobility Pre p slow Pre p P
Main apolipoproteins Bioo, C, E Bioo, C, E B
Chemical composition 
%FC 7 9 8
%EC 12 29 42
%TG 55 23 6
%PL 18 19 22
VLDL, very low density lipoprotein; IDL intermediate density lipoprotein; 
LDL, low density lipoprotein; Ep mobility, electrophoretic mobility; %FC, 
%EC, %TG, %PL, percentages o f  free cholesterol, esterified cholesterol, 
triglyceride, and phospholipid within the lipoprotein respectively; C/P ratio;, 
cholesterol to protein ratio.
Among the four major categories (apoA, apoB, apoC, and apoE) of these 
apolipoproteins, apoBioo has the highest molecular weight (550 kDa), with 4536 
amino acid residues (Yang et al 1986, Chen et al 1986). It is important in 
maintaining the structural integrity of the lipoprotein, and serves as a ligand, 
through its positively charged arginine and lysine amino acid residues, for the 
cell surface LDL receptor (Brown & Goldstein 1986, Shepherd et al 1979, 
Brown et al 1975).
ApoB is a glycoprotein containing 5-9 % carbohydrate, consisting of galactose, 
mannose, glucosamine and sialic acid (Ehenholm et al 1972, Marshall & 
Kummerow 1962, Swaminathan & Aladjem 1976, Vauhkonen et al 1985). 
Mannose residues constitute the highest percentage, 37% of the total 
mono saccharides amounting up to 10% of the total high mannose 
oligosaccharides m serum (Vauhkonen et al 1985) (Fig 1.1). The presence of 
terminal mannopyranosyl and glucopyranosyl or sterically related residues, on
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the carbohydrate moiety o f LDL, gives it the property o f binding avidly to the 
sugar lectin “Concanavalin-A” (Con-A) ( McConathy & Alaupovic 1974). 
Con-A is a phytohaemagglutinin isolated from Jack beans (Fig 2.5, chapter 2) 
which specifically binds a-D  mannopyrano syl and a-D  glucopyranosyl.
Figure 1.1
Mannose Structure of apoB from human LDL
Man (a  1-6)
Man (a  1-6)
M a n (a l-3 ) '^  ^  Man (pi-4) GlcNAc
y 'Man (a  1-3)
ApoBlOO is synthesised mainly by the liver and intestine and occurs in VLDL, 
IDL and LDL. ApoB4g, which is half the size of apoBioo, is produced in the 
intestine by editing o f the mRNA transmitted from the apoB gene and occur 
only in chylomicrons and their remnants. ApoA (Al, All) are synthesised in the 
liver and intestine and are carried on CM and HDL. Finally apoE, present in 
three iso forms (apoE2, apoE3, and apoE4) and apoC (Cl, CII and CHI) are 
synthesised in the fiver and are found in CM, VLDL, IDL and HDL. ApoE is 
another ligand for the receptor-mediated uptake of cholesterol in tissues 
(Mahley 1988) while apoCII and CIII are regulators o f lipoprotein lipase 
activity.
1.4 Lipoprotein heterogeneity
Heterogeneity can be readily demonstrated in the major lipoprotein classes by 
high resolution techniques such as density gradient ultracentrifugation which 
subfractionate lipoproteins into relatively discrete components. Investigation of 
this phenomenon has improved our knowledge of the role o f lipoproteins in the 
pathophysiology of CHD. It was first suggested by Gofinan et al that the 
occurrence of atherosclerosis was more predicted by the existence of specific
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lipoprotein subclasses than by total blood cholesterol (Gofman et al 1950). 
Evidence suggests that lipoprotein heterogeneity may have a genetic basis and 
be influenced by environmental factors (Gaw et al 1990).
1.5 Very low density lipoprotein (VLDL)
VLDL particles (30-100nm particle diameter) are apoB containing triglyceride 
rich particles isolated from plasma at a density of 1.006 g/ml (Table 1.2). 
VLDL consists of heterogeneous particles (Streja et al 1977) whose size and 
lipid composition may vary in response to changes in nutritional status 
(Hamilton 1983). They can be isolated from plasma by cumulative flotation 
density gradient centrifugation into a large VLDLl and a small VLDL2 
fraction (Lindgren et al 1972). VLDL are synthesised in the liver and are 
mainly responsible for the transport of endogenous triglyceride in plasma. A 
small proportion of VLDL may be also synthesised in the small intestine to act 
as a vehicle for the reabsorption of the endogenous cholesterol and fatty acids 
of biliary origin. VLDL also contain carbohydrate associated with its lipid as 
well as its protein components. The function of the carbohydrate moiety has 
not been fully illustrated. However, it may have a significant influence on 
VLDL and LDL metabolism and their subfraction profile, since LDL is 
produced by delipidation of VLDL (discussed below).
1.6 Intermediate density lipoprotein (IDL)
These particles are formed during the conversion cascade of VLDL to LDL 
(discussed below), hence the term IDL. Sometimes they are called VLDL 
remnants. They are smaller in size than VLDL (25-35mn) (Table 1.2) can be 
isolated at a density 1.006-1.019 g/ml (Herbert et al 1978) and a flotation rate 
of Sf 12-20. They contain apoBlOO, apoC and apoE and show a slow pre B 
mobility on agarose gel electrophoresis. They have been shown to consist of 
two subpopulations (IDL1&IDL2) on gradient gel electrophoresis (Musliner et 
al 1986).
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1.7 LDL structure
LDL is the main cholesterol carrying hpoprotein in plasma. The physicochemical 
properties o f which are shown in Table 1.2. The lipid core consists mainly of 
cholesteryl ester and little triglyceride. Its major protein component is apoBioo 
It is produced either directly by the liver (Gaw et al 1993, 1995) or indirectly by 
delipidation of VLDL through IDL (NichoUs & Lewis 1980) (Discussed below). 
LDL consists of a heterogeneous population of particles, distinct in size and 
floatation rate which are distributed over a density range o f 1.019-1.063 g/ml. 
LDL heterogeneity was not described until the early eighties where Burke and 
Krauss were among the first to provide evidence for the existence of distinct 
LDL subclasses that can be identified by ultracentrifugal and gel electrophoretic 
techniques (Krauss & Burke 1982). These subclasses are present in both 
normal and hyperlipidémie patients (Austin et al 1988). Based on non­
denaturing gradient gel electrophoresis performed using 2-16% polyacrylamide 
gel, two distinct LDL subclass phenotypes denoted subclass pattern “A” and 
“B” have been described (Austin et al 1988). LDL subclass pattern A was 
characterised by large buoyant LDL particles with a peak diameter o f more than 
255°A and LDL subclass pattern B had small dense LDL particles with the peak 
diameter of less than 255°A. ApoB is reported to be the result of a single 
dominant gene which is expressed in 15- 25% of population (Austin & Krauss 
1986). The regulation and formation of these LDL subclass patterns are 
governed by compounding influences of environmental and genetic factors. 
With the development o f a new centrifugation procedure Griffin et al were able 
to isolate three LDL subfl-actions directly fl'om plasma analogous to those seen 
on gradient gel electrophoresis (Griffin et al 1990) (Figure 1.2) In this 
procedure, a buoyant LDL-I (d= 1.025-1.034 g/ml) (particle diameter =27- 
27.5nm), an intermediate LDL-II (d= 1.035-1.044 g/ml) (particle diameter 
=25.5-27nm) that represent the main LDL subclass in terms o f lipoprotein mass 
in adult males and a small dense LDL-III particle (d= 1.044-1.060 g/ml) 
(particle diameter =24.25.5nm) were isolated. The last is depleted in cholesteryl 
ester and relatively enriched in protein (Griffin et al 1990). A smaller particle
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(LDL-IV) with a smaller particle diameter <24 nm is seen in 
hypertriglyceridemic patients (Musliner & Krauss 1988, Griffin et al 1990, 
Griffin 1995) (Fig 1.2).
A profile predominated by LDL-I (phenotype A ) is mainly present in young 
healthy subjects and premenopausal females. High LDL-III levels (phenotype 
B) are found in males, post menopausal female, subjects with 
hypertriglyceridemia and coronary artery disease (CAD) positive patients 
(Griffin et al 1990, Austin et al 1990, Watson et al 1994).
Figure 1.2





Density (g /m l)’
1.034 1.044 1.060
L D M
27.5 27.0 25.5 24.2
LDL Particle S ize (Diam eter nm)**
21.8
*LDL subclass density profile obtained by density gradient ultracentrifugation
and representative o f a typical normal healthy female (----- ), male (  - -  ) and
coronary artery disease patient (___  ) **LDL: particle size as determined by
2-16% gradient gel electrophoresis. (Griffin et al 1990)
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1.8 Lipoprotein metabolism
1.8.1 Exogenous lipid transport
Daily each individual takes approximately 120g of fat in the form of cholesterol 
and triglyceride. Both lipids are hydrolysed if necessary by the action of 
pancreatic enzymes, mixed with phosphohpid cholesterol and bile acids from 
büe in the intestinal lumen prior to being absorbed mainly in the duodenum and 
upper jejunum (Danielson & Sjovall 1975). All the glyceride and about half of 
the cholesterol which is reesterlfied by the action o f acyl coenzyme A 
cholesterol acyl transferase (ACAT) (Norum et al 1983), (the other half is lost 
in the faeces) are packaged within intestinal enterocytes into large TG-rich 
chylomicron particles to be secreted into the blood stream via the thorasic duct. 
Chylomicrons contain apoAl apoB4g. The latter has been shown to represent 
the N-terminal half of apoBioo and therefore lacks the receptor binding domain 
(Marcel et al 1982, Hospattaker et al 1986) wliich is a prerequisite for the 
uptake o f apoBlOO containing lipoproteins by the liver and cells. Once in 
plasma, chylomicron particles acquire apoC and apoE from HDL (Havel et al 
1973) (Fig 1.3). Both of these apolipoproteins are required for subsequent 
processing of chylomicrons by lipoprotein lipase, the activity o f which is 
modulated by apoCII and apoCIII (Ginsberg et al 1986).
Endothehum bound lipoprotein lipase in adipose tissue and striated muscle 
hydrolyses the chylomicron triglyceride core into fatty acids and glycerol. 
Redundant phospholipid and protein from the surface of the particle are shed to 
HDL (Shaefer et al 1978) and the process result in the production of CM 
remnants. Thus, postprandiaUy two lipoprotein species appear CM and CM 
remnants. The cholesteryl ester content of the latter is obtained by transfer of 
the lipid from LDL and HDL in exchange for triglyceride (NichoU & Smith 
1965) facihtated by cholesteryl ester transfer protein (CETP). CM remnants are 
recognised and taken up through specific apoE receptors by the hepatocytes, 
thereby dehvering dietary cholesterol into the liver (Sherrill et al 1980, Mahley 
et al 1981).
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No circulating daughter particles are formed from the chylomicron remnants 
therefore, their contained lipid is used in the synthesis and secretion of VLDL 
(Fig 1.3).
1.8.2 Endogeno us Iipid transport
The liver acquire exogenous cholesterol and TG, by the chylomicron pathway 
but can also synthesise phospholipid and TG either from fatty acids released 
from adipose tissue or following the generation of fatty acids from small 
molecular weight precursors (Barter et al 1972). Similarly cholesterol is 
produced by liver cells by a metabolic pathway where key pacemaker enzyme 
is 3-hydroxy 3-methylgluteryl Coenzyme A reductase (HMG-Co A reductase). 
A significant proportion of intrahepatic lipid exported in association with 
newly synthesised apoB^oo particles, which undergo glycosylation before being 
secreted (Hamilton 1983). The rest are stored in the cytoplasm or secreted in 
the bile.
Nascent VLDL particles are heterogeneous encompassing a size range of 40- 
70nm. Their apoBlOO is bound with such high affinity that it remains with a 
single lipoprotein particle from secretion to ultimate endocytosis. In plasma, 
these particles gain more apoE and apoC from HDL, required for their 
delipidation cascade. They contain a higher phospholipid and TG with less 
esterified cholesterol than the plasma counterpart (Hamilton et al 1991). Large 
TG-rich VLDL enter a metabolic cascade similar to that of CM. They under go 
lipolysis by the action of lipoprotein lipase a process which requires apoCII as 
a cofactor (Nilsson-ehle et al 1980). The rate of hydrolysis of triglycerides is 
also regulated by the inhibitory effect of apoCIII. During LDL metabolism CE 
are acquired from other lipoproteins such as HDL, in exchange for TG, by the 
process of neutral lipid exchange mechanism under the influence of CETP. 
Delipidation leads to the generation of VLDL remnants and IDL particles (Fig 
1.3). In normal individuals, most of the TG depleted remnant particles, rich in 
apoE, are endocytosed by the liver by LDL receptor mediated mechanisms 
(Shepherd & Packard 1987). The remainder, are further delipidated to LDL by 
the hepatic lipase activity (Nicholl & Lewis 1980) (Fig 1.3).
Chapter 1 Introduction 12
Figure 1.3
Lipoprotein metabolism
Dietary lip id i.







Schematic diagram o f lipoprotein transport pathways showing the 
interrelationship between exogenous and endogenous lipid metabolism. LPL; 
lipoprotein lipase; HL, hepatic lipase; A, apoprotein A; B; apoprotein B; C, 
apoprotein C
It is known that the affinity o f lipoprotein lipase is greater for large, TG-rich 
particles than for smaller remnants, whereas hepatic lipase, which has both 
triglyceride lipase and phospholipase activities, seems to favour smaller VLDL 
and IDL particles. Therefore, the absence of lipoprotein lipase results in 
accumulation o f particles o f flotation rate greater than Sf 100 that contain both 
apoBlOO and apoB48 (Behr et al 1981, Goldberg et al 1982). While, antibody 
induced inhibition of hepatic hpase in cynomolgus monkeys (Goldberg et al
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1982) causes the accumulation of smaller VLDL and IDL, and LDL becomes 
relatively enriched in triglyceride (Demant e/ a/ 1988). In conditions that lead 
to hypertriglyceridaemia, such as impaired clearance o f postprandial 
lipoproteins, obesity and insulin resistance, failure of hormone sensitive lipase 
suppression is believed to promote the release of fatty acids from adipose tissue 
into the circulation (Frayn 1993) and thereby increase production of 
endogenous VLDLl (Fisher et al 1993, James & Pometta 1991). Both CM and 
VLDLl are removed from plasma by a common saturable pathway regulated by 
LPL (Bjorkegren et al 1996). The preferential affinity of LPL for CM increase 
the residence time o f VLDL in plasma during the postprandial phase and so 
increases its availability for neutral hpid exchange by CETP. This involves the 
transfer o f TG from both CM and TG-rich VLDLl to LDL in exchange for CE, 
generating a TG-rich LDL. The latter undergo further reduction in size by the 
activity of increased hepatic Hpase (Karpe et al 1993, Watson et al 1994, Tan g/ 
al 1995) resulting in the production o f small dense LDL (Karpe et al 1993). 
Since VLDL is precursor to LDL formation, heterogeneity in VLDL particles 
may account for the production of different LDL subclass patterns. It is not 
known which particular structural features regulate metaboHc heterogeneity in 
LDL and LDL protein composition and conformation is likely to be important. 
The high mannose glycosylation of apoB synthesised in the Hver might also 
account for differences in the carbohydrate structure of LDL synthesised by 
direct or indirect mechanisms as mentioned above.
1.9 LDL subfraction profile in relation to plasma lipids and lipoproteins
Large buoyant LDL-I (subclass pattern A), shows a strong correlation with the 
concentration of large HDL2 and HDL cholesterol, and an inverse relationship 
correlated with the plasma triglyceride, VLDL and small dense LDL-III 
(McNamara et al 1992, Williams et al 1990, Watson et al 1994, Griffin et al 
1995). In contrast, small dense LDL-III (subclass pattern B ) shows a strong 
positive association with plasma triglyceride (Austin et al 1990, Griffin et al
1994) and an inverse association with HDL cholesterol. Plasma triglyceride 
level has been shown to be the most important determinant factor in the
■i.
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distribution o f these LDL subclass patterns ( Campos et al 1992, McNamara et 
al 1992, Coresh et al 1993, Griffin et al 1994) independent of age, sex, 
diabetes, high density lipoprotein (HDL) and LDL cholesterol level in plasma. 
A hirther key factor determining LDL size is hepatic lipase aetivity. It is higher 
in male than female subjects (Tikkanen & Nikklla 1987, Karpe et al 1993, 
Watson et al 1994) and its activity related to LDL-III concentration (Tan et al
1995). Further, hepatic Hpase deficiency has been shown to be associated with 
the accumulation o f large LDL-I (Auwerx et al 1989), LDL-III is beHeved to be 
generated by transfer of triglyceride into LDL-II and subsequent Hpolysis o f the 
particle by hepatic Hpase (McNamara et al 1987, Zambon et al 1993) which has 
been shown to be responsible for 30% of the variation (Watson et al 1994).
1.10 Plasma lipids and lipoproteins and relative risk of CHD
1.10.1 Cholesterol as a coronary risk factor
For many years cholesterol and its esters, phosphoHpids and fatty acids have 
been known to be prominent components o f atheromatous lesions. The 
cholesterol hypothesis states that raised blood cholesterol is directly related to 
CHD and that lowering cholesterol by diet and drugs reduces the risk o f CED 
(LRCP 1984a, 1984b). Epidemiological studies (NCEP 1991, Davis et al 1990) 
suggest that for every 1% increase in total cholesterol the risk o f CHD rises by 
2%. This has been supported by the results o f clinical trials (LRCP 1984a 
; 1984b), which have shown that for every 1% reduction in cholesterol levels, 
risk decreases by 2%. Several intervention trials have attributed the reduction 
m CHD event rate in treated subjects to the elevation in HDL cholesterol as 
weU as the decrease in LDL and total cholesterol (LRCP 1984a, 1984b, Frick et 
al 1987). This has led to the formulation of recommendations for the treatment 
o f hyperHpidaemia. However, lower blood cholesterol levels are associated in 
epidemiological studies with higher rates o f cancer (Hiatt & fireman 1986, Isles 
et al 1989) and stroke (Iso et al 1989) and some have suggested that the 
existence o f those relationships should caution against aggressive reduction in 
cholesterol levels. However, recent data on cholesterol lowering in the West of 
Scotland (WOSCOPS) (Shepherd et al 1995) and the 4S study (Scandanavian
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Simvastatin Survival study 1994) have clearly shown that the lowering of 
plasma cholesterol levels brings benefit in terms of reduction o f coronary 
disease without an increase in morbidity and mortahty related to non 
cardiovascular factors.
1.10.2 Triglyceride as coronary risk factor
The vast majority of trials have focused on the significance of serum cholesterol 
as a risk predictor. This has diverted attention fi*om the other major hpid 
“triglyceride” (TG) circulating in plasma. Results fl'om most case control and 
prospective studies have shovm in univariate analysis (CasteUi et al 1977,
Simons 1986, Barrett-Connor & Khaw 1987) an association between 
triglyceride and CHD. The relationship is lost when other risk faetors are taken 
into account, notably HDL cholesterol concentration with which triglyceride 
level is strongly, inversely related (Castelli et a l\911 , CasteUi 1994, Griffin et al 
1994). The reason behind this might be the existence of a metabolic link between 
abnormalities o f TG and HDL, so that they cannot be treated as independent 
covariates. Fasting levels of plasma triglyceride level may not be the best index 
of risk. Most of the hpid is found in bloodstream during the postprandial period 
and postprandial hpaemia has been shown to be enhanced in patients with CHD 
(Patsch et al 1992, Groot et al 1992). Zilversmit suggested that atherosclerosis 
is a postprandial phenomenon (Zilversmit 1979). Postprandial increases in TG 
are associated mainly with chylomicrons and their remnants. CM remnant 
particles in postprandial lipaemia have been shown in cell culture studies to 
promote rapid accumulation of cholesterol within arterial ceUs (EUsworth et al
1986). While in-vivo an increased plasma concentration of chylomicron remnant 
particles as determined by measuring apoB4g: apoBioo ratio in the density 
(d<1.006) fraction of postprandial plasma has been demonstrated in those with 
CHD.
There is evidence that TGRL particles may be atherogenic per se, but also that -elevation in plasma triglyceride might exert an indirect influence on CHD risk, 
by promoting structural changes in LDL and HDL in particular by perturbing 
the subfiaction distribution within these density classes (Fisher et al 1993,
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James & Pometta 1991). This is reflected in the dyslipidémie syndrome termed 
atherogenic hpoprotein phenotype (ALP) with its hpid and hpoprotein 
abnormahties (Austin et al 1990) as discussed in section 1.10.4.
1.10.3 LDL subclass pattern, LDL carbohydrate and relative risk of CHD
There is now incontrovertible evidence to link plasma low density hpoprotein 
cholesterol level to the development of coronary heart disease . However not 
ah LDL may be equaUy atherogenic. A predominance o f smaU dense LDL has 
been consistently associated with an increased risk of CHD and may be directly 
involved in the atherogenic process via a number of. Mechanisms. A size 
profile in which small dense LDL is predominant is associated with a 3-fold 
increase in risk o f CHD (Austin et al 1988). Griffin et al (Griffin et al 1994) 
demonstrated an even greater relative risk (7-fold) with a plasma smaU dense 
LDL >100mg/dl.
LDL kinetic studies have provided evidence for the existence o f two metabohc 
pools with the hpoproteins, one with “fast” clearance and another which is 
cleared more slowly from plasma (Caslake et al 1992). SmaU dense LDL 
appears to arise in subjects with slowly catabolised LDL. Thus, the 
atherogenicity o f smaU dense LDL could be partly attributed to its prolonged 
residence time in circulation. This increases the opportunity for infiltration into 
the arterial waU and trapping by ceUular and extraceUular components in the 
arterial intima-media (Camejo et al 1990). Furthermore, smaU dense LDL has 
also been shown to be more susceptible to oxidative modification in-vitro (de 
Graaf et al 1991) which would promote its internahsation into ceUs involved in 
the plaque formation.
Earlier work has proposed that the carbohydrate moiety of apoB may be linked 
to the atherogenicity of the hpoprotein (Swaminathan & Aladjem 1976).
A strong relationship has been demonstrated between LDL subclass pattern and 
both the quahty and the quantity of carbohydrate on the hpoprotein (LaBelle & 
Krauss 1990). In this study, the hpid and hpoprotein (apoBioo) components of 
LDL firom subjects with LDL subclass pattern A were shown to contain more 
carbohydrate compared to LDL fi*om pattern B subjects (LaBelle & Krauss 
1990). The variation in the hpid carbohydrate per particle may be explained by
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the difference in the total lipid mass between large and small dense LDL but this 
would not apply to variation in the carbohydrate associated with the LDL 
protein. Different LDL subclasses also differed m their sialic acid content 
(LaBelle & Krauss 1990), where less sialic acid was associated with the 
glycolipid, rather than the glycoprotein in LDL from subjects with pattern B. 
LDL from CHD patients has been shown to have lower sialic acid content 
compared to LDL from normal volunteers (Tertov et al 1993). This sialic acid 
poor (SAP-LDL) was shown to induce 2-4 fold increase in intracellular lipid 
accumulation in cultured cells compared to the sialic acid rich (SAR-LDL) LDL 
from healthy volunteers (Tertov et al 1993). Desialation in-vivo of LDL from 
patients with atherosclerosis was suggested to confer potentially atherogenic 
properties on this lipoprotein (Orekhov et al 1989, 1991). All of these were 
supported by the finding that in-vitro desialation o f LDL by treatment with 
neuraminidase and LDL glycation in diabetic patients increased the lipoproteins 
capacity to induce intracellular lipid accumulation (LaBelle & Krauss 1990, 
Sobenin et al \99 \). In addition , increased reactivity of LDL from survivors o f 
myocardial infarction towards arterial wall proteoglycans (APG) (Linden et al 
1989) was suggested to be due to the presence of small dense LDL fraction 
with a lower siahc acid content and a higher isoelectric point (Camejo et al 
1985b). Sialic acid are negatively charged residues, its presence reduces the net 
positive charge on the hpoprotein particle thus render the particle less 
susceptible to interact with the negatively charged APG, thereby increasing 
potential atherogenicity of the hpoprotein. This is supported by the increase in 
APG-LDL interaction after desialation of LDL by neuraminidase treatment 
(Camejo et al 1985b). The role of carbohydrate and siahc acid content of LDL 
subfractions and apoB containing hpoproteins in relation to its interaction with 
arterial waU proteoglycan binding is examined in this thesis.
1.10.4 ALP , insulin resistance, obesity and CHD risk
The dyshpidemic syndrome o f atherogenic hpoprotein phenotype (ALP) is a 
term which describes abnormahties in plasma hpoproteins characterised by a 
predominance o f smaU dense LDL (phenotype B), moderately raised plasma
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triglyceride level (circulating as TG-rich very low density lipoprotein) and low 
HDL cholesterol (Austin et al 1990). ALP is associated with 3-7 fold increase 
risk of CHD. It is a recognised feature of the insulin resistance syndrome 
(Reaven 1988, Reaven et al 1993a) and associated with enlianced postprandial 
lipaemia. It is believed that these metabolic disorders confer increased risk of 
CHD through their link with the ALP (Fig 1.4).
There is evidence that insulin resistance exerts its effect as a CHD risk by
underlying a cluster of several risk factors such as ALP, abnormalities in 
clotting mechanisms (increases in fibrinogen and plasminogen activator 
inhibitor-1), hypertension, central obesity and smoking (Reaven 1988, Laws & 
Reaven 1993, Despres & Marette 1994, Stern 1995, Davidson 1995). High 
insulin levels and insulin resistance have been shown to be associated with 
high total and VLDL triglyceride (through failure of insulin to suppress the 
activity of hormone sensitive lipase and activate lipoprotein lipase in adipose 
tissue (Frayn 1993) low HDL cholesterol (Haffner et al 1992, Mykanen et al
1994), small dense LDL (Reaven et al 1993a, Stewart et al 1993, Austin & 
Selby 1995) and postprandial lipaemia (Taskinen 1995). These metabolic
disturbances appear to be consequences of the prevailing
hypertriglyceridaemia which itself may be caused by insulin promoting VLDL 
secretion from the liver.
In the past two decades the role of obesity in the causation of CHD has been 
investigated (Hubert et al 1983, Hartz et al 1984, Manson et al 1987; 1992, 
Grobbe et al 1990, Kissebah & Krakower 1994, Willet et al 1995). Although 
increase in body mass index (BMI) has been shown to be associated with 
increase risk of CHD (Willett et al 1995, Rimm et al 1995), the distribution of 
adiposity in the body estimated by the waist to hip ratio (WHR) was suggested 
to be a better predictor of CHD risk in both men (Rimm et al 1995) and women 
(Prineas et al 1993, Folsom et al 1993). A recent refinement has been the 
demonstration that an increase in visceral fat area is an even better predictor of 
CHD risk in patients with similar BMI (Nakamura et al 1994).
Chapter 1 Introduction 19
Figure 1. 4
Insulin resistance syndrome and related disorders associated with 
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Hypertension and obesity are associated with the syndrome o f insulin 
resistance and all are influenced both by genetic and environmental factors. 
BP, blood pressure, 1RS insulin resistance syndrome.
Obesity appears to be an independent risk factor leading to a number of 
metabolic alterations that contribute to an increased cholesterol level, but more 
frequently its major effect is to raise plasma TG level and lower HDL 
cholesterol (Walton et al 1995). It also promotes increase risk of CHD by 
acting through other risk fectors. For example it promotes insulin resistance 
(Bjortrop 1990, Fukioka et al 1991) and hypertension (Garrison et al 1996). 
Decrease in visceral fat has been reported by Kanai et al (Kanai et al 1996) to 
be accompanied by a significant fall in blood pressure and the amount o f visceral
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Abnormal lipoprotein patterns, mainly o f apoB containing lipoproteins have 
been consistently associated with an increased relative risk o f CHD. These 
patterns o f which familial hypercholesterolaemia, familial combined 
hyperHpidaemia and ALP examples are produced as a result o f genetic and 
environmental factors which affect the synthesis, processing or cataboHsm of 
Hpoprotein particles. The underlying disease mechanism in CHD is 
atherosclerosis a term which comes from the Greek “athere” meaning porridge 
and “Scler” meaning hard.
Initiation of atherosclerotic lesions is dependant on focal accumulation of Hpids, 
mainly cholesterol in the form of cholesteryl ester, and Hpoproteins (mainly 
apoB containing Hpoproteins, such as VLDL, IDL LDL and lp(a)) in the arterial 
intima-media. The presence o f these substances causes the migration o f blood 
monocytes to lesion site. These ceUs ingest the Hpid/Hpoprotein and retain the 
cholesterol. I f  Hpid uptake is excessive the monocyte becomes a resident 
macrophage. Lipid and macrophage recruitment leads to formation of fatty 
streak. The earHest atherosclerotic lesions. Further pathological changes in 
which the artery waU is damaged, endotheHum though replace the surface o f a 
fatty streak leads to the involvement of the blood haemostatic system. High 
fibrinogen and white ceU counts aU appear to accelerate the atherosclerotic 
process (Getz et al 1969). Elevated levels of serum cholesterol (mainly in LDL) 
promote lesion development through its association with increased intimai influx 
o f Hpoproteins (Nordestgaart et al 1992, Nordestgaart & Nielsen 1994), 
through vascular damage, promotion o f hypercoagulabHity and enhanced 
platelet reactivity (Badimon et al 1991). Evidence in support o f the direct link
fat was correlated strongly with blood pressure (Matsuzawa et al 1995). This is 
beHeved to be through an increase in the sympathetic nerve activity which leads "ft
to renal sodium retention and hypertension (Reaven et al 1996, Macdonald |
1995) in individuals with appropriate genetic predisposition and environmental 
exposure. Similar mechanism Hnks the association between hypertension and 
insulin resistance (Swislocki et al 1989).
1.11 Pathogenesis of atherosclerosis
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•i;between lesion development and plasma apoB containing lipoproteins is their f
existence and isolation from atherosclerotic plaque (Mawhinney et al 1978, |
Hoff & Bond 1983, Rapp et al 1994) both in human and animal models.
For lipoprotein particles to cause atherosclerosis they need to cross the single- fs
cell- thick membrane, the vascular endothelium to be retained in the intimai
' ■subendothelial space. Subsequent modification, internalisation and degradation 
by cellular and extracellular components of the arterial wall leads to cholesterol 
deposition and plaque formation. Lipoprotein retention can be influenced either 
by factors related to the constituents of the arterial wall such as: the vascular 
endothelial barrier, cellular and extracellular components of the intima-media 
or structure, function, and modification of different lipoproteins. It is this early 
step in the formation of lesions that is the principal topic of this thesis.
1.11.1 Endothelial dysfunction and lipoprotein influx into the arterial wall
The contributory role of vascular endothelium in vascular physiology and 
lesion development has now been well studied. Although endothelial 
denudation and injury, described in the response to injury hypothesis (Ross et 
al 1977) play an important role mainly in restenosis after balloon injury, it is 
now clear that atheroma develops in areas with intact endothelial layer 
(Katsuda et al 1992, Dicorleto & Soyombo 1993, Stary et al 1994).
Nevertheless, changes in the endothelial function such as increased 
permeability, which can occur as a result of cholesterol load in :î
hypercholesterolaemia (Nielsen et al 1992, Fry et al 1993, Herrmann et al
1994, Wu et al 1995) and shear stress induced endothelial alterations (Gibson 
et al 1993) have been implicated in lesion development. Increased endothelial
■'4'permeability facilitate the influx of lipoproteins into the subendothelial space.
The size of the particle, then, is of critical value to determine which lipoprotein
crosses more. Therefore, LDL and particularly small dense LDL are more 
prone to cross the endothelial barrier (Nordestgaard et al 1992). This is 
followed by enhanced retention of apoB containing lipoproteins in the arterial 
intima (Falcone et al 1984, Schwenke & Carew 1989a, 1989b, Spring & Hoff |
■ -‘s
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1989, Schwenke & Clair 1992). The rate of lipoprotein entry into the arterial 
wall is not different in lesion susceptible versus unsusceptible sites (Schwenke 
& Carew 1989b), it exceeds the rate of intimai lipoprotein accumulation 
(Carew et al 1984). Retention, rather than enhanced influx of lipoproteins is a 
critical pathological event in lesion development.
Endothelial dysfunction has also been shown to cause the release of platelet 
derived factors which enhance smooth muscle cell proliferation and promote 
extracellular proteoglycan synthesis leading to lipoprotein entrapment and 
retention. Proliferating smooth muscle cells can also act as macrophages 
undeitaking lipoprotein internalisation and degradation. Vascular cell adhesion 
molecule- 1 has been shown to be expressed by dysfunctioning endothelial 
cells. These molecules promote intimai recruitment of human monocyte 
derived macrophages from plasma leading to foam cell formation (Williams & 
Tabas 1995). On the other hand, endothelial cell layer may be as important in 
preventing apoB containing lipoproteins from leaving the intima as permitting 
their influx into the arterial wall (Nordestgaart 1996).
1.11.2 Arterial wall proteoglycan (APG) binding
The most directly relevant functional changes related to entrapment and 
retention of lipoproteins in intima-media, leading to lesion development, is 
believed to be altered extracellular matrix proteoglycan structure (Mahley & 
Hawksworth 1965, Wight et al 1983, Hoff & Wagner 1986, Camejo et al 1990, 
1993, Cardoso & Mourao 1994). Selectivity in proteoglycan binding of
different lipoproteins is also critical in lipoprotein entrapment e.g LDL binds to 
a greater extent than VLDL while HDL (Camejo et al 1980b).does not bind at 
all to APG (Camejo et al 1993).
Proteoglycans are a group of complex macromolecules present in all living 
tissue. They consist of a protein core to which glycosaminoglycan (GAG) 
chains are covalently attached through O and N-linked glycosidic linkages 
(Fig 1.5). APG constitute only 2-5% of the vascular tissue, yet it has been 
demonstrated to play an important role in influencing viscoelasticity,
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permeability, lipid metabolism, hemostasis and thrombosis (Williams & Tabas 
1995, Olivercrona et al 1993, Bourin & Lindahl 1993, Wight 1989).
Figure 1.5
A schematic structure of the proposed proteoglycan monomer
Protein cone
chain





The molecule consists o f a central protein core to which GAG chains are 
covalently attached through O and N-linked oligosaccharides. Usualy one 
type o f GAG chain is associated with a single protein core. CS,DS,HS, and KS 
are chondroitin sulphate, dermatan sulphate, heparan sulphate and keratan 
sulphate GAG respectively.
Four main families, on the basis o f their attached GAG chain, are identified in 
blood vessels (Table 1.3). Chondroitin sulphate rich proteoglycan (CSPG) are 
synthesised mainly by arterial smooth muscle cells and also by differentiated 
arterial wall blood derived cells, such as human monocyte derived 
macrophages. They have been shown to be responsible for the entrapment of 
apoB containing lipoproteins mainly LDL (Camejo et al 1988, Srinivasan et al 
1986, Wagner et al 1989 ) and lp(a) (Bihari-Varga et al 1988) in the arterial 
intima-media. Synthesis o f CSPG is regulated by different growth factors , such 
as platelet derived growth factor (PDGF), transforming growth factor pi (TGF- 
pi) and interleukin I (IL-I) (Schonherr et al 1991, 1993). Heparan sulphate
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proteoglycans (HSPG) are synthesised by endothelial cells which also produce 
dermatan sulphate proteoglycan (DSPG) after modulation of the cell to a 
migratory state (Wight 1989). These proteoglycans form complexes with LDL 
through proteins (e.g lipoprotein lipase and apoE) which act as bridging 
between the lipoprotein and APG (Mulder et al 1993, Williams & Tabas 1995). 
A subset of these proteoglycans may be protective against atherosclerosis by 
inactivating clotting enzymes (Bourin & Lindahl 1993, Marcum & Rosenberg
1987).
Table 1.3
The four main types of proteoglycan of vascular tissue
proteoglycan common
name
P  core 
(kDa)
GAG type Synthesis




Heparan-S PerHcan 467 HS EC
Keratan-S Lumican 35 KS
CS,DS,HS, and KS are chondroitin sulphate, dermatan sulphate, heparan 
sulphate and keratan sulphate GAG respectively. SMC, smooth muscle cells; 
EC endothelial cells.
Accumulation o f proteoglycans in the arterial wall is a characteristic feature of 
atherosclerosis (Camejo 1982, Berenson et al 1984, Wight 1989). Alteration in 
APG structure has been shown to occur in atherosclerosis, hypertension, 
diabetes and restenosis (Williams & Tabas 1995). Changes in the nature of 
proteoglycans such as increased GAG chain length and degree of sulphation 
increase proteoglycan interaction with lipoproteins (Wagner et al 1989, Alves & 
Mouroa 1988, Sambandam et al 199, Camejo et al 1993, Cardoso & Mouroa 
1994). However, Hpoprotein heterogeneity may influence the interaction 
process to a greater extent.
Since, proteoglycans, mainly CSPG, have been impHcated in the pathogenesis 
of atherosclerosis through interaction specifically with apoB containing
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lipoproteins such as VLDL, LDL lp(a) (Vijayagopal et al 1981, Camejo et al 
1985a, 1988, 1989, Bihari-Varga et al 1988) but not HDL (Camejo et al 
1980b), many studies have been focusing on the factors determining this 
interaction process. The interaction between proteoglycans and lipoproteins can 
take many forms and depend on several parameters. It has been suggested to be 
charge related, between the negative charges on APG and positively charged 
aminoacid sequences on apoB (Camejo et al 1988, Olsson et al 1993). 
Lipoprotein particle size (Wagner et al 1989), cholesteryl ester enrichment 
(Avila et al 1978) and low sialic acid content (Camejo et al 1985b) have also 
been shown to be critical in the binding process. Therefore, structure, 
particularly carbohydrate content which can modulate the net charge o f the 
paiticle, may be an important determinant of APG-Lipoprotein interaction. 
Small dense LDL has many features which favour binding and may be the most 
vulnerable candidate among the apoB containing lipoproteins for APG mediated 
lipoprotein retention (Fig 1 .6 ).
Other extracellular matrix structures, such as collagen (Jimi et al 1994), 
fibronectin (Labat-Robert & Bihari-Varga 1990) may also play a role in 
lipoprotein retention.
L 11.3 LDL oxidation
Another process proposed to be central to atherogenesis is lipoprotein oxidative 
modification by cells generated fi'ee radicals (Parathasarathy et al 1989, Hurt- 
Camejo et al 1992, Camejo et a l \9 9 \)  within the arterial wall.
It was Goldstein and Brown who first proposed that modification of LDL was a 
prerequisite for macrophage uptake by acetyl LDL receptor (Goldstein et al 
1979). A series of studies then followed demonstrating that oxidative 
modification o f LDL, produced by a variety o f techniques, led to enhanced 
uptake by macrophages and cholesteryl ester accumulation (Steinberg et al 
1989, Steinberg & Witztum 1990). Oxidation of LDL can be induced by 
incubation with cells (endothelial, smooth muscle cells and macrophages) 
(Parathasarathy et al 1989). These cells can generate fi'ee radicals which
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mediate the oxidative modification process. Oxidation o f LDL also occur by 
interaction with proteoglycans (Camejo et al 1991 , Williams & Tabas 1995) 
and heavy metal ions such as copper (Cominacini et al 1991, de Graaf et al 
1991, Tribble et al 1995). The latter has been used in-vitro to reproduce the 
modification process that occur in-vivo and has been shown to produce physical 
changes in LDL which are remarkably similar to that of oxidised LDL isolated 
fl'om coronary lesions. The mechanism of LDL oxidation appears to involve 
lipoxygenase and cycloxygenase systems (Steinberg et al 1989) and occurs in 
different stages. The initial stage (lag phase) involves the consumption of 
endogenous antioxidants, such as vitamin E, carotinoids and ubiqunol-10. This 
is followed by a rapid peroxidation o f unsaturated fatty acid side chains called 
the propagation phase (Cominacini et a / 1991). A variety of reactive aldyhydes 
generated fl'om lipid peroxidation form covalent bonds with lysine amino groups 
of apoB, thus producing a negatively charged apolipoprotein. As a 
consequence o f this new epitopes are formed within the modified LDL that are 
not recognised by the LDL receptor. This leads to preferential uptake o f the 
lipoprotein by scavenger pathways (Parathasarathy et al 1992) and ultimately 
deposition of LDL cholesteryl ester in coronary plaque (Steinberg et al 1989). 
In addition oxidised LDL has been shown to have a number o f potentially 
atherogenic properties. These include cytotoxicity affecting endothelial cells, 
promotion of expression o f cell adhesion molecules on endothelial cell surface, 
chemotaxis o f monocytes (Parathasarathy et al 1992). AU these together 
demonstrate the important role o f LDL oxidation m promoting atherosclerotic 
lesion progression from fatty streaks to advances plaque formation.
The extent o f lipid peroxidation has been determined by various measures of 
antioxidants, lipid peroxides, reactive aldehydes, such as thiobarbituric acid 
reactive substances (TBARS) as well as fluorescence spectroscopy. The latter 
has been used as a convenient method for detecting fiuorophores generated 
fiom the oxidatively modified protein moiety and has been vaUdated by direct 
comparison with other measures o f oxidation (Cominacini et al 1991).








Pathophysiology of atherosclerosis: an increase concentration of small dense LDL, 
such as seen in an ALP, enhances the influx of these particles into the arterial wall 
by increasing endothelial permeability. Owing to their small size these particles 
cross the endothelial barrier more readily. Once in the arterial subendothelial space, 
they bind with a greater affinity to CSPG. This promotes oxidative modification of 
the LDL particles on the one hand, and on the other hand these complexes are rapidly 
taken up by macrophages via both LDL and scavenger receptors leading to foam cell 
formation
1.11.4 Determinants o f  LDL oxidation
Susceptibility to LDL oxidation varies among individuals and is enhanced in 
various forms of dyslipidemia. Increased LDL oxidation has been reported in 
association with elevated serum cholesterol (Maggi et al 1994) (Type Ila
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hyperlipoproteinemia (Cominacini et al 1993) and famiHal hypercholesterolemia 
(Lavy et al 1991)). Antioxidant levels such as alpha-tocopherol, the most 
important antioxidant in LDL, and the modulatory effects o f factors such as 
polyunsaturated fatty acid (PUFA) content in LDL might be responsible for 
variation in oxidation hi different individuals (Tribble 1995). PUFA are known 
to promote oxidation and a low ratio of alpha-tocopherohPUFA in 
hyperHpidemic individuals has been attributed to LDL enrichment with 
arachidonic acid (Lavy et al 1991, Cominacini et al 1993). In addition, in-vitro 
LDL oxidation studies have shown that LDL enrichment with hnoleic acid 
(Reaven et al 1994) or arachidonic acid (Lavy et al 1991) leads to increased 
oxidative susceptibility.
A predominance o f small dense LDL is a component o f the dyslipidémie 
syndrome o f an ALP (Austhi et al 1990). The latter is associated with a 3-fold 
increase in risk o f CHD (Austin et al 1990) and is a characteristic feature of the 
insulin resistance syndrome (Reaven 1988, Reaven et al 1993a). Therefore, it 
is reasonable to postulate that the increase CHD risk in these patients may be 
attributed to enhanced susceptibility o f their small dense LDL to oxidation. 
Another lipid abnormality which characterises both ALP and diabetics with 
insulin resistance is low plasma HDL level (Uusitupa et al 1986). This also 
contributes to the enhanced LDL oxidation by associated lower serum 
paroxygenase enzyme activity (Mackness et al 1991, 1993). The same group 
o f investigators has attributed the enhanced LDL oxidation in diabetics to 
increase glycation o f apo B seen in these patients (Tames et al 1992). This was 
based on the knowledge that glycated LDL show enhanced susceptibility to 
oxidation (Hunt et al 1990).
Since a predisposition of small dense LDL is associated wih 3-7 fold increase in 
CHD risk and is suggested to have a greater binding reactivity to APG, it would 
be reasonable to postulate that, an increase concentration of small dense LDL, 
such as seen in an ALP, enhances the influx o f these particles into the arterial 
wall (Nordestgaart & Nielsen 1994) by increasing endothelial permeability 
(Henry et al 1995). Owing to their small size these particles cross the 
endothelial barrier more readily. Once in the arterial subendothelial space, they 
bind with a greater affinity to CSPG (Hurt camejo et al 1990, Wagner et al
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1989). This promotes oxidative modification of the LDL particles (Camejo et 
al 1991) on the one hand, and on the other hand these complexes are rapidly 
taken up by macrophages via both LDL and scavenger receptors ( Hurt et al 
1990, Hurt-Camejo et al 1992, Camejo et al 1993, Williams & Tabas 1995) 
leading to foam cell formation. In turn, this leads to the secretion of platelet 
derived growth factor (PDGF) and transforming growth factor pi (TGF p i) 
(Schonherr et al 1991, 1993) which stimulate smooth muscle cell to synthesise 
more CSPG that trap more LDL and so on (Fig 1.6)
1.12 General aims and objectives
It is evident Ifom the above discussion that heterogeneity and structure of 
lipoproteins mainly those o f apoB containing lipoproteins determine their fate 
and potential atherogenicity. An extensive body of work has already been 
performed to elucidate the pathophysiology o f atherosclerosis through 
exanuning the interaction of lipoproteins with arterial wall proteoglycans and 
oxidative modification studies which are thought to be prerequisite in lesion 
development. Lipid abnormalities particularly those related to an ALP and the 
role in modulating the structure and function o f apoB containing lipoproteins 
are tested in this thesis. The present work has two aims. Firstly, to exaniine the 
interaction of apoB containing lipoproteins with CS-PG dissodatively extracted 
firom human aorta. A series o f studies are designed to achieve this. We 
hypothesise that small dense LDL-III might be more reactive towards APG. 
Therefore the objective o f study 1 is to determine the association between a 
predominance of small dense LDL within total LDL and APG binding reactivity. 
This hypothesis together with the knowledge that small dense LDL is a 
component of the atherogenic lipoprotein phenotype, in addition to the wide 
variation in PG-LDL reactivity between different individuals, prompted us to 
seek abnormalities within the other apoB containing lipoproteins (VLDL, IDL 
and LDL), This is aimed in study 2 to determine the relative reactivity of 
different apoB containing lipoproteins across Sf 0-400 spectrum with the
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postulation that this might be affected by phannacological modulation o f the 
LDL subffaction profile. Since LDL subtractions have been shown to differ in 
their neutral carbohydrate and sialic acid content, the question which arises next 
is whether this structural variability is related to LDL ability to interact with 
APG and thus possibly revealing the mechanisms related to this interaction 
process. Study 3 and 4 are set to possibly answer these questions.
Interestingly, LDL oxidation is believed to be a prerequisite step in lesion 
development Therefore the second major aim of this work is to evaluate the 
susceptibility of LDL subfi-actions to oxidative modification in a group of 
NTDDMs and examine the effect of dietary supplementation with Evening 





The mechanisms linking apolipoprotein B containing lipoproteins with 
atherogenesis may be explained by several theories. Two of which are 
considered to be most critical, interaction of lipoproteins with arterial wall 
proteoglycans and LDL oxidative modification, were studied.
First, the interaction o f chondroitin sulphate-rich traction arterial wall 
proteoglycan, extracted and purified fi-om human aorta, with low density 
lipoprotein and triglyceride rich (VLDL and IDL) apoB containing lipoproteins 
was examined in-vitro. Determinants and mechanisms related to this interaction 
process with respect to structure and fimction of the lipoprotein particles were 
studied.
In-vitro APG-Lipoprotein binding assay was established and was used to 
examine the extent of apoB containing lipoproteins reactivity towards APG.
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Second, the effect o f Evening Primrose OU (EPO), containing linoleic acid and 
gamma linolenic acid (PUFA), which has been shown to have a lipid lowering 
effect, on LDL subfraction profile and oxidative modification was studied.
The extent o f LDL oxidative modification, in-vitro, was determined by 
measuring the relative fluorescence unit/hr at 430nm (excitation 350) after 
incubation with a heavy metal (copper).
2.2 Materials
All reagents used were o f analytical grade and names and addresses of all 
suppliers are shown m the appendix together with the manufacturers or 
suppliers of all har dware and software used m this book.
2.3 Proteoglycan-Lipoprotein interaction
The interaction between human chondroitin sulphate-rich arterial wall 
proteoglycan with total LDL (native or modified) and apoB containing 
lipoprotein subfractions was studied using an in-vitro binding assay (Anber et al
1996).
2.3.1 Isolation of total LDL
After 12h fast, 50ml o f blood was obtained from the subject by venepuncture 
and collected in K2EDTA (final concentration 1 mg/ml) as an anticoagulant. 
Plasma was harvested at 4°C by low speed centrifugation (3000rpm).
To 4ml plasma 0.32ml, 1.182 g/ml density solution was added and overlaid 
with 1.68ml , 1.019g/ml density solution to give a total volume o f 6 ml. This 
was centrifuged in a fixed angle Beckman Ti 50.4 rotor in L7-55 Beckman 
ultracentrifuge at 35,000rpm for 24h (15°C ). VLDL and IDL (d=1.006- 
1.019g/ml) were removed from the top 2 ml.
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To the remaining 4ml 1.47ml of 1.182 g/ml density solution was added and 
overlaid with 0.53ml of 1.063g/ml density solution to give a final volume of 
6 ml. Centrifugation was performed as above and total LDL (d=1.019- 
1.063g/ml ) was removed in the top 2 ml.
The isolated hpoprotein was dialysed against appropriate buffer solutions for the 
different studies.
2.3.2 Isolation of apoB containing lipoproteins
After 12hr fast, 50ml o f blood was obtained from the subject by venepuncture 
and collected in K2EDTA (final concentration 1 mg/ml) as an anticoagulant. 
Plasma was harvested at 4°C by low speed centrifugation (3000rpm).
From this plasma apoB containing lipoproteins were fi'actionated into large 
VLDLl (S f  60-400), small VLDL2 (S f  20-60), large IDLl (S f  16-20), small 
IDL2 (S f  12-16), large LDLA (S f  8-12) and small LDLB (S f  0-8) by a 
modification o f the cumulative density gradient centrifugation technique 
described by Lindgren et al (Lindgren et al 1972 ).
Density solutions
The density gradient was prepared from 1.006 g/ml and 1.182 g/ml NaBr 
density solutions, containing EDTA, as follows and were checked with a digital 
densitometer (DMA 35 Paar Scientific Ltd):
Density (g/ml) Density l,006g/ml Density 1.182 g/ml
1.0988 25 ml 27.89 ml
1.0860 25 ml 20.83 ml
1.0790 25 ml 17.72 ml
1.0722 75 ml 50.05 ml
1.0641 25 ml 12.31ml
1.0588 25 ml 10.73 ml
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The density of 2 ml plasma was increased to d = 1.118 g/ml by addition of 
0.341 g NaCl. This was laid over 0.5 ml d = 1.182 g/ml in a coated (with 
polyvinylalcohol) Beckman polyallomer tube and overlaid with a discontinuous 
NaBr gradient from the above density solutions (Fig 2.1) using an AAII pump 
(Technicon Ltd).
Figure 2.1
Isolation of plasma lipoprotein fractions by cumulative density gradient 
centrifugation



















Centrifugation was performed in a Beckman SW 40 swinging bucket rotor in a 
Beckman L-5 centrifuge over 48h at 23°C. Lipoprotein subfractions were 
removed by a fine tipped pipette from the top of the tube after deceleration 
without brake. The following centrifugation conditions were applied: Ih 38min 
at 39,000 rpm for VLDLl (remove in a volume of 1ml and replace with 1.0 ml 
of d =1.0588 g/ml), centrifugation was resumed at 18,500 rpm 15h 46min after 
which VLDL2 was recovered from the top 0.5ml of the gradient which was 
replaced with 0.5 ml d =1.0588 g/ml. IDLl and IDL2 were collected each in 
0.5 ml after centrifugation for Ih 15min and Ih 22min at 39,000 rpm 
respectively, following centrifugation at 39000rpm 2h 9min LDLA was
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removed from the top 0.5ml and finally LDLB was isolated from the top 0.5 ml 
after further centrifugation at 40000rpm for 17 h.
2.3.3 Extraction and purification of human arterial wall proteoglycans (APG).
Human arterial wall proteoglycan was extracted in 4 mol/1 guanidine 
hydrochloride and purified by isopycnic density gradient ultracentrifugation in 
CsCh as described before (Ogema et al 1979, Salisbury and Wagner 1981, 






Tris-HCl 5.0 mmol/1 pH 5.8, containing 0.15 mol/1 
NaCl, 0.01 mol/1 EDTA, 0.01% (w/v) NaNs, and 
0 . 0 1  mol/1  e-amino caproic acid (as protease 
inhibitors.
0.788 g Tris-HCl + 8.76 g NaCl + 3.722 g EDTA + 
0.1 g NaN] + 1.312 g e-amino caproic acid in Ihtre 
o f distilled water.
4 mol/1 guanidine -HCl pH 5.8, containing 0.05mol/l 
Na acetate, 0.01 mol/1 EDTA, 0.1 mol/1 e-amino 
caproic acid and 0.005 benzamidine- HCl.
5.0mmo]/l Tris-HCl buffer pH 7.2, containing 
6.0mmol/l KCl, 4.0mmol/l CaCL, l.Ommol/1 MgCL, 
0.1 mo 1/1 e-amino caproic acid and 0.005 
benzamidine- HCl (as protease inhibitors).
0.788 g Tris-HCl + 0.4473 g KCl + 0.444 g CaCLz + 
0.2033 g MgCb + 0.656 g e-amino caproic acid and
0.783 g Benzamidine-HCl in 1 litre o f distilled water.
'I
.S '
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• Binding buffer = dialysis buffer without the protease inhibitors.
2.3.3a Aortic tissue selection and handling
An aorta (Thoracic and abdominal segments) from 70-year old deceased female, 
<24h post mortem, was obtained from Department of Pathology, Glasgow 
Royal Infirmary, the cause of death was aortic valve stenosis and pulmonary 
embolism with no history of MI. The tissue was placed in 5.0 mmoI/1 Tris-HCl 
buffer pH 5.8, containing 0.15 mol/1 NaCl, 0.01 mol/1 EDTA, 0.01% (w/v) 
NaNs, and 0 . 0 1  mol/1 e-amino caproic acid (as protease inhibitors) and 
transported to the laboratory on ice.
The aorta extending from the aortic arch down to the common Uiac artery was 
cleaned of adventitial tissue, opened longitudinally, examined and any visible, 
heavily atheromatous and calcified plaques were excised. The remaining tissue, 
which appeared normal, was cut into small cubes and weight for extraction. 
Handling of the tissue was performed on ice at all times.
2.3.3b Extraction o f  APG from aortic tissue
The cleaned material (approximately 20 mg of aortic tissue) was homogenised 
in quickfit flasks (Bibby Science Products) using an ultra-Turrax homogeniser 
(Janke and Kunkle), and the resulting homogenate extracted with 15 volumes of 
4.0 mol/1 guanidine hydrochloride solution containing 0.05 mol/1 sodium acetate 
pH 5.8, 0.01 mol/1 EDTA, in the presence of 0.1 mol/1 e-amino caproic acid 
and 0.05 mo PI benzamidine-HCl (as protease inhibitors). The extract was mixed 
on an orbital shaker for 48 h at 4°C and then ceU debris was removed by low 
speed centrifugation (3,000 rpm) for 10 min at 4"C (Fig 2.2 ).
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The supernatant containing a crude proteoglycan preparation was filtered 
through Whatman No.l filter paper and further purified by isopycnic gradient 
centrifugation.
Figure 2.2
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2.3.3 c Purification and fractionation ofAPG
The density of the extract was adjusted to 1.5 g/ml by the addition of 0.59 g
CsCh per gram o f supernatant. 1ml of which was placed in each polyallomer
.tube with caps. Centrifiigation was performed in a fixed angle Ti 60 rotor with 
Delrin adapters for 48 hr at 18°C (40,000 rpm).
After centrifugation a thick 3-4 mm gelatinous membrane covering the top of 
the tube was removed by a fine tipped forceps composed mainly of protein and 
collagen.
The tube content were fractionated by downward displacement using an MSE 
tube piercer (Fisons) and the density o f each fraction was measured by a digital 
densitometer (DMA 35 Paar Scientific Ltd).
All fractions were dialysed initially against PBS and then against distilled H2O at 
4°C using (spectra pore dialysis tubing) for 72 h and lyophilised. The freeze 
dried fractions were stored at -70°C for fiirther characterisation and binding 
assay.
Calculation of the density gradient using Beckman polyallomer centrifuge (16 x 
76 mm, 13.5 ml) tubes in Beckman Ti 60 rotor with Delrin adapters (303307) as 
follows (Fig 2.3):
Maximum speed for this is 40,000 rpm.
r'max “  r max -\_{d\-d2)!T\ - [/ - ((c/i-f/z)/^)] ski^
= 89.9- [(25.65-16.51)/2] - [12.7 - ((25.65 - 16.51)/2)] sin 23.5 
r ’max = 82.09 mm
r ’ min "= r max - {d\!2) -(t - d\l2 + L) sin6 -^(6/2/2 ) cos6>
= 89.9-12.825 - (12.7-12.825 +71.42) 0.399 - 8.225 x 0.91 
Pmin = 41.085 mm
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= V [ 82.09^ + (82.09 x 41.085) + 41.085^] / 3 
re = 62.71 mm
(0.010966 X 160,000 000 x 6.271)/ 1.245 x lO’
?
r max = the distance in millimetres from the axis o f rotation to the farthest part of 
the tube cavity (= 89.9mm for 60 Ti)
Tmin = the distance in millimetres from the axis of rotation to the nearest part o f 
the tube cavity (=36.9 for 60 Ti)
Tav = the distance in millimetres from the axis of rotation to the middle part of 
the tube cavity (=63.4 for 60 Ti)
d\ = outside diameter o f the adapter
d2 = inside diameter of the adapter
L = adapter cavity length J
t = thickness of the adapter bottom 1
0 = tube of the rotor being used
re — [r max + (r max " r min) r mill ]/3 :1
dp at r = (r-re) dp/dr + P° 
dp/dr = (D^ r  /  /3{p)
m = 2 rirp m /6 0  
= 0.10472 rpm 
dp/dr = (0.10472rpm)^ re / j3(p)
= 0.088 g/ml cm
density at r,„ax = (Anax - re) Q M + p °  J
= (8.209 -6.271) 0.088 + 1.5 
= 1.67 g/ml 
density at r,mn =p° - (re-rmin) 0.088
= 1.5 -(6.271 -4.1085) 0.088 
= 1.3097 g/ml
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Figure 2.3






r max, the distance in millilitres from  the axis o f  rotation to the farthest part o f  
the tube cavity (= 89.9mm), rmin, the distance in millimetres from the axis o f  
rotation to the nearest part o f  the tube cavity (=36.9mm), rav, the distance in 
millimetres from the axis o f  rotation to the middle part o f  the tube cavity (= 
63.4mm)
The amount of CsCh used for a given density was calculated as follows: 
wt in grams per 100 g of solution = 137.48 - [138.11 (1//?° at 25°C) w 
wt in g = 0.59 g/ g solution 
p° = starting density
2.3.3e Alcian Blue colorimetric assay fo r  chondroitin sulphate determination
The freeze dried fractions were redissolved in a 50 mmoPl sodium acetate buffer 
pH 5.8 containing 0.2 moPl MgCb and 0.002% (w/v) NaNg. Proteoglycans 
were quantified by chondroitin sulphate as measured by an alcian blue 
microassay based on the method described by Hinnie and Serafini-Fracassini 
(Hinnie & Serafini-Fracassini 1986) and protein determinations by the modified 
procedure of Lowry et al (Lowry et al 1951 ).
Chapter 2 Materials and Methods 41
2. 2% SDS (electrophoresis quality) (20.00 g/1) 
50 mmoPl Na acetate trihydrate (6.804 g/1) 
adjust pH to 5.8 with HCl
Standards:
chondroitin sulphate A (Sigma cat. No. C-0914) is dried overnight at 4°C in a 
dessicater. 50 mg o f the dried chondroitin sulphate was dissolved in 100 ml of 
solution 1 to give a concentration of 0.5 mg/ml and standard solutions are made 








1 0 0 0 - 0.500
Solutions:
1. 200mmoPl MgC12 hexahydrate (40.66 g/1) 
50 mmoPl Na acetate triliydrate (6.804 g/1) 
0.002% Na azide (0.02 g/1)
adjust pH to 5.8 with HCl
chondroitin sulphate (pi) solution 1 (pi) concentration (mg/ml)
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Assay procedure:
Day 1. Prepare a 0.05% solution of Alcian Blue 8 GX in solution 1 (12.5 mg in 
25 ml for one micro well plate). Stir overnight to ensure maximal 
dissolving o f dye.
Day 2.
• spin dye solution at 3,000 rpm for 15 min and discard pellet.
• add lOpl of standard, blank and sample to duplicate weUs of the 
mierowell plate (Nunc Cat. No. 269620). Use solution 1 as blank.
The plate format is defined in program 24 (“ALCIAN”) on Dynatech 
MR5000.
• add 200 pi of dye solution to each well and mix on Varishaker 
(Dynatech) (setting 3.5) for 2 h.
• spin plate at 3000 rpm for 15 min.
• discard supernatant (one flick with plate inverted do not reinvert the 
plate till dry), wash pellet in 2 0 0  pi absolute ethanol and mix on 
Varishaker setting 3.5 for 2min.
• spin plate at 3000 rpm for 15 min.
• discard supernatant, wash pellet in 2 0 0  pi absolute ethanol and mix on 
Varishaker setting 3.5 for 2min.
• spin plate at 3000 rpm in for 15 min.
• discard second ethanol supernatant and allow ethanol residue to 
evaporate.
• dissolve pellet in 200 pi o f solution 2 and mix on Varishaker setting 
3.5 for 30 min.
Chapter 2 Materials and Methods 43
• burst any bubbles on the surface and read plate on Dynatech MR 5000 
at 630nm using program 24 (“ALCIAN”) which will draw a calibration 
curve and calculate the unknown samples.
2.3.3f Characterisation o f  glycosaminoglycan (GAG) chains
Further characterisation o f the GAG components o f the proteoglycan was 
performed by Mr Martin Langly, Department of Basic Dental Sciences, Dental 
School, University o f Wales, with thanks, using SDS-PAGE as described by 
Waddington et al (Waddmgton et al 1989).
2.3.4 Lipoprotein - APG in-vitro binding assay
The assay was established (Anber et al 1996) and used in all the studies (Fig 
2.4). The amount of chondroitin sulphate in the freeze dried material was 
measured by alcian blue assay (section 2.3.3e). The chondroitin sulphate 
concentration in the preparation was then adjusted to 2.5pg/100pl (This 
concentration was selected after mixing 0.1 mg/ml LDL with different 
concentration o f the chondroitin sulphate-rich APG, chapter 3) and used in all 
the assays. Total LDL samples isolated by sequential gradient 
ultracentrifugation (section2.3.1), all lipoprotein subfractions (VLDLl-LDLB) 
isolated by cumulative density gradient centrifugation (section 2.3.2) and 
modified LDL samples (section 2.5), were dialysed at 4°C for 1 h against the 
dialysis buffer o f 5.0 mmoFl Tris-HCl buffer pH 7.2, containing 6.0 mmol/1 KCl,
4.0 mmoFl CaCL and l.OmmoFl MgCE (section 2.3.3) using spectrapore 
dialysis tubing. The buffer was changed and dialysis continued for 3 h and then
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following another change, overnight. The protein concentration o f dialysed 
samples was measured by a modification of the procedure o f lowry et al (lowry 
et al 1951) and adjusted to 0.1 mg/ml by dilution in the binding buffer (section 
2.3.3). Diluted lipoprotein samples were divided into two 1 ml aliquots, one of 
which served as a control, and placed in plastic LP3 (Sarstedt). A standard 
amount (100 pi) o f APG solution containing 2.5 pg chondroitin sulphate was 
mixed with the test sample, but not with the control and both tubes were 
vortexed and incubated at 25°C for 30 minutes. FoUowiag incubation, turbidity 
was measured by absorbance at 600nm (visible wavelength) using a Beckman 
DU70 spectrophotometer. The samples were centrifiiged at 3,000 rpm for 30 
min to separate the lipoprotein-APG complex fi'om the unreacted lipoprotein in 
the supernatant. The pellet was dissociated with 0.2 ml of 2.0 mo FI NaCl buffer 
and cholesterol was measure in this fraction, the control tube and the 
supernatant by a modification o f the lipid research clinic protocol (LRCP 1975).
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Figure 2.4
Schematic diagram of the APG-Lipoprotein binding assay
Isolated lipoprotein samples
Dialysis against 3-changes of the 
dialysis buffer pH 7.2
I
Protein & cholesterol determination 
1
Protein adjusted to 0.1 mg/ml by 
dilution in the binding buffer pH 7.2
i
1 ml lipoprotein sample 100pi APG preparation
containing 0.1 mg protein eontaining 2.5pg CS-PG
\
mixed & incubated at 25C for 30min
The extent o f APG-Lipoprotein complex 
formation was determined by turbidity 
measurement at 600nm using DU 70 spectrophotometer1
Centrifuge for 30min at 3,000rpm
I Isupernatant dissociate pellet in 2moFl NaCl
'  I  '
Cholesterol measurement
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2.3.5 Data analysis
The extent of complex formation was determined both by absorbance at 600 
nm, having subtracted the control tube as a blank, and by the percentage of 
precipitated cholesterol by measuring the cholesterol content o f the precipitate 
divided by the total cholesterol added to the incubation mixture. Repeated 
analysis using the same LDL preparation showed an intraassay coefficient of 
variation of <3% and an interassay coefficient of variation of <6 % (chapter 3, 
Fig 3.2).
2. 4 Determination of LDL carbohydrate
The heterogeneity o f hmnan plasma total and LDL subfraetions with respect to 
the carbohydrate content o f the lipoprotein particle was investigated by 
fractionation o f total LDL by affinity chromatography on Concanavalin-A, using 
the method described by McConathy & Alaopovic (McConathy & 
Alaopovicl974). Neutral sugars and sialic acid content o f the total and LDL 
subfractions were determined using phenol sulphuric acid (Beeley 1985, LaBelle 
& Krauss 1990) and resorcino 1-hydrochloric acid (Svennerholm 1957) assays 
respectively.
2.4.1 Separation of LDL subfractions by affinity chromatography on 
Concanavalin-A.
Con-A, is a plant lectin purified from Jack bean. It binds molecules which 
contain a-D-mannopyranosyl, a-D-glucopyranosyl and sterically related 
residues. The binding sugar requires the C-3, C-4, and C-5 hydroxyl groups for 
the reaction with Con-A (Goldstein et al 1965) (Fig 2.5).
Con-A-Sepharose is concanavalin A coupled to Sepharose 4B by cyanogen 
bromide method. The concentration of coupled lectin is approximately 8 mg/ml 
gel and the binding capacity for porcine thyroglobulin (MW 670,000) is
■Ï
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approximately 8.5 mg/ml gel. The high capacity is due to the macroporous 
structure of the matrix. The binding of substances with Con-A requires the 
presence o f both Mn^^ and Ca^  ^ and the active protein-metal ion complex is 
stable at neutral pH in the absence of free metal ions.
Figure 2.5
Schematic diagram of the Con-A tetramer
III
Con-A is a tetramer o f identical subunits at physiological pH. One binding 
site for Calcium, Manganese and specific saccharide units are indicated by 
Ca, Mn and S respectively.
Con-A- Sepharose was supplied by Pharmacia pharmaceuticals as a suspension 
of 100ml sedimented gel in acetate buffer solution (0.1 moFl, pH 6.0) 
containing ImoFl NaCl, ImmoFl CaCh, ImmoFl MgCh, ImmoFl MnCb and 
thimerosal (0.02%) (as a preservative). The gel should be stored at 4-8°C.
Buffer solutions
Equilibrating buffer
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Tris-HCl 0.02 moFl pH 7.2 containing 0.5 
mo FI NaCl, ImmoFl CaCL2 , ImmoFl MgCE and 
ImmoFl MnCb.
3.152 g Tris-HCl + 29.22 g NaCl + 0.111 g 
CaCLz + 0.2033 g MgCE + 0.1979 g MnCb 
were dissolved in 1 litre of distilled water and the 
pH was adjusted to 7.2.
Eluting buffer 1 (a-DG)
Eluting buffer 2 (a-DM)
0.2 moFl a-D-methylglucopyranoside (19.42 g 
Methyl- glucopyranoside in 500 ml o f the Tris- 
HCl equilibrating buffer)
0.3 mo FI a-D-methylmanopyrano side (29.13 g 
Methyl- manopyranoside in 500 ml of the Tris- 
HCl buffer)
• Regeneration buffer 1(R1) = 0.1 mo FI Tris-HCl pH 4.5, containing 0.5 moFl
NaCl.
= 7.88 g Tris-HCl + 29.22 g NaCl.
• Regeneration buffer 2 (R2)= 0.1 moFl CHsCOONa pH 8.5, containing 0.5
mmoFl NaCl and ImmoFl CaCb.
= 8.203 g CHsCOONa + 29.22 g NaCl + 
0.111 g CaCb in 1 litre of distilled water.
8  ml of Concanavalin-A gel was washed with 10 volume of the equilibrating 
buffer. It was loaded on the column with a Bio-Rad pump at a flow rate of
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Total LDL was desalted using LO x 10 cm columns of Sephadex G-25 (PDIO 
column, Pharmacia). 2.5ml LDL was loaded on to the column and 3.0ml was 
eluted with the equilibrating buffer, pH 7.2 and was used immediately.
Img of LDL protein, as measured by a modification of Lowry et al (Lowry et al 
1951) was applied to the column and fractions were collected under the 
following conditions:
Sample volume = 3ml 
Protein = Img LDL protein 
Flow rate = O.lml/min
Fraction size collected = 0.5 mV Tube (collect peak and non-peak)
The elution timing and pattern was as follows:
NB: The last four fimctions was started again as the Bio-Rad system only has 
nine functions.
After sample application the unbound fractions were eluted using the 
equilibrating buffer. The elution o f the bound substance was performed in two 
stages; the weakly bound fraction was eluted by 0.2 mo FI a-DG. This was 
followed by the elution of the strongly bound fraction by 0.3 mo FI a-DM. The
inction Time (min) Valve buffer (volume in ml) v-e
1 0 A Tris-HCl (32) 1t!
;l
2 320 B Sample (lmg/3ml)
3 350 A Tris-HCl (32)
4 670 C 0.2 a-DG (32)
5 990 D 0.3 a-DM  (32) 1'
6 1310 E R1 (32)
7 1630 A R2 (32) i;
8 1950 B R1 (32) /:>9 END 1
1 0 A R2 (32)
2 320 B R1 (32) 4
3 640 A R2 (32 3
4 960 B Tris-HCl (32) 1
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Con-A column was regenerated between different samples by regeneration 
buffer 1 and 2 alternately three times each. The affinity chiomatography 
procedure was performed using Bio-Rad Econosystem with an automatic 5 
valve controller (A, B,C,D and E) to switch between buffers. Protein was 
determined on collected fractions by optical density measurement at 280nm 
(UV wave length ) using DU-70 spectrophotometer.
2.4.2 Labelling of total LDL
RadiolabeUing o f isolated total LDL (d=1.019-1.063 g/ml) was carried out by 
iodine monochloride method o f MacFarlane (1958) as modified by Shepherd, 
Bedford and Morgan (1976).
The following iodination mixtures were used:
Two 1.0ml aliquots o f total LDL (d=1.019-1.063g/ml) (protein concentration 
=1.6mg/ml) were mixed separately with 0.5ml o f LOmol glycine, pH 10 and 
2.0mCi o f Na ['“ !].
An appropriate volume o f iodine monochloride solution (25mmol in Imol NaCl) 
was added to yield an ICI:protein ratio o f approximately 20mol:500,000 Da of 
protein, and mixed gently. This procedure introduces an iodine atom into 
tyrosine residues at a level o f less than lOmol iodine /molecule o f LDL protein.
Bound and free radio-iodide were separated by passing the two iodination 
mixtures over separate 1.0 x 10 cm columns of Sephadex G-25 (PDIO column, 
Pharmacia). The eluting buffer used was 0.15 NaCl containing 0.01% 
NazEDTA (pH 8.1).
The radio activity concentration (pCi/ml ) was determined by counting lOpl 
aliquots of'^^I-LDL and comparing with ^^ I^ simulated standards.
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2.4.3 Separation of ^^ I^-LDL subfractions by Concanavalin-A in a tube assay.
2 ml Con-A washes with 10 volume equihbrating buffer (section 2.3.1) and left 
to settle. The excess supernatant buffer was removed by a fine tipped pipette. 
lOOpl I'^^-LDL, containing 0.16mg protein, was diluted in equilibrating buffer 
(final volume =2ml). Radio activity was determined as counts per minute 
(epm) on a gamma counter (Canberra Packard). The 2ml I^^^-LDL sample in 
buffer was mixed with the Con-A gel and radio active counts was measured 
again. This was done to compare the effect of Con-A on count measurement. 
For clarity the next steps are illustrated in diagram as foUow:
1. 2nd Con-A gel +2ml I^^^-LDL (0.16 mg protein) 
counts measured in epm
2. Mixed on a roller mixer for Ihi- 
at room temperature
Stand to settle
3. Remove supernatant 
with a fine tipped pipette
i
4. Measure counts on bo th , supernatant and 
remaining Con-A on a gamma counter (epm)
I
5. Add 2nd 0.2 a-DG and repeat steps2-4
I
6 . Add 2nd 0.3 a-DM  and repeat steps 2-4
2.4.4 Data analysis
The amount o f radioactivity, in epm, o f the unbound, eluted by equilibrating 
buffer, the weakly bound, eluted by 0.2 a-DG and the strongly bound, eluted by 
0.3 a-DM, fractions was measured directly on the supernatant as well as by
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2.4.5 Phenol sulphuric acid assay for neutral carbohydrate
This procedui'e , as by Beeley (1985), is a scaled down version o f the method of 
Dubois et al (1956).
Reagents:
subtracting the epm on the remaining Con-A from the previous measurement in I
each step.
The percentage o f the unbound, the weakly bound and the strongly bound 
fractions were calculated by dividing the amount of radioactivity of each of the 
fractions by the total multiplied by 1 0 0 .
• Concentrated H2 SO4 (DBH Aristar grade)
• Phenol: aqueous solution of colourless phenol crystals (5% w/v); solution 
Stable for several weeks at room temperature
• Standard D-mannose solution (stoke standard 4 mg/ml) stored at -18°C.
LDL (d=1.019 -1.063 g/ml) and LDL subfractions, LDLI (d = 1.025 - 1.034 
g/ml), LDLII (d =1.034 - 1.044 g/ml) and LDLHI (d = 1.044 -1.060) isolated 
by sequential and density gradient centrifugation respectively, were desalted by
*3gel filtration on Sephadex G-25 columns (NAP 5, Pharmacia). 0.5 ml o f the 
sample was applied and eluted in 1.0 ml with 0.15 moFl PBS pH 7.1 containing 
0.01% EDTA.
preparation of standard curve:
D- mannose stock standard 1:50 (80 pg/ml) was diluted to prepare solutions as 
follows
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D-mannose (pi) PBS(pl) pg sugar /tube
500.0 - 40
375.0 125.0 30
250.0 250.0 2 0
188.0 312.0 15




The reaction was carried out in round - bottomed “Labco” glass boiling tubes. 
LDL protein coneentration was determined by the modification o f the procedure 
of Lowry et al (1951). To a 100 pi of desalted total LDL and 200 pi of LDL 
subfractions (containing 0.3 - 2.0 mg/ml protein) in a final volume of 0.5 ml in 
PBS 0.3 ml of the 5% phenol was added and mixed. 2.0 ml of concentrated 
H2SO4 was added rapidly from a fast - flowing glass pipette and mixed 
immediately. Stand tubes at room temperature for 30 min.
Absorbance was read at 484 nm visual wavelength.
The neutral carbohydrate concentration of the samples were expressed as pg 
carbohydrate /mg protein.
Warning : Gloves and safety spectacles should be worn during the assay
procedure which was carried out in a safety cabinet.
2.4.6 Estimation of the sialic acid in LDL and lipoprotein subfractions
determination o f sialic acid was performed using a modification of the resorcinol 
hydrochloric acid method by Svennerholm (1957).
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Reagents:
■ N-acetyl neuraminic acid standard (Several N-acetyl neuraminic acid are 
available from Sigma, basically they are aU similar, however the purer the 
standard the better, 98% pure neuraminic acid from Sigma).
■ Stock Resorcinol 0.2% w/v in water (store at 4°C ).
■ ION HCl.
■ 0.1 M copper sulphate (add 0.25 g CUSO4 to 10 ml H2O).
■ Butyl Acetate: n-butanol (85:15 v/v)
Procedure:
A stock standard solution of (98% pure) N-acetyl neuraminic acid (Sigma) 
32pg/ml was prepared in distilled H2O.
A working standard curve in the range of 0 - 8  pg /250pl were prepared by 
taking appropriate volumes o f the stock standard (0 - 250 pi). The final 
volume was adjusted to 250pl with distilled H2O.
Resorcinol - HCl reagent was prepared by adding 10 ml o f stock resorcinol to a 
mixture of 250 pi o f 0.1 M CUSO4 and 80ml of ION HCl.
Sample blank was prepared by adding 10 ml of distilled water to 250 pi o f 0.1 
M CUSO4 and 80ml of ION HCl.
250 pi of resorcinol - HCl reagent was added to 250 pi standard, control and 
samples in glass screwcapped tubes. These were heated for 45 min at lOOC 
using DB3 block heater. After cooling in a water bath at room temperature for 
5 min, 400 pi o f butylacetate: n- butanol solution was added to each tube, the 
mixture was vortexed and centrifuged for 5 min at 3,000 rpm at 4°C
Absorbance was measured on the organic layer at 580 nm visual wavelength 
against a water blank.
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2.5 Chemical and enzymatic modification of LDL
Total LDL isolated by preparative sequential gradient ultracentrifugation was 
modified by various ehemical and enzymatic modification to investigate the 
mechanism of APG-lipoprotein interaction.
CHD modification, Carbamylation and reductive méthylation were performed 
following the technique described by Weisgraber et al (Weisgraber et al 1978). 
Neuraminidase treatment of LDL was performed as described by Camejo et al 
(1985b).
2.5.1 CHD Modification o f  arginine residues
1.0 ml LDL at a protein concentration of 1-2 mg/ml was added to 2.0 ml of 
freshly prepared 0.15 mol/1 1,2-cyclohexandione (CHD) in 0.2 mo FI borate 
buffer, pH 8.1 in a 50 ml Universal tube (total volume 10.5 ml).
This mixture was incubated on a roller mixer at 37°C for 2 h.
Modified LDL was separated from unbound by passing the mixture over a 1.0 x 
10 cm column of Sephadex G-25 (PDIO column, Pharmacia) and eluted with d 
= 1.006 g/ml NaCl . The eluted sample was stored at 4°C overnight before 
dialysis for APG binding.
2.5.2 Carbamylation o f  lysine residues
1.5 ml o f LDL (protein concentration = 1-2 mg/ml) was diluted with 0.75 ml 
of 0.3 mo FI sodium borate buffer, pH 8.0, to this 50 mg of potassium cyanate 
was added (20 mg/mg protein).
The mixture was incubated at 37°C for 2 h, after which it was stored at 4°C 
overnight before dialysis for APG binding.
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2.5.3 Reductive méthylation o f lysine residues
1.5 mi o f LDL (protein concentration = 1-2 mg/ml) was diluted with 0.75 ml 
of 0.3 moFl sodium borate buffer, pH 8.0, to this 0.5 mg of sodium borohydrate 
was added.
1.0 pi o f 40% formaldehyde was added every 6 min to the sample for 30 min at 
room temperature.
The reaction was then stopped by passing the mixture over a 1.0 x 10 cm 
column of Sephadex G-25 (PDIO column, Pharmacia) and eluted with d =
1.006 g/ml NaCl and stored at 4°C overnight before dialysis for APG binding,
2.5.4 Neuraminidase treatment
0.3 ml neuraminidase gel containing 0.136 units neuraminidase type VI-A from 
Clostridium Perfringens was placed in a screweap culture tube and washed 3 
times with water and 2 times with 1:10 dilution of the incubation sodium acetate 
buffer, pH 5.2 containing NaCl and EDTA. To this 2.0 ml of LDL containing 
mg protein was added along with 1.0 ml incubation buffer.
The mixture was incubated on a roller mixer (Danley) at 37°C for 25 h. 
Following incubation the tubes were centrifuged for 1 min at 1000 rpm, the 
supernatant was collected and the pellet was washed with 0.5 ml Saline. After 
recentrifugation the supernatants were mixed and stored at 4°C overnight 
before dialysis for the APG binding assay and siahc acid measurement.
The extent of charge modification on the native total, chemically modified 
and neuraminidase treated LDL samples was tested on agarose gel 
electrophoresis.
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2.5.5 Incubation with ganglioside
A  stock solution o f appropriate ganglioside 15-25pg/ml (Crude ganglioside 
from brain, GM3 ganglioside from plasma, GMl and asialo-GMl ganglioside) 
was prepared I in the APG binding. Different dilutions (0-40 mol/mol apoB ) 
were prepared from the appropriate ganglioside stock solution. These were 
incubated with LDL (final protein concentration of 0.1 mg/ml) for Ih at 30°C.
2.5.6 Incubation with apoE2, E3 and apoCIII
A stock solution o f the appropriate apoprotein (apoE2, apoE3, apoCIII) was 
prepared in the APG binding buffer. A range of 0-1 mol (apoE2, apoE3, 
apoCIII)/mol apoB were prepared by taking appropriate volumes of the stock 
solution. These were incubated with LDL (to give a final LDL protein 
concentration o f 0.1 mg/m ) for Ih at 30°C.
2. 6 LDL oxidation
Fluorescence can be used to measure the extent o f LDL oxidative modification 
after 24 h or by, deternfining the rate at which this fluorescence develops to 
measure the susceptibility of LDL to oxidative modification.
The method used was described by Comanicini et al (Comanicini et al 1991).
Reagents and solutions
QS : a standard solution o f quinine sulphate (59.17 ng/ml in 0.1
N H2SO4
PBS buffer : PBS + chloramphenicol 0.1 mg/ml pH 7.3
2 mmoFl CUSO4 : 50 mg/100ml H2O
1.5 mg/ml EDTA
4'
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Lipoprotein isolation and desalting
Total LDL and LDL subfractions were prepared for oxidative studies from fresh 
plasma by sequential and density gradient centrifugation respectively. LDL
preparations were dialysed for 1 h at 4°C against PBS buffer, pH 7.3 containing 
0.1 mg/ml chlorumphenicol using Spectra/For dialysis membrane tubing No.2 
(molecular cut off 12,000 - 14,000, 10 mm x 50ft). The buffer was changed 
and dialysis continued for 3 h and then following another change, overnight with 
no more than six 1 ml samples per 1 litre buffor. All solutions were prepared in 
deionised water. n5
"S.
After dialysis the protein concentration o f the LDL samples were determined by 
the modified procedure o f Lowry et al (1975) and adjusted to 100 pg/ml by 
dilution in PBS.
Diluted LDL samples were divided into two 2 ml aliquots in LP3 tubes, each
,containing 2 0 0  p.g o f protein, one of which was incubated in the presence o f 1 0
p,l of 2 mmol/l CUSO4 , final concentration o f copper ions was 1 0  pmol, the other 
served as a native control.
;Incubation was carried out by continuous mixing on an orbital shaker (Danley- 
Tech Ltd) at 37° C for 24 h in the dark. Oxidation was quenched after 24 h by 
addition o f 45 p,l EDTA.
Fluorescence spectroscopy
The fiuorimeter (Perkin - Elmer Ls-50) was calibrated by adjustment o f the 
emission slit width to give a deflection of 1 0 0  relative units with a standard 
solution o f quinine sulphate (59.17 ng/ml). Qs fluorescence was measured 
between emission (EM 380 - 550nm) and excitation (Ex. 350nm) with the Ex. 
peak at 450nm.
r
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Fluorescence emission spectra of both native and oxidised LDL samples were 
measured between 380 - 550 nm, an excitation of 360 nm and scan speed of 
500.
2.6.1 Data analysis
Five ml of plasma was placed in an Ultra-clear tube (13 x 64 mm) (Beckman 
Instruments, Fullerton, CA) and overlayered with 2 ml of d 1.006 g/ml solution.
Fluorescence measurement was performed at 0, 1 h, 2 h, 3 h, 4 h, 5 h and 24 h. 
The spectra of PBS was recorded and subtracted from the lipoprotein spectra 
using the “ARITH” function.
In the event of visible lipoprotein aggregation, fluorescence spectra were 
recorded before and after filtration (using 0.45 p millipore filter).




2.7 Plasma lipids, proteins and lipoproteins
,!
These were assayed using a variety of chemical, enzymatic, centrifugal and 
immunoassay techniques as described in detail below.
2.7.1 Plasma lipid assays (p Quantification)
Lipoprotein classes in fresh, whole plasma by a combination of 
ultracentrifugation and selective precipitation, using standard methodologies 
(Lipid Research Clinics Program 1975). VLDL was separated as a floating 
fraction. The infranatant was then treated with heparin (at a final 4:
concentration of 1.3 g/ml heparin and 0.092 mol/1 Mn^^) to precipitate LDL and 
leave HDL in solution. The cholesterol content o f whole plasma, of the top 
(VLDL), and bottom (LDL and HDL) fractions and that o f HDL were 
measured as described below. i
■ . . .4 4 T i l
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Tubes were capped and centrifuged overnight at 35,000 rpm (4°C) in a 
Beckman 50.4 rotor, then sliced 25 mm from the top and the supernatant 
collected into a 3 ml volumetric flask. The contents o f the bottom fraction were 
transferred to a 5.0 ml volumetric flask, the tube washed with saline, the wash 
added to the flask, and the volume adjusted to 5.0 ml with 0.15MNaCl.
A 1.0 ml aliquot o f this bottom fraction was then placed in a Beckman 
centrifuge tube and 50 pL of precipitating reagent [9.56 g MnCl2 . 4  H2 O + 1.05 
g (approximately 5x10^ units) heparin sodium salt in 25 ml 0.15M NaCl] were 
added and mixed. The mixture was kept at 4°C for 15 min then centrifuged at
10,000 rpm for 30 min, and the supernatant separated immediately for 
cholesterol analysis.
2.7.2 Compositional analysis
Total cholesterol and triglyceride were determined in whole plasma and in 
lipoprotein preparations by enzymatic colorimetric assays on Hitachi 704 auto- 
analyser.
Total cholesterol was assayed using the oxidative method (Boerhringer Kit No. 
704121), the principal o f which is shown below:
Cholesterol esters + H2 O cholesterol esterase ^  + rcO O H
1 1 X 1 , cholesteroloxidase . , . , _cholesterol + O2  ►4-cholestenone + H2O2
2 H2O2 + 4-aminophenazone + phenol 4-(p-benzoquinone-mono-imino)-
phenazone+ 4 H2O
Triglyceride was assayed using an enzymatic method the principal o f which is 
shown below:
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Triglyceride + 3 H2O ► glycerol + 3 RCOOH
GKglycerol + ATP ------- ► glycerol-3-phosphate + ADP
glycerol-3 -phosphate + O2 dihydroxyacetone phosphate + H2O2
H2O2 + 4-aminophenazone + 4-chlorophenol —  4-benzoquinone-
mono-imino)-phenazone + 2 H2O + HCl
The resultant colour changes were measured spectrophotometrically at 505 nm. 
Free (unesterified) cholesterol and phospholipid were determined by enzymatic 
colorimetric assays on a centrihchem Encore centrifugal analyser (Baker 
instruments).
Free cholesterol was estimated with Boerhmger Kit No. 310328 and esterified 
cholesterol was calculated by difference.
Phospholipid was estimated with Boerhinger Kit No. 691844 by an enzymatic 
colorimetric assay.
2.7.3 Modification of the Lowry Protein assay
Protein measurements were performed by a modification of the procedure of 
Lowiy et al (Lowry et al 1951).
Reagents and solutions 
Stock Reagents:
Solution A - 2% Na2C0 3  in 0.1 moFl NaOH (w/v)
Solution B - 2% NaK Tartrate in H2O (deionised)
Solution C - 1% CUSO4 in H2O (deionised)
Folin Ciocalteu reagent (BDH): dilute 1:1 with deionised H2O
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Working reagents:
Biuret reagent : To a 100 ml solution A, 1ml solution B and 1ml solution C 
was added. To this 1 mg/ml of SDS (sodium dodecyl lauryl sulphate) is added 
if the sample to be analysed is turbid.
Standards:
A stock standard solution of human serum albumin 1 mg/ml stored in aliquots at 
-20°C.
A working standard curve in the range o f 0 - 5 0  pg were prepared by taking 
appropriate volumes o f the stock standard (0 - 50 pi). The final volume was 
adjusted to 400pl with deionised H2O.
Quality control:
Bovine serum albumin 0.15 mg/ml and 0.30 mg/ml stored at -20C.
100 pi will be equivalent to 15 pg and 30 pg respectively. The final volume in 
the assay was adjusted to 400 pi to deionised water.
Sample preparation
Sample requiring dilution were adjusted to a final volume o f 400 pi with 
deionised water. For VLDLl and VLDL2 fractions 100 pi sample was used 
for IDL, 50 pi and for LDL 20 pi sample was used.
Method
2.0 ml biuret reagent was added to 400 pi standard, control and samples. These 
were vortexed and then allowed to stand for lOmin. To this 200 pi of Folin 
Ciocalteu reagent was added with immediate mixing and allowed to stand for 
30 min at room temperature. Optical density was measured by absorbance at 
750 nm visual wavelength on a DU 70 densitometer.
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2.7.4 Analytical ultracentrifugation of HDL
Plasma concentration o f HDL2 and HDL3 were estimated by analytical 
ultracentrifugation in Beckman L8-70 ultracentrifuge equipped with an 
ultraviolet scanning attachment, using an AnF rotor with double sector 
centrepiece. HDL subfraction masses were estimated by Mrs Dorothy Bedford 
and Mrs Elizabeth Murray (Institute of Biochemistry, Glasgow Royal 
Infirmary).
2.7.5 LDL subfraction analysis
The LDL subfraction distribution in all the patients were estimated following the 
method established by Griffin et al (1990) using a non-equilibrium density 
gradient centrifugation (Fig 2.6).
All density solutions used were prepared from density 1.006 g/ml and 1.182 
g/ml and checked with a digital densitometer.
Figure 2.6
Isolation of LDL subfractions using density gradient ultracentrifugation
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3 ml fresh plasma was adjusted to a density of 1.09 g/ml by adding 0.25 g KBr 
and 0.3 ml of density 1.182 g/ml solution. The sample and a 6-step salt gradient 
were layeredover 0.5 ml o f 1.182 g/ml density solution in polyvinyl alcohol 
coated Beckman polyaUomer SW 40 tubes (Fig 2.6) by a peristaltic pump. 
Centrifrigation was carried out at 23°C with slow acceleration at 40,000 rpm 
for 24 h in a Beckman L8-60 and deceleration with out brake. After 
centrifrigation the LDL subfractions were eluted by upward displacement using 
a heavy density solution (Maxidens, 1.9 g/ml, Nyegaard) by a constant infusion 
pump (Sage instruments) at a flow rate o f 0.69 ml/min and detected by 
continuous monitoring by a UV detector (MSE/Fison) at 280nm. Three distinct 
LDL subfractions, LDLI, LDLII and LDLIII were resolved in all subjects. The 
individual subfraction areas under the concentration curve were integrated 
(Data Graphics: Beckman), corrected for differences in extinction coefficient 
and then expressed as percentage of total LDL. LDLI optical density unit (OD) 
-  2.63 mg lipoprotein /ml, LDLII OD = 2.94 mg lipoprotein /ml, LDLIII OD = 
1.92 mg lipoprotein /ml. Total LDL (d = 1.019 -1.063 g/ml) lipoprotein mass 
(free cholesterol + triglyceride + cholesteryl ester + phospholipid + protein), 
determined as above, was distributed on the basis o f LDL subfraction 
concentrations in mg o f lipoprotein /dl plasma.
2.7.6 Apolipoprotein E phenotyping
Apolipoprotein E phenotyping was performed on all patients by Mrs Dorothy 
Bedford (Institute o f Biochemistry, Glasgow Royal Infirmary). To detect apoE 
isoforms, 10 pi o f plasma were delipidated, redissolved in 6 mo 1/1 urea 
containing 0.1 mol/1 TRIS pH 10.0, 5% 2-mercaptoethanol and 1% sodium 
decyl sulphate and applied to a vertical polyacrylamide slab gel o f 5% (w/v) 
acrylamide in 8 moFl urea containing 1% ampholyte (pH range 4-6). The 
cathode buffer was 0.2 mol NaOH and anode buffer 0.1 H3PO4. Isoelectric 
focusing was carried out at 3W per gel for 16 h. Transfer by electrophoresis 
from acrylamide slab gels to nitro-cellulose membranes was performed as 
described by Towbin et al (Towbin et al 1979). The transfer buffer contained 
0.2 mol/1 glycine, 0.025 mol/1 TRJS and 20% methanol and the current applied
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was 0.4 A for 3 h. The apoE isoforms bound to the membrane were visualised 
by irnmunostaining using a monoclonal or polyclonal apoE-specific antibody and 
an appropriate IgG-binding second antibody linked to horseradish peroxidase.
2.7.7 Lipoprotein (a)
Plasma lipoprotein (a) [ Lp(a)] was determined using the commereial kit, 
Innotest Lp(a) (Innogenetics SA, Belgium). This assay consists of a solid phase 
mouse monoelonal anti-Lp(a), and a sheep anti-apoB polyclonal second 
antibody, which is labelled with the enzyme horseradish peroxidase. This label 
binds to any solid phase antibody/Lp(a) complex because it can bind to the 
apoB moiety o f the Lp(a) complex. Further incubation with enzyme substrate 
produces a blue colour, which turns yellow when the reaction is stopped with 
sulphuric acid. The intensity o f the colour formed is proportional to the amount 




Focal deposition o f lipids in the form of lipoproteins is an important step in the 
pathogenesis of the early, fatty streak and the later advanced, atherosclerotic 
plaque. Lipid accumulation occurs both intracellularly and in association with 
components o f the extracellular matrix of the arterial wall (Srinivasan et al 
1970; 1982; 1986, Bihari-Varga et al 1964; 1983, Camejo 1982) consisting of 
collagen , elastin, microfibrillar protein, laminin and proteoglycans. The last are 
highly-electronegative glycoproteins, consisting of glycosaminoglycan (GAG) 
chains covalently attached to a protein core through an O or N- glycosidic 
linkage (Fig 1.5, chapter 1). These macromolecules influence the viscoelasticity 
and permeability of the arterial wall intima and media (Berenson et al 1984, 
Wight 1980). There is now general agreement that arterial wall proteoglycans 
play a key role in the development of atherosclerosis by interacting with plasma 
lipoproteins (Srinivasan et al 1970; 1982; 1986; 1990, Bihari-Varga et al 1964; 
1983, Camejo 1982, Camejo et al 1993, Schwenke & Carew 1989a; 1989b, 
Berenson et al 1984, Wight 1980 ). It has been shown that intimai pericellular
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and extracellular proteoglycans, particularly those rich in chondroitin sulphate 
(CS) and dermatan sulphate (DS) which are synthesised by smooth muscle cells 
(Wight 1989, Srinivasan et al 1989), bind specifically to apoB containing 
lipoproteins (Bihari-Varga et al 1964, Srinivasan et al 1970), VLDL, LDL and 
lipoprotein (a) but not to HDL (Srinivasan et al, 1989; 1990, Bihari-Varga et al 
1988). This binding reaction is believed to modify the structure of the 
lipoprotein, increase its residence time in the arterial wall and stimulate its 
uptake by macrophages (Camejo et al 1993a, Schwenke & Carew 1989a;
1989b, Srinivasan et al 1990, Berenson et al 1986), all o f which may contribute 
to foam cell formation. Furthermore, APG-LDL complexes have been isolated 
firom sites of lipoprotein deposition in arterial wall lesions (Srinivasan et al 
1975; 1984, Mawhinney et al 1978, Camejo et al 1985a).
The interaction o f plasma total LDL with APG, particularly with the CS rich 
fraction, has been studied both by hnmuno -histochemical techniques (Hoff &
Bond 1983, Lark et al 1988) and by in-vitro binding assays (Bihari-Varga et al 
1964; 1986, Camejo 1982, Srinivasan et al 1989, Camejo et al 1980, Kempen et 
al 1989, Steele & Wagner 1987, Sambandam et al 1991). Total plasma LDL 
isolated from post - MI patients has been shown to have a greater binding 
reactivity to APG than that fi^om normal subjects (Linden et al 1989). This 
observation suggests that inter-individual variation in the properties o f LDL 
may influence the interaction. LDL is known to consist o f a heterogeneous 
population of particles which differ in their size, density and metabolic 
properties (Krauss & Burke 1982). They can be separated by high resolution 
techniques such as density gradient ultracentrifugation (DGUC) or gradient gel 
electrophoresis (GGE). The former method distinguishes 3 major subfiractions,
LDL-I {d -1.019-1.033 g/ml), LDL-II {d -1.033-1.044 g/ml) and LDL-III {d 
-1.044-1.063 g/ml) in normolipaemic individuals (Griffin et al 1990). In case-
control studies it has been shown that an LDL profile m which there is a 7
;predominance of small dense LDL, determined either by GGE as pattern B
(Austin et al 1988), or by DGUC as an LDL-III >100mg/dl (Griffin et al 1994),
.is associated vvdth a 3-7 fold increase in risk of myocardial inferction (MI).
■iiiPredominance of small dense LDL is linked to a pattern of dyslipidaemia in 
which there is a moderately raised plasma triglyceride level and a low HDL
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cholesterol concentration, a profile which has been termed the “atherogenic 
lipoprotein phenotype” (ALP). This is the commonest lipid disorder seen in 
patients with coronary heart disease (CHD) (Austin et al 1990). In the present 
study we examined the hypothesis that the perturbed structure o f LDL in 
subjects exhibiting an ALP alters the ability o f the lipoprotein to interact with 
APG and hence contributes significantly to the risk of arterial disease. It was 
found that the extent o f interaction between LDL and APG did vary with 
plasma lipid levels in general and was enhanced in the presence o f an ALP.
3.2 Subjects
Plasma samples were obtained after an overnight fast (12h) fi*om 59 patients (39 
men and 20 women) aged 45-73 years who were undergoing diagnostic 
coronary angiography in the Department of Medical Cardiology, Glasgow 
Royal Infirmary. Subjects in the fasting state donated 50ml of blood wliich was 
collected by venepuncture using K2EDTA (final concentration 1 mg/ml) as 
anticoagulant. Plasma was harvested at 4°C by low speed centrihigation 
(3000rpm) and aliquots for hpid, Hpoprotein measurements and LDL 
subjBractionation used immediately. Subjects with recent MI (i.e. in the previous 
3 to 6 months), renal disease, thyroid disease, diabetes or those taking lipid- 
lowering medications were excluded, as were those with a plasma cholesterol 
concentration of >9.0mmol/l and a plasma triglyceride level o f >5.0mmol/l. All 
eligible subjects undergoing angiography were recruited to the study over a 6 
month period. The study was approved by the Research Ethics Committee o f 
Glasgow Royal Infirmary and each volunteer gave written informed consent.
3. 3 Statistical analysis
Statistical analysis and manipulations were performed using the PC version o f 
MINTTAB Release 10 for Windows (Minitab Inc., PA). All variables were 
assessed by drawing normality plots and the ones which were not normally 
distributed were normalised by appropriate transformations. Plasma triglyceride 
was normalised by log transformation, and LDLI, LDLII, LDLIII
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concentrations and HDL cholesterol were normalised by taking their square 
root. Associations between variables were tested by calculating the Pearson 
correlation coeffecient. The significance of association between pairs of 
variables was determined by linear regression.
3.4 Identification and characterisation of proteoglycans
An aorta (Thoracic and abdominal sigments) from 70-year old deceased female, 
<24h post mortem, was obtained from Department of Pathology, Glasgow 
Royal Infirmary, the cause of death was aortic valve stenosis and pulmonary 
emboHsm with no history o f MI. Extraction and purification o f proteoglycans 
was performed as described in chapter 2, section (2.3.3). Eleven fractions (d = 
1.38 - 1.63g/ml) were obtained from the CsCb gradient following dissociative 
extraction of proteoglycans from the arterial homogenate with guanidine-HCl 
(total freeze dried weight = 0.9g) (Table 3.1).
Table 3.1
Chondroitin sulphate (CS), measured by Alcian blue assay, and the 
protein content of the different APG fractions.
Fraction No. 1 2 3 4 5 6 7 8 9 10 11
Density g/ml 1.38 1.40 1.42 1.44 1.47 1.49 1.52 1.54 1.57 1.60 1.63
CS pg/mg* 29 30 43 85 78 181 187 195 457 443 459
Protein mg/mg* 0.95 1.00 0.95 0.80 0.70 0.65 0.55 0.50 0.26 0.25 0.24
*pg/mg, mg/mg dry weight
The three most dense bottom fractions (d>1.57g/ml) contained the highest CS 
concentration determined by Alcian blue colorimetric assay (63% of the total 
GAG present) (Hennie & Seraffini 1986 and lowest percentage of protein, while 
the fractions at the top o f the gradient were GAG poor. Fractions 9, 10 and 11 
which had similar CS content (Table 3.1) gave an LDL binding reactivity that 
was 4-8 folds greater than any of the other fractions (Table 3.2).
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Table 3.2
The amount of chondroitin sulphate proteoglycan and the LDL binding 
reactivity of each APG fraction extracted dissociatively with 4mol/l 
guanidine hydrochloride.
Fraction No. 1 2 3 4 5 6 7 8 9 10 11
CS/Protein
Ratio <0.1 <0.1 <0.1 0.1 0.1 0.3 0.3 0.4 1.8 1.8 2.0
%CS* 3 3 4 9 8 8 18 20 46 44 50
LDL-Binding
reactivity? 0.06 0.06 0.07 0.09 0.10 0.16 0.16 0.18 0.54 0.54 0.57
* %CS, the percentage o f  chondroitin sulphate per weight freeze dried 
material in each fraction isolated by CsCh density gradient 
ultracentrifugation, measured by Alcian Blue colorimetric assay described by 
Hennie & Seraffini (1986).
f  LDL-Binding reactivity o f  each APG fraction measured by absorbance at 
600nm.
The gradient contents were divided in to 4 main pools designated “A” (least 
dense) to “D” (most dense) and the differing proportions of chondroitin 
sulphate, dermatan sulphate, keratan sulphate and hyaluronic acid was 
determined (Table 3.3). Heparan sulphate was present in only trace amount in 
all fractions.
Table 3.3






A 0.03 0.01 nd 0.02 0,06 0.95
B 0.07 0.03 nd 0.05 0.15 0.80
C 0.18 tf'‘ 0.08 0.07 0.33 0.58
D 0.45 nd'" 0.15 0.11 0.71 0.25
* mg/mg dry weight, ^APG, arterial proteoglycan; GAG, glycosaminoglycan; 
CS, chondroitin sulphate; DS, dermatan sulphate; KS, keratan sulphate; HA, 
hyaluronic acid. “ tr, traces; ^nd, not detectable.
^A, (d, 1.38-1.42g/ml); B, (d L44-L47g/ml); C, (d  I.49-I.54g/ml); D, (d 
1.57-1.63g/ml). Heparan Sulphate is present in trace amount in all fractions.
Chapter 3 APG-LDL interaction 71
pool “A” was composed of fractions 1-3 (d -  1.38-1.42 g/ml), pool “B” 
composed of fractions 4-6 (d -  1.44-1.49 g/ml), pool “C” composed o f  
fractions 7 & 8 (d = 1.52-1.54 g/ml) and pool “D” composed o f fractions 9-11 
(d -  1.57-1.63 g/ml). These fractions were pooled on the basis o f their content 
of CS measured by alcian blue assay, as their LDL complexing activity increased 
with increasing CS content (Table 3.2, 3.3).
The amino acid analysis o f the pools A-D showed (Table 3.4) that the 
chondroitin rich sulphate fractions had a different aminoaeid composition which 
was higher in thrionine, serine, leucine and glutamic acid and lower in glycine, 
cystine, methionine, tyrosine, lysine and arginine, in agreement with the results 
of other investigators (Kapoor et a / 1981).
Table 3.4
Amino acid composition of the four different APG pools.
Am ino Acid* Pool A P oolB P oolC Pool D
Aspartic acid 107 109 109 125
Thrionine 69 78 93 108
Serine 36 41 49 58
Glutamic acid 89 80 92 96
Proline 100 71 77 73
Glycine 88 110 86 79
Alanine 102 74 74 80
Cystine 8 3 2 2
Valine 38 37 44 42
Methionine 16 7 6 4
Isoleucine 43 106 61 66
Leucine 88 94 95 144
Tyrosine 30 19 14 18
Phenylalanine 38 33 39 35
Lysine 73 65 55 48
Histidine 21 21 27 21
Arginine 54 49 38 36
* Residues /1000
Freeze dried material from pool D was stored at -70°C and was reconstituted in 
the proteoglycan binding buffer pH 7.2 (Section 2.3, chapter 2). It was used in 
the binding assay because it contained the highest concentration o f chondroitin
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sulphate (CS = 45% of the freeze dried material) and the highest LDL reactivity 
(Table 3.2, 3.3).
3.5 Turbidity measurement and the amount of cholesterol precipitated by 
APG.
A standard amount o f pool D containing 2.5 pg chondroitin sulphate was 
selected for the in-vitro binding assay after mixing different concentrations of 
APG (0, 0.5, 1.5, 2.5 & 5 pg/ml) with a fixed concentration o f total LDL 
protein (0.1 mg/ml), measured by the modified procedure o f Lowry et al (Lowry 
et al 1951). APG-LDL complex formation increased with increasing 
concentration o f APG from 0-2.5 pg/ml thereafter it started to plateau in almost 
all the LDL samples. Figure 3.1 shows the binding reactivity o f total LDL, from 
15 subjects with variable lipid profile, with the different concentrations of APG.
Figure 3. 1
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Total LDL protein (0.1 mg/ml) from 15 subjects was mixed with APG (pool D) 
0-5pg CS. The extent o f  APG-LDL complex formation, as measured by 
absorbance at 600nm visual wave length, increased significantly from 0 to 2.5 
pg APG concentration (p<0.001). There was no significant differences 
between complex formation at 2.5 and 5 pg.
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The reproducibility o f the APG-LDL binding assay was verified with the same 
sample of LDL. Figure 3.2 show 10 determinations of the binding reactivity of  
an LDL sample performed in one assay.
Figure 3. 2
The interaction of APG with LDL. 10 determinations o f the same LDL 
sample.
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0.1 mg/ml LDL protein was mixed with APG (0-5 pg). CV = 3%, P<0.0001
The increase in the turbidity measurement by absorbance at 600nm was 
associated with a decrease in the percentage of unreacted cholesterol in the 
supernatant (Fig 3.3) and correlated strongly with the amount o f cholesterol 
precipitated in the pellet (r= 0.77, p<0.0001). The former was used as a 
convenient index o f LDL reactivity with APG, although the relationships below 
were also observed with the amount of LDL precipitated.
In order to verify the effect o f storage, we performed the binding assay on 20 
total LDL samples before and after fi-eezing at -20°C for one week. This 
resulted in a change in the binding reactivity of the LDL. Most o f the samples 
were found to have a lower reactivity after freezing (Fig 3.4) (Table 3.5). Fresh 
LDL samples up to 72 hr after isolation stored at 4°C gave the same binding
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reactivity in different assays (Table 3.5). Fresh LDL samples were used 
immediately after isolation for all the in-vitro binding assays.
Figure 3. 3
Correlation between turbidity measurement and the percentage of 














% precipitated cholesterol in the pellet # -------% unreacted cholesterol in
the supernatant 0 ......C>, Turbidity measurement by absorbance at 600nm
e  #  . r=0.77, p<0.0001
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Figure 3. 4
The effect of storage by freezing at -20°C for 1 week on the LDL 
interaction with APG
0.5  1
0 .4  -
ro c  0 . 3 -
l ê
E S  0.2 -
fresh frozen
Samples
2.5pg CS-PG was mixed with 0.1 mg/ml LDL protein, from 20 subjects, before 
(immediately after isolation by sequential gradient ultracentrifugation) and 
after freezing the same samples for I week at -20X1. All determinations were 
performed in duplicates.
Table 3.5
APG-LDL complex formation, comparison between fresh and stored LDL 
samples in two different assays
LDL Sample Assay 1 Assay 2
Fresh-1 0.23 ± 0.006 0.24 ± 0.004
Fresh- 2 0.46 ± 0.004 0.46 ± 0.002
Fresh- 3 0.55 ± 0.006 0.55 ± 0.005
Frozen 0.29 ± 0 .1 0 0 0.22 ± 0.100*
* p<0.01, values represent mean and standard deviation. Five determinations 
o f  fresh LDL samples used within 72 hr after isolation. Duplicates o f  frozen 
samples (n=20) were used before and after freezing for 1 week at -20X1.
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3. 6 Lipids and lipoprotein profile
Mean plasma lipid levels and LDL subJ&action profile in the subjects are shown 
in Table 3.6. Plasma triglyceride level was positively correlated with total 
cholesterol (Fig 3.5), LDL cholesterol (Fig 3.6) and apolipoprotein B 
concentration within the plasma (Fig 3.7) and negatively correlated with HDL 
cholesterol (Fig 3.8). Plasma triglyceride was also the strongest and most 
constant correlate o f LDL subfraction concentrations showing a negative 
correlation with the percentage and concentration of LDL-I (Fig 3.9) and LDL­
II (Fig 3.10) and a positive association with small dense LDL-III (Fig 3.11) 
(Table 3.6) within total LDL.
Table 3.6
The patients lipid and lipoprotein profile. Correlation with Plasma 





Age 52.5 ± 12.8 0.18 -0.08
Gender — -0.36** -0.33**
Total cholesterol mmoFl 5.6 ± 1.2 0.45* 0.10
VLDL cholesterol mmoFl 0,6 ± 0.4 0.84* 0.37
LDL cholesterol mmoFl 3.8 ± 1.1 0.39** 0.18
HDL cholesterol mmoFl 1.3 ± 0.4 - 0.57* - 0.37**
plasma triglyceride mmoFl 1.6 ± --- 0.37**
Apolipoprotein B mg/dl 1.0 ± 0.4 0.44** 0.33***
LDL-I 19 ± 12.4 - 0.57* -0.47*
LDL-II 54 ± 14.8 -0.33** -0.19
LDL-III 27 ± 19.4 0.65* 0.48*
HDL/ApoB ratio 1.5 ± 1.1 - 0.53* -0.41**
T riglyceride/ApoB ratio 1.4 ± 1.1 0.55 0.21
"^Plasma triglyceride, fAPG-LDL complex determined by turbidity 
measurement by absorbance at 600nm, Values represent mean ±  standard 
deviation. r, Pearsons correlation coefficient. *p<0.0001, "^^p<0.001, 
***p<0.05
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Figure 3.5
correlation between total cholesterol and plasma triglyceride level
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Figure 3.7
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Figure 3.11
Correlation between plasma triglyceride level and the percentage of small 









when the subjects were divided on the basis o f gender. Plasma cholesterol , 
LDL cholesterol, VLDL cholesterol were similar between the sexes (Table 3.7). 
Male patients had higher plasma triglyceride, plasma cholesterol/HDL ratio and 
small dense LDLIII concentration within total LDL and a lower total HDL 
cholesterol and LDLI concentration within total LDL (Table 3.7). A typical 
LDL subfraction profile for men and women is shown in Figure 3.12.
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Table 3.7
Lipid and lipoprotein profile in male and female subjects
Lipid and LDL subfraction 
__________ profile__________
Mean
Male n —39 Female n = 20
Total cholesterol mmol/l 5.7 ± 1.2 5.4 ± 1.3
LDL cholesterol mmol/l 3.8 ± 1.1 3.5 ± 1.3
VLDL cholesterol mmol/l 0.7 ± 0.4 0.4 ± 0.2**
HDL cholesterol mmoPl* 1.1 ± 0.3 1.5 ± 0.4**
Plasma triglyceride mmol/l* 1.8 ± 0.8 1.1 ± 0.5**
% LDLI 14 ± 8.3 30 ± 12.5*
%LDLII 54 ± 16.8 54 ± 10.0
%LDLIII 33 ± 21.1 17 ± 9.5*
APG-LDL complex AU 0.4 ± 0.2 0.3 ± 0.1***
* P <0.0001, **p<0.001, P = 0.007, AU; absorbance units at 600 nm 
Figure 3.12
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3.7 Lipid profile and APG-LDL complex formation
The extent of APG- LDL complex formation was found to be inversely related 
to HDL cholesterol concentration (Fig 3.13) , positively related to triglyceride 
(Fig 3.14) but showed no relationship with plasma total (Fig 3.15) or LDL 
cholesterol (Fig 3.16) (Table 3.6).
Figure 3.13















APG-LDL complex absorbance at 600nm
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Figure 3.14
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Figure 3.15
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Figure 3.14
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Figure 3.15
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Figure 3.16
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In general, LDL from males with higher plasma triglyceride level and small 
dense LDL-IIl showed a greater reactivity for AFG than that from females 
(0.40 ± 0.16 vs 0.29 ± 0.13, p = 0.007) (Fig 3.17).
Figure 3. 17
The extent of APG-LDL complex formation. Comparison between male 
and female
Fern  a le-
M ale
0 1  0 . 2  0 . 3  0 4 0 . 5  0 . 6  0 7  0
A P G - L D L  a b s o r b a n c e  at  6 0 0 n m
The inner box represents the 25-75 percentile, the median value is indicated by 
a vertical line, the outer box represents the 5th and the 95th percentile while 
the range o f  values are indicated by the horizontal lines. p =  0.007
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When the subjects were divided on the basis of their plasma triglyceride being 
higher or lower than 1.5 mmol/1, APG-LDL complex formation was found to be 
higher in the subjects with the higher triglyceride level (Fig 3.18)
Figure 3.18
APG-LDL interaction in subjects with plasma triglyceride above and 
below 1.5mmol/l
T G < 1  .5
T 0 1 . 5  -
—T----------1--------- 1----------1--------- 1----------1--------- 1----------1
0.1 0 . 2 0 .3  0 .4  0 .5  0 . 6  0 .7  0.8
A P G - L D L  c o m p l e x  a b s o r b a n c e  at 6 0 0 n m
The inner box represents the 25-75percentile, the median value is indicated by 
a vertical line, the outer box represents the 5th and the 95th percentile while 
the range o f  values are indicated by the horizontal lines. p= 0.007.
3.8 Arterial proteoglycan - LDL interaction and LDL subfraction distribution
The extent to which total LDL {d = 1.019-1.063g/ml) interacted with APG was 
positively correlated with the percentage of small dense LDL-III (p<0.0001) 
(Fig 3.19) and inversely with the percentage of large buoyant LDL-I (p<0.0001) 
within total LDL (Fig 3.20). There was no correlation between the extent of 
LDL-APG complex formation and the percentage o f the major, intermediate 
density LDL species, LDL-II (Table 3.6). Males in general had a greater 
proportion o f LDL-III (P<0.001) and a lower proportion o f LDL-I (P<0.001) 
percentage within total LDL than female subjects (Table 3.7) in agreement with 
previous studies (Grifiin et al 1994). This finding explained the different 
reactivity between men and women (Figure 3.17).
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Figure 3.19
Correlation between the extent of APG-LDL complex formation and the 
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Figure 3.20
Correlation between the extent o f APG-LDL complex formation and the 
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When the subjects were subdivided on the basis of their LDL-III concentration 
into those with LDL-III above and below lOOmg/dl as an indication o f the 
presence of ALP (Griffin et at 1994), it was found that those in the high LDL- 
III group had an elevated plasma triglyceride (p<0.0001) level, a low HDL 
cholesterol concentration (p<0.0001) but the same plasma cholesterol (Table 
3.8). The extent o f APG-LDL complex formation seen in those with ALP was 
significantly different from those without (p<0.002) (Figure 3.21) (Table 3.8).
Figure 3.21
APG-LDL complex formation in patients with LDL-III above or below 
lOOmg/dl.
L D L-IIK IO O
L D L - m >  100
I  I  I  I  I  I  I- - - - - - - - - - - - - - - - - - - - - - 1
0.1 0.2 0.3 0 . 4 0.5 0 . 6 0.7  0.1
A P G - L D L  c o m p l e x  a b s o r b a n c e  at 6 0 0 n m
The inner box represents the 25-75 percentile, the median value is indicated by a 
vertical line, the outer box represents the 5th and the 95th percentile while the 
range of values are indicated by the horizontal lines. p= 0.002.
Chapter 3 APG-LDL interaction 8 I
Table 3.8
Lipid, Lipoprotein profile and APG-LDL interaction in subjects with 
LDL-III mass above and below 100 mg/dl within total LDL
* P<0.0001, **p<0.001, values represent mean ±standard deviation.
f  AU, absorbance unit determined by turbidity measurement by absorbance at
600nm.
3.9 DISCUSSION
The nature o f the APG-LDL interaction is not yet understood although a 
number of studies have focused on elucidating factors that influence the binding 
reaction (Srinivasan et al 1982; 1989, Berenson et al 1986, Camejo et al 1980b; 
1985a; 1989, Steele & Wagner 1987). Clearly variation in the structure of APG 
as well as lipoprotein could contribute to the variation observed. The 
composition o f proteoglycans dissodatively extracted from arterial wall by 





Age 54 ± 8.8 52 ± 14.3
Total cholesterol mmoPl 6.0 ± 1.4 5.5 ± 1.1
VLDL cholesterol mmol/l 1.0 ± 0.4 0.4 ± 0.2*
LDL cholesterol mmoPI 4.0 ± 1.2 3.7 ± 1.1
HDL cholesterol mmoPl 0.9 ± 0.2 1.4 ± 0.4*
Plasma Triglyceride mmoPI 2.4 ± 1.0 1.2 ± 0.4*
LDL-I mass mg/dl 31.9 ± 21.3 70.5 ± 37.0*
LDL-II mass mg/dl 130.8 ± 61.2 193.0 ± 74.3**
LDL-III mass mg/dl 186.3 ± 80.4 47.5 ± 18.8*
Apolipoprotein B mg/ml 1.2 0.5 1.1 ± 0.4
HDL/Apo B ratio 1.6 ± 1.0 0.9 ± 0.4**
APG-LDL AUÎ 0.46 + 0.1 0.32 ± 0.1**
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1979, Salisbury & Wagnerl981, Wagner et al 1986, Kapoor et al 1981). CS
has been shown to be the predominant GAG of the aorta and a major 
component o f the 4.0M Gdn-HCl extract (Wagner et al 1986). It binds most 
avidly to LDL (Srinivasan et al 1989, Kempen et al 1989, Olsson et al 1993) 
and our findings were consistent with this observation. Pool D contained ~ 15- 
times more CS-PG than pool A and showed a higher LDL binding reactivity 
(Table 3.2). The next most abundant GAG species was keratan sulphate as 
described previously (Ogema et al 1979, Kapoor et al 1981) and a small 
amount o f hyaluronic acid (11%) (most hyaluronic acid remains in the residual 
tissue ( Kapoor et al 1981)). DS-PG was present in the lower density fractions 
(pool A&B) (Table 3.3) but not in pool D used in the assay. Since dermatan 
sulphate has been shown to be on the same GAG chain as C-4 -S0 4  (Berenson et 
al 1986), this finding suggest that the CS present in pool D is mainly o f C-6- 
SO4 . In addition amino acid analysis showed similar results as the 
proteochondroitin-6-sulphate isolated by Kapoor el al (Kapoor et al 1981). 
Heparan sulphate is resistant to Gdn-HCl extraction (Berenson et al 1986, 
Salisbury & Wagner 1981, Kapoor et al 1981) therefore was only present in 
traces in the APG preparation. The CS-PG which binds most avidly to LDL 
has been described to be a C-6-S04 isomer with a large protein core (Breneson 
et al 1986) and a high molecular weight ( Wagner et al 1986, Alves & Mourao 
1988) and oversulphation rather than chain length has been shown to be 
important in the binding process (Sambandam et al 1991). In the present study 
fiirther characterisation of the CSPG with regard to ehain length or the degree 
o f sulphation was not performed, rather the limited amount of material from a 
single aorta was used in all binding assays to reduce the potential APG variation 
and reveal lipid and lipoprotein factors that affected binding. In-vitro, optimal 
binding o f LDL to APG occurs near physiological pH and ionic strength (Steele 
& Wagner 1987) and the interaction is known to be a function of charge 
(Camejo et al 1985b). It has been suggested that LDL with a high isoelectric 
point and a low sialic acid content is particularly reactive towards APG (Camejo 
et al 1985, Hurt-Camejo et al 1990). Olsson et al (Olsson et al 1993) have 
recently identified a peptide segment of apoB, rich in arginine and lysine
" i
residues, which appears to be the principal site mediating the APG-LDL
I
■Î
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interaction. They have also shown that patients with acute or chronic CHD 
show increased reactivity o f then LDL for APG ( Camejo et al 1989) and 
suggest that APG can distinguish from within total LDL a subclass with a higher 
isoelectric point, a lower ratio of surface to core lipids and a higher affinity for 
CS-APG that is present variably in different individuals (Hurt-Camejo et al 
1990). The present study builds on these earlier observations by providing 
evidence that the APG-LDL interaction is indeed highly variable and related to 
the plasma lipid profile and distribution o f LDL subfractions.
Total LDL was chosen as the substrate for the reaction with APG because it is 
the complete lipoprotein class that is presented to the arterial wall o f an 
individual. Plasma or serum was not used to eliminate the effect of other 
factors present in plasma which can affect the interaction such as plasma 
frbronectm which inhibit LDL-APG complex formation (Kampen et al 1989, 
Labat-Robert et al 1990) or Lp(a) level which has a higher affinity to APG 
(Bihari-Vai-ga et al 1988). LDL is known to be heterogeneous and composed 
of at least tlnee subpopulations (Griffin et al 1990), the distribution of which in 
a subject is strongly influenced by plasma triglyceride and HDL levels (Griffin et 
al 1994), the presence o f insulin resistance syndrome (Reaven et al 1993) and 
by gender. We found that variation in HDL (consistent with previous findings 
by Camejo (Camejo et al 1980b)) levels and plasma triglyceride was associated 
with altered reactivity of total LDL towards APG (Figure 3.13, 3.14) and 
hypothesised that these influences derived from metabolic disturbances which 
altered LDL structure (GrifSn et al 1994). When the LDL subfraction pattern 
itself was related to APG reactivity, it was observed that there was a negative 
association with the relative abundance of the least dense LDL-I (which is found 
in high concentration in the plasma o f young females and is thought not to be 
atherogenic (Griffin et al 1994)) and a positive association with the relative 
abundance of small dense LDL-III. This subfraction is present in liigh 
concentrations in the plasma of subjects with CHD and is believed to be the 
most atherogenic LDL species, in part, because it is readily oxidised (deGraaf et 
al 1991), a pre-requisite step in the uptake of lipoproteins by macrophages. 
The variation in the LDL-APG binding for the same value of LDL-I or LDL -III 
in different individuals might be due to different medications taken by the
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patients such as beta-blockers which has been described to lower LDL-APG 
interaction (Linden et al 1990). An ALP is the most eommon dysiipidaemia 
seen in MI survivors (Griffin et al 1994, Austin et al 1990) and it was observed 
that when patients were divided into those who had an LDL-III above or below 
lOOmg/dl, the group with the higher LDL-III concentration show significantly 
greater reactivity for APG. The difference in the LDL subfi’action profile 
(LDL-III is, in general, more prevalent in males) was also the likely cause of the 
sex difference. If the reactivity between APG and LDL is due to specific 
epitopes present on apoB (Kinoshita et al 1990) as opposed to differences in 
lipid and carbohydrate content ( Camejo et al 1985) then our findings suggest 
that this binding site may be differentially expressed in individuals and revealed 
to a greater extent in small dense LDL. This proposal accords with the 
knowledge that the conformation of apoB is influenced by LDL particle size 
(Galeano et al 1994). These findings help to explain, in part, the association of 




Interaction of very low density, intermediate density 
and low density lipoproteins with arterial wall 
proteoglycans...
Most investigators now agree that one or more apoB containing lipoproteins 
either in their native form or modified by oxidation or complex formation is 
responsible for cholesterol deposition in the artery. The atherogenic role of low 
density lipoprotein, especially small dense LDL, is well established by
■ i"'
epidemiological studies, clinical findings and controlled trials (Gordon et al 
1977, Frick et al 1987, LRCF 1984a, 1984b). One possible mechanism by 
which LDL can cause atherosclerosis is its interaction with arterial wall 
proteoglycans (APG). APG, especially chondroitin sulphate proteoglycans (CS- 
PG), have long been known to specifically interact with apoB containing 
lipoproteins mainly LDL, LP(a) and to a lesser extent VLDL, but not HDL 
(Vijayagopal et al 1981, Bihari-Varga et al 1988, Camejo et al 1980a; 1980b;
1985, Srinivasan et al 1989, Olsson et al 1993, ). This interaction leads to their 
entrapment, modification and uptake by macrophages in the intimai extracellular 
space leading to foam cell formation.
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The isolation of LDL from atherosclerotic lesions, the higher affinity of LDL 
from survivors of myocardial infarction towards APG by in-vitro binding assays 
(Srinivasan et al 1975, Camejo et al 1985a, Linden et al 1989) and our findings 
of the positive association between atherogenic lipoprotein phenotype (ALP) 
and APG-LDL complex formation (Chapter 3, Anber et al 1996) provides 
further evidence for the atherogenicity o f LDL. There is now evidence that 
VLDL and IDL have atherogenic potential too. They have also been isolated 
from atherosclerotic plaque and have been shown to enter the arterial wall and 
share with low density lipoprotein (LDL) the potential for causing lipid 
accumulation ( Shaikh et al 1991, Nordestgaard et al 1992, Nordestgaard& 
Nielson 1994). Their low efflux rate due to their particle size (Nordestgaard et 
al 1992) augments the rate o f cholesterol delivery to the arterial wall as they 
contain 5 or more times cholesterol and cholesteryl ester per particle than LDL 
(Mahley et al 1979).
We have shown that individuals with an increase percentage of LDL III (small 
dense LDL) possess LDL with a greater binding affinity towards APG ( Chapter 
3, Anber et al 1996) an extension o f the interesting finding by Hurt-Camejo et 
al (Hurt-Camejo et al 1990) that when APG was used to fr actionate LDL it had 
a preference for small dense LDL. However the absolute reactivity o f each 
subfraction within an individual is not known nor the relative reactivity of 
lipoprotein species across the Sf 0-400 spectrum. Lipid lowering treatment with 
fibrates affects both plasma triglyceride and cholesterol and is associated with a 
change in the LDL subfraction profile (Caslake et al 1995). Recently it has 
been shown that a number of lipid lowering therapies reduce total LDL binding 
with APG (Wiklund et al 1996). To explore further the mechanism of this 
binding process and to support the concept that triglyceride rich lipoprotein 
particles (TGRL) are atherogenic we undertook a series o f studies, the 
objectives of which were: 1) to compare the reactivity of different apoB 
containing lipoprotein subfractions with APG, 2) to test the effects of lipid 
lowering treatment with ciprofibrate, which changes an individuals LDL 
subfraction pattern, on different apoB containing lipoprotein subfractions and 
their interaction with APG.
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4.2 Subjects
A total o f twenty eight subjects were recruited for both studies. All donated 
50ml o f blood after an overnight (12h) fast. Fasting blood was collected by 
venepuncture using K2EDTA (final concentration 1 mg/ml) as an anticoagulant. 
Plasma was separated at 4°C by low speed centrifugation (3000rpm) and 
aliquots for lipid, lipoprotein measurements and LDL sabh^actionation used 
immediately.
4.2.1 Study I: The reactivity of different apoB containing lipoproteins with 
APG
Eighteen subjeets aged 19-60 years were divided into three groups (six subjects 
in each group) on the basis o f their LDL subfi-action profile and the presence or 
absence of ALP (Table 4.1). Group I were young healthy normolipidemic, aged 
19-22 years, (5 female and 1 male) whose LDL profile predominated by LDL-I, 
group II were healthy normolipidemic (2 female and 4 male) aged 34-46 years, 
had mainly LDL-II profile, and group III were hyperlipidémie (1 female and 5 
male) aged 39-60 years with a profile in which LDL-III was the major species 
present.
4.2.2 Study II: The effect of lipid lowering treatment with Ciprofibrate on 
APG-Lipoprotein interaction
Twelve male patients aged 40-60 yr. were selected on the basis of their cardiac 
catheterisation results (all with angiographically positive coronary artery 
disease) fi’om the cardiac catheterisation unit at the Glasgow Royal Infirmary. 
They had a total cholesterol >5.2mmol/l and a plasma triglyceride <3.5mmol/l. 
Baseline assessment of lipid and lipoprotein levels, LDL subfiraction profile and 
APG reactivity were performed. Patients were then commenced on eiprofibrate 
lOOmg/day for 8 weeks. After the eighth week a second assessment o f lipids 
and lipoprotein levels, LDL subfi-action profile and APG reactivity were 
performed. The characteristics of each patient are summarised in Table 4.1.
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All the patients studied were receiving prescribed medications for other clinical 
conditions, and these were continued unchanged throughout the course o f the 
study.
Ciprofibrate was well tolerated by all subjects participating in the study. Two of 
the patients withdrew fi*om the study, one had a myocardial infarction and the 
other could not continue because of difficulty in commuting..
The following Exclusion Criteria were applied:
1. any Hpid lowering medications at the time or up to 6 weeks before 
recruitment.
2. known or suspected hypersensitivity to the fibrate group of drugs.
3. a reeent MI (i.e. in the previous 3 to 6 months).
4. signs o f renal or hepatic impairment or thyroid disease.
5. diabetics or had an impaired glucose tolerance test.
6. consumption o f more than 22 units of alcohol per week.
Both studies were approved by the Research Ethics Committee of Glasgow 
Royal Infirmary and each volunteer gave written informed consent.
4,3 Statistical analysis
Statistical analysis and manipulation were performed using MINITAB release 
10 for windows (Minitab Inc., PA). Pearsons correlation , simple regression, 2 
sample t-test and one way analysis o f variance (ANOVA) were used to asses 
the relationship between variables.
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4.4 Results
4.4.1 Study I: Lipid and LDL subfraction profile
Mean plasma lipid level and LDL subfraction profile for the three groups of subjects 
are shown in Table 4.2. A one way analysis of variance showed that plasma total 
cholesterol, triglyceride level and LDL subfraction profile in Group III subjects were 
significantly different from groups I & IT subjects (p<0.0001). Group I & II had 
similar lipid levels but differed in their LDL subfraction profile p<0.0001 (Table 4.2) 
(Fig 4.1).
Figure 4. 1
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ApoB containing plasma lipoproteins (VLDL, IDL, and LDL) were subfractionated 
from fresh plasma by a modification of a previously published cumulative density 
gradient ultracentrifugation procedure (Lindgren et al 1972), as described in chapter
2. Six subfractions, two from each lipoprotein class were obtained from each subject,
i.e. VLDLl S f (Svedberg flotation rate) (60-400), VLDL2 S f (20-60), IDLl S f (16- 
20), IDL2 S f (12-16), LDL A S f (8-12) and LDL B S f (0-8) (Table 4.3).
VLDLl, VLDL2 and LDLB fractions were significantly different between the three 
groups o f subjects. They were higher in group III compared to group I & II subjects. 
Table 4.3 shows that there were no significant differences between the IDLl, IDL2 
and LDLA mass among the three groups o f subjects.
Total plasma apoB containing lipoprotein mass was significantly lower in groups I & 
II (327mg/dl & 334mg/dl respectively) compared to group III subjects (605mg/dl) 
p<0.001 (Fig 4.2).
Figure 4.2
Total apolipoprotein B containing lipoprotein mass among the three groups of 
subjects
G ro u p  I
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G ro u p  III —
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T o ta l l ip o p ro te in  m ass
800
Group I, young healthy normolipidemic with predominantly LDL-I suhfraction 
profile, Group II, normolipidemic with predominantly LDL-II profile, Group III, 
hyperlipidémie with predominance o f  small dense LDL. The inner box represents 25- 
75 percentile, the median value is indicated by a vertical line, the outer box 
represents the 5th and the 95th percentile, while the range o f  values are indicated by 
the horizontal line. The total lipoprotein mass was lower in group I  & I I  compared 
to group II (p<0.0001).
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4.4.2 ApoB containing lipoprotein subfractions and APG complex formation
The amount o f cholesterol precipitated by interaction with APG measured directly in 
the precipitate or calculated by subtraction o f the supernatant from the blank divided 
by the total cholesterol correlated highly significantly with the turbidity measurement 
by absorbance at 600nm (Fig 4.3). Therefore we used the latter in our analysis as the 
more convenient index for the amount of complex formed.
Figure 4.3
Correlation between turbidity as measured by absorbance unit (AU) at 600nm 
and the amount of cholesterol precipitated measured after the dissociation of the 
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% precipitated cholesterol, the amount o f  lipoprotein cholesterol precipitated by 
AFG divided by the total cholesterol applied multiplied by 100.
A  similar pattern o f lipoprotein-APG complex formation was observed in all 
individuals (Fig 4.4).
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The relative reactivity o f  the different apoB containing lipoproteins with APG were 
compared by adding 0.1 mg apoB to fixed concentration o f  2.5pg /ml APG. The 
graph represents the median value fo r  the APG reactivity o f  each lipoprotein as 
measured by absorbance at 600nm and the % cholesterol precipitated by APG.
The mean reactivity for the lipoprotein sublfactions in the three groups was highest in 
IDL2 and LDLA followed by LDLB and IDLl and the least reactivity was observed 
in the VLDL subfractions (Fig 4.5). The highest APG reactivity for all fractions was 
found in group III i.e. those with raised lipid levels and a predominance of small dense 
LDL, intermediate in group II normolipidemic subjects with mainly LDLII subfraction 
and lowest in group I young healthy subjects with a high LDLI level (Fig 4.5). This 
pattern supports our previous findings (chapter 3, Fig 3.19; 3.20) of the positive 
correlation between the percentage of LDLIII, and the negative correlation between 
the percentage of LDLI within total LDL, and the extent of APG -LDL complex 
formation (Anber et al 1996).
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the percentage of LDLI within total LDL, and the extent of APG -LDL complex 
formation (Anber et al 1996).
Figure 4.5
The pattern o f lipoprotein-APG interaction of the different lipoprotein 
subfractions with arterial wall proteoglycans.
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*p<0.0001, **p= 0.007
The relative reactivity between the three different groups o f  subjects were compared 
by adding 0.1 mg apoB to a fixed concentration o f  APG. The graph represents the 
median value fo r each lipoprotein subfractions with standard error bars in all the 
subjects, the line is median connect. O; group I, M; group II, ♦ ;  group III.
4.4.3 Study II: Effect of ciprofibrate treatment on APG-Lipoprotein complex
formation
Lipid lowering treatment with ciprofibrate resulted in a significant decrease in total 
cholesterol (18%, p=0.039), plasma triglyceride (44%, p<0.05), a 10% reduction in
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Figure 4. 6
LDL subfraction profile of the patients before and after treatment with 















LDL subtraction profile at base line (------- ) and after ( )ciprofibrate treatment.
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A significant reduction in the total plasma apoB containing lipoprotein mass was 
found after lipid lowering treatment (703 mg/dl ±185 vs 524 mg/dl ± 140, p<0.04). 
VLDLl mass was significantly decreased by 57% (p<0.05). There was a 47% and 
26% decrease in VLDL2 and IDLl mass respectively and an 18% increase in IDL2 
mass (Table 4.5). The increase in LDLA (33%) and the decrease in LDLB (25%) 
(Table 4.5) was due to the shift o f the LDL subfraction profile from LDL-III to LDL- 
I with ciprofibrate treatment.
Table 4.5
ApoB containing lipoprotein mass before and after ciprofibrate
Lipoprotein subfractions Ciprofibrate treatment*
Before After p
VLDLl* mg/dl 207 ± 128 90 ± 72 =0.03
VLDL2* mg/dl 112 ± 83 60 ± 32 0.13
IDLl* mg/dl 59 ± 47 44 ± 36 0.48
IDL2* mg/dl 50 ± 12 59 ± 10 0.16
LDLA* mg/dl 112 ± 57 150 ± 32 0.14
LDLB* mg/dl 161 ± 65 121 ± 40 0.17
"^ciprofibrate treatment lOOmg/day fo r  8 weeks; * lipoprotein mass, Very low density 
lipoprotein =VLDL1 (Sf 60-400) and VLDL2 (Sf 20-60), intermediate density 
lipoprotein ^  IDLl (Sf 16-20) and IDL2 (Sf 12-16), low density lipoprotein = LDLA 
(Sf8-12) and LDLB (SfO-8).
The lipid lowering effect o f ciprofibrate on the compositional analysis o f the 
lipoprotein subfractions was significant mainly in reducing the percentage triglyceride 
(p<0.05) and phospholipid (p<0.05) in the VLDLl fraction (Table 4.6). It also 
decreased the ability of each lipoprotein subfraction to form complexes with APG. 
IDL l, IDL2 and LDLA reactivity were significantly reduced by 54% (p=0.03), 49% 
(p^O.006) and 40% (p==0.03) respectively and that of small dense LDL by 42% but 
this was not statistically significant (Table 4.7) (Fig 4.7). There was little or no 
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Figure 4.7
Lipoprotein-APG relative reactivity of the different lipoprotein subfractions 
before and after treatment with Ciproflbrate (lOOmg/day for 8 weeks) compared 
by adding 0.1 mg apoB to a fixed concentration of APG.
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Lipoprotein subfractions
The graph represents the median value for each lipoprotein suhfractions with 
standard error bars in all the subjects, the line is median connect. ■; before 
ciproflbrate, □; after treatment with ciproflbrate. * p= 0.006, ** p=0.03,
***p=0.037.
The amount of precipitated apoB in each lipoprotein subfraction was calculated by 
multiplying the percentage o f precipitable apoB (derived from the percentage of 
precipitated cholesterol multiplied by the apoB/cholesterol ratio) by apoB 
concentration of each subfraction. From this data it was seen that the biggest changes 
were seen in the LDL range rather than the IDL (Fig 4.8) i.e. ciproflbrate was 
effective in reducing the number of APG reactive LDL particles more than any o f the 
other lipoprotein species.
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Figure 4.8
The total amount of apoB precipitated in different lipoproteins by APG, before 
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The amount o f  precipitated apoB in (mg) was calculated by multiplying the 
percentage o f  precipitable apoB (derived from the percentage o f  precipitated 
cholesterol multiplied by the apoB/cholesterol ratio) by apoB concentration in each 
lipoprotein subfraction, before (  %) ; and after (O ) treatment with Ciproflbrate.
4.5 Discussion
Structural diversity exists throughout the apoB containing lipoprotein spectrum. High 
resolution centrifugation or electrophoretic techniques have been employed to 
demonstrate the presence o f discrete subfractions within VLDL (Lindgren et al 1972, 
Packard et al 1984), IDL (Musliner et al 1986) and LDL (Griffin et al 1990, Krauss 
1994). These all have varying functional and metabolic properties and are likely to 
differ in their atherogenic potential. LDL in particular has been shown to consist of 
discrete subpopulations o f particles, o f which the small dense species have been most 
closely linked to increased risk of CHD (Krauss 1994). The observation that the
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strength o f the interaction between LDL and APG was related to the subfraction 
profile (Anber et al 1996) and the knowledge that small dense LDL was but one 
component o f the dyslipidaemia termed the atherogenic lipoprotein phenotype (Austin 
et al 1990) prompted us to seek further abnormalities within the Sf  0-400 lipoprotein 
spectrum. The principal finding of the present study was that a small dense IDL 
fi-action and large LDL were the most reactive species towards APG. This 
contradicted our initial supposition that there would be a monotonous increase in 
APG reactivity fi*om VLDLl through to LDLB. If APG trapping of lipoprotein is, as 
we believe, a key early step in atherogenesis, then the data provide strong support for 
the suggestion that IDL is a particularly atherogenic lipoprotein (Rapp et al 1994, 
Tatami a / 1981, Steiner et al 1987, Krauss et al 1987).
The pattern o f APG-lipoprotein interaction was remarkably similar in all subjects 
studied regardless o f their plasma lipid levels (Fig 4.5). However between individuals 
the relative reactivity of each lipoprotein subclass increased as the plasma triglyceride 
level and the proportion of LDLIII rose. Furthermore in subjects treated with 
ciprofibrate, the reactivity of aU species fell in concert, with again the same general 
pattern being maintained. The basis o f lipoprotein-APG interaction tliroughout the Sf  
0-400 spectrum is unknown, although for LDL the work of Olsson et al (Olsson et al 
1993) pinpointed certain sequences of apoB as important. What is suggested by the 
data in Figures 4.5 and 4.7 is that the relative reactivity of VLDL2, IDLl, 1DL2, 
LDLA and LDLB are linked, probably by a common denominator. The findings also 
provide further insight into possible association between plasma triglyceride 
concentration and CHD risk.
On the basis o f current knowledge, two mechanisms can be postulated to explain the 
link between the plasma triglyceride concentration and lipoprotein-APG reactivity. 
First, high levels of plasma triglyceride may cause remodelling o f IDL and LDL to 
more atherogenic forms. As plasma triglyceride rises so does the extent of cholesterol 
ester transfer protein mediated triglyceride exchange into denser lipoproteins such as 
LDL and HDL. Lipolysis o f these triglyceride-enriched particles results in the 
generation o f smaller and denser lipoproteins (Patsch et al 1984, Tan et al 1995). It 
is tempting to speculate that IDL is affected in the same way and that small, dense 
IDL are active in binding APG. Second, it can be argued that APG reactive species
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within the IDL and LDL density intervals are the products o f the lipolysis of large 
VLDLl. Metabolic studies have shown that VLDLl is converted to VLDL2 
remnants, IDL and LDL particles that have a prolonged residence time in circulation 
compared to lipoproteins whose initial precursor is in the VLDL2 density range 
(Packard et al 1984). The properties o f IDL and LDL particles which circulate for a 
long time in plasma may be modified, for example by altered surface glycosylation or 
oxidation, to enhance their APG binding. When VLDLl levels fall on ciprofibrate 
(the major change in the Sf 0-400 ) possibly due to decreased hepatic secretion (Gaw 
& Shepherd 1991) so does the relative reactivity o f IDL and LDL.
We conclude that an ALP leads to abnormalities throughout the apoB containing 
lipoprotein spectrum and that the enrichment o f VLDL2, IDL and LDL in lipoprotein 
species which bind avidly to APG is one o f the ways in which elevated plasma 
triglyceride levels contribute to the atherogenic process. These abnormalities are 
coiTected by appropriate lipid lowering therapy.
Chapter 5
Sialic acid and Neutral carbohydrate concentration 
and APG binding. ••
5.1 Introduction
Low density lipoprotein (LDL) is known to be composed o f a population of 
particles different in size and density, that can be identified either by 
polyacrylamide gel technique into two subclass pattern A or B (Austin et al 
1988) or by density gradient ultracentrifugation to three LDL subfiractions, 
LDLI, LDLII and LDLIII. These subtractions are present in each individual in 
differing proportions (Griffin et al 1990). Pattern A or LDLI are characterised 
by large particles with a higher buoyant density that are present mainly in young 
healthy males and premenopausal female subjects. Pattern B or LDLIII are 
smaller and denser and are present predominantly in patients with CHD (Austin 
e fa / 1988, Griffin et al 1990). Small dense LDLIII is strongly associated with 
the plasma triglyceride level, both o f which are key components o f the 
atherogenic lipoprotein phenotype (ALP). ALP is a recognised feature o f the 
insulin resistance syndrome and is associated with a 3-7 fold increase in risk of 
MI (Austin et al 1990).
Although triglyceride rich particles may be atherogenic per se, much o f the 
attention has been directed to their modulatory effect on the substructure of
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LDL and HDL and in particular on the link between raised triglyceride and small 
dense LDLIII. The later has been shown to be enriched with PUFA mainly 
linoleic acid which increases its oxidative susceptibility leading to cholesteryl 
ester accumulation and foam cell formation (de Graaf et al 1991, Reaven et al 
1993) compared to LDLI. In addition we have shown a positive correlation 
between the percentage o f LDLIII within total LDL, i.e. the presence o f ALP, 
and APG-LDL complex formation Anber et al 1996, chapter 3).
The question arises as to whether there are other structural differences between 
the LDL subtractions that may relate to the genetic basis o f the LDL subfraction 
profile and that might contribute to differences in their atherogenicity and the 
coronary disease risk associated with differing patterns.
LDL subfractions have been shown to differ in their carbohydrate and sialic acid 
content (LaBelle & Krauss 1990, Tertov et al 1993). Labelle and Kraus 
observed that large LDL from pattern A contain higher neutral carbohydrate 
and sialic acid compared to LDL from pattern B (LaBeklle & Krauss 1990). 
This has been supported by the findings o f Tertov in which siahc acid poor 
(SAP) LDL fraction, isolated by Ricin-agglutinin, from CHD patients contained 
less carbohydrate and sialic acid than sialic acid rich (SAR) LDL from the same 
individuals and normal subjects (Tertov et al 1993). Siahc acid content o f LDL 
has been related to its capacity to stimulate intracellular hpid accumulation 
(Orekhov el al 1992, Sobenin et al 1991) and Camejo has suggested that LDL 
with low siahc acid content binds to a greater extent to APG (Camejo et al 
1985b). Taken together, these findings suggest that desialation and low 
carbohydrate content may increase the atherogenicity of LDL.
Carbohydrate accounts for 4-9% o f the mass of the single large glycoprotein 
(=550KD), apoB, present in LDL (Vauhkonen et al 1985, Swaminathan & 
Aladjem 1976), 37% o f which is high mannose. ApoB high mannose residue 
contributes about 10% of the total high mannose chains present in plasma 
(Vauhkonen et al 1985). This gives LDL the unique property of a high binding 
affinity to the sugar binding lectin Concanavalin-A (Con-A), a 
phytohemagglutinin isolated from Jack bean (Fig 2.5, Chapter 2), which has 
been used to characterise soluble and membrane bound glycoproteins 
(McConathy & Alaupovic 1974, Tavella et al 1991).
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LDL has been isolated from human plasma by con-A affinity chromatography, 
since it binds avidly to the lectin in contrast to VLDL and HDL (Tavella et al 
1991). In fact, the later does not bind at all (Mitamura 1981). The unbound 
fraction in LDL accounts for 4-5%, the strongly bound fraction accounts for 
37% which is the high mannose structure (Vauhkonen et al 1985) and the rest 
are weakly bound including sialic acid (Harmony & Cordes 1975).
The aim of this study was: i) to determine the association between LDL total 
carbohydrate and LDL subfraction distribution and plasma lipid level, ii) to 
separate LDL subfractions on the basis of carbohydrate content by affinity 
chromatography on Concanavalin-A and examine the ability of the eluted 
fractions to interact with APG, hi) to determine the influence o f sialic acid 
concentration o f apoB containing hpoproteins and their interaction with APG, 
and finally iv) to examine the effect o f hpid lowering treatment with ciprofibrate 




A total of seventy five subjects were recruited for ah the studies. Ah donated
50ml o f blood after an overnight (12h) fast. Fasting blood was cohected by
venepuncture using K2EDTA (final concentration 1 mg/ml) as anticoagulant.
Plasma was separated at 4°C by low speed centrifiigation (3000rpm) and
ahquots for hpid, lipoprotein measurements and LDL subfractionation used
.immediately. Subjects with recent MI (i.e. in the previous 6 months), renal
disease, thyroid disease, diabetes or those taking hpid-lowering medications 
were excluded, as were those with a plasma cholesterol concentration of 
>9.0mmoFl and a plasma triglyceride level o f >5.0mmol/l. All ehgible subjects 
undergoing angiography were recruited to the study over a 6 month period. 
The study was approved by the Research Ethics Committee of Glasgow Royal 
Infirmary and each volunteer gave written informed consent.
I
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5.2.1 Study la: LDL carbohydrate measurement, its relation to the LDL
subfraction profile and APG-LDL complex formation
Thirty five subjects were recruited for this study (15 normal volunteers and 20 
patients undergoing diagnostic coronary angiography in the Department of 
Medical Cardiology, Glasgow Royal Infirmary). Carbohydrate measurement 
was performed by the phenol sulphuric acid method (Dubois et al 1956, Beely 
1985) on total and LDL subfractions prepared by sequential gradient and 
density gradient centrifugation respectively as described in the method section 
(Chapter 2).
5.2.2 Study Ib: Separation of LDL subfraction on the basis of their 
carbohydrate content by affinity chromatography on Con-A.
Total LDL firom a subgroup o f 18 subjects (9 normal and 9 CHD) was used for 
this. Total LDL was applied to column containing 8mls Con-A Sepharose as 
described in chapter 2.
5.2.3 Study II: Sialic acid concentration of apoB containing lipoproteins and its 
influence on APG-lipoprotein reactivity
Twenty eight subjects were examined in this study. Eighteen o f which, aged I9­
60 years, were divided into three groups (six subjects in each group) on the 
basis o f their LDL subfraction profile and the presence or absence of ALP 
(Table 4.1, Chapter 4). Group 1 were young healthy normolipidemic, aged 19- 
22 years, (5 female and 1 male) whose LDL profile predominated by LDL-I, 
group 2 were healthy normolipidemic (2 female and 4 male) aged 34-46 years, 
had mainly LDL-II profile, and group 3 were hyperlipidémie (1 female and 5 
male) aged 39-60 years with a profile in which LDL-III was the major species 
present (chapter 4). The data Ifom the ten male subjects recruited for the 
ciprofibrate study prior to treatment, whose characteristics are described below, 
was included.
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5.2.4 Study III: The effect of lipid lowering treatment with Ciprofibrate on 
sialic acid content of apoB containing lipoproteins and APG-Lipoprotein 
interaction
Twelve male patients aged 40-60 yr. were selected on the basis of their cardiac 
catheterisation results (all with angiographically positive coronary artery 
disease) from the cardiac catheterisation unit at the Glasgow Royal Infirmary. 
They had a total cholesterol >5.2mmol/l and a plasma triglyceride <3.5mmol/l. 
Baseline assessment of lipid and lipoprotein levels, LDL subfraction profile, 
sialic acid and APG reactivity were performed. Patients were then commenced 
on ciprofibrate lOOmg/day for 8 weeks. After the eighth week a second 
assessment of lipids, lipoproteins, LDL subfraction profile and APG reactivity 
were performed. The characteristics of each patient are summarised in Table
4.1 (Chapter 4). All the patients studied were receiving prescribed medications 
for other clinical conditions, and these were continued unchanged throughout 
the course o f the study. The exclusion criteria which applied are summarised in 
section 4.2.2 (Chapter 4).
Ciprofibrate was well tolerated by all subjects participating in the study. Two of 
the patients withdrew from the study, one had a myocardial infarction and the 
other could not continue because of difficulty in commuting.
5.3 Statistical analysis
Statistical analysis and manipulations were performed using the PC version of 
MINITAB Release 10 for Windows (Minitab Inc., PA). All variables were 
assessed by drawing normafity plots and the ones which were not normally 
distributed were normalised by appropriate transformations. Plasma triglyceride 
was normalised by log transformation, and LDLI, LDLII, LDLIII 
concentrations and HDL cholesterol were normalised by taking their square 
root, associations between variables were tested by calculating the pearson 
correlation coeffecient. The significance of association between variables was 
determined by simple regression, 2 sample t-test and one way analysis of 
variance (ANOVA) were used to asses the relationship between variables.
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5.4 Study I
5.4.1 lipid and LDL subfraction profile
In general (as we have shown in chapter 3, Table 3.6), plasma triglyceride level 
was positively correlated with total cholesterol (r= 0.45, p<0.0001) and LDL 
cholesterol (r=0.43, p< 0.001) within the plasma and negatively correlated with 
HDL cholesterol (r=-0.57, p<0.0001). Plasma triglyceride was also the 
strongest and most constant correlate of LDL subtraction profile showing a 
negative correlation with the percentage and concentration of LDL-I (r= -0.44, 
p<0.001) and LDL-II (r= -0.40, p<0.001) and a positive association with small 
dense LDL-III (r= 0.64, p<0.0001) within total LDL.
Mean plasma lipid levels and LDL subfraction profile in both groups o f subjects 
(normal volunteers and coronary heart disease patients) are shown in Table 5.1.
Table 5. 1
Mean Plasma lipid and LDL subfraction profile in the normal volunteers 
and the CHD patients.




Age 33.0 ± 6.6 56.4 ± 8.8*
Total cholesterol mmol/1 4.9 + 0.8 5.8 ± 1.1**
LDL cholesterol mmoPl 3.0 ± 0.8 3.9 ± 0.9**
HDL cholesterol mmol/1 1.6 ± 0.3 1.1 ± 0.3**
plasma triglyceride mmoPl 0.9 ± 0.3 1.7 ± 0.9*
APG-LDL complex AU 0.32 ± 0.1 0.41 ± 0.2***
%LDL-I 25 ± 12.4 15 ± 10.1***
%LDL-II 61 ± 11.7 52 ± 14.5
%LDL-III 15 ± 4.9 32 ± 19.5*
*p<0.001, **p<0.01, CHD, coronary heart disease; APG-LDL
complex determined by turbidity measurement by AU, absorbance unit at
600nm visible wavelength, Values represent mean ±  standard deviation.
5.4.2
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The patients with coronary heart disease were older (p<0.0001), had a higher 
plasma total cholesterol (p<0.01), plasma triglyceride (p<0.001), LDL 
cholesterol (p<0.01) and a lower HDL cholesterol concentration in plasma 
(p=0.002), compared to the normal volunteers (Table 5.1). They also had a 
different LDL subfraction profile where the former had lower LDLI (p<0,05) 
and a higher small dense LDLIII (p<0.001) within total LDL (Table 5.1).
Neutral carbohydrate, LDL subfraction profile and APG-LDL binding 
reactivity
The neutral carbohydrate concentration in the LDLI subfraction (175.4 pg/mg 
apoB ± 51.0) was significantly higher compared to its concentration in smaU 










C a rb o h y d ra te  c o n ce n tra tio n  (ug /m g ap o B )
300
The inner box represents the 25-75 percentile, the median value is indicated by 
a vertical line, the outer box represents the 5th and the 95th percentile while 
the range o f  values are indicated by the horizontal lines. p< 0.001
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Low density lipoprotein Carbohydrate content
normal CHD
LDL-I 192.0 ± 49.4 166.7 ± 51.0 =0.21
LDL-II 183.8 ± 47.8 163.8 ± 50.8 =0.31
LDL-III 137.9 ± 66.6 111.7 ± 35.2 =0.28
T-LDL 165.4 ± 19.1 143.9 ± 33.6 <0.04
-t
Table 5.2 shows the mean neutral carbohydrate concentration of total and LDL 
subfractions in both normal volunteers and CHD patients. The former had 
higher carbohydrate in total and LDL subfractions compai'ed to the later. This 
was only statistically significant for the total LDL (Table 5.2).
Table 5.2
Neutral carbohydrate concentration (pg/mg apo B) of total and LDL 
subfractions. Comparison between the patients and normal volunteers.
T- LDL, total low density lipoprotein (d=l.019-1.063 g/ml); LDL-I, large 
buoyant low density lipoprotein (d= l.025-1.033 g/ml); LDL-II, intermediate 
low density lipoprotein (d= l.033-1.043 g/ml); LDL-III, small dense low 
density lipoprotein (d ^ l .044-1.060 g/ml); CHD, coronary heart disease 
patients
Pearsons correlation was used to examine the relationship between total LDL
carbohydrate, hpid variables and the APG-LDL reactivity. Total LDL 
carbohydrate was not significantly correlated with plasma total cholesterol, LDL 
cholesterol, HDL cholesterol or plasma triglyceride (Fig 5.2) (Table 5.3), LDL- 
I subfraction contained more carbohydrate than LDLIII (Table 5.2), however 
the carbohydrate concentration of total LDL did not correlate with the LDL 
subfraction profile (Table 5,4) (Fig 5.3).
As we have shown before (chapter 4), the extent of APG-LDL complex 
formation was positively correlated with plasma triglyceride (p=0.04) and the 
concentration o f small dense LDL (p=0.007) within total LDL and negatively 
correlated with HDL cholesterol (P=0.02) and LDLI concentration within total 
LDL (P<0.01) (Table 5.3, 5.4). However, the APG binding reactivity showed g
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no significant correlation with the amount of carbohydrate in total LDL (Table 
5.3).
Figure 5.2
correlation between total LDL carbohydrate content and plasma lipids.
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T-Cholesterol, plasma total cholesterol (mmol/l); HDL-C, high density 
lipoprotein cholesterol (mmol/l); Triglyceride; plasma triglyceride (mmol/l).
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Figure 5.3
Correlation between total LDL carbohydrate and the LDL subfractions.
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%LDL-I, %LDL-I1, %LDL-III, percentage o f  large LDLI , intermediate LDLII 
and small dense LDLIII within total LDL.
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Table 5. 3
Correlation between the mount of carbohydrate in total LDL, subjects 
lipid variables and the extent of APG-LDL interaction.
Variable CHO APG-LDL
complex
Age -0 .09 0.15
Total cholesterol mmol/l 0.06 0.10
LDL cholesterol mmol/l 0.13 0.22
HDL cholesterol mmol/l 0.06 - 0.38*
plasma triglyceride mmol/l -0 .20 0.36*
T-CHO — 0.23
APG-LDL complex AU 0.23
^p<0.05; CHO, neutral carbohydrate; CHO, total LDL neutral
carbohydrate concentration; APG-LDL complex determined by turbidity 
measurement by A U, absorbance unit at 600nm visible wavelength, values 
represent pearsons correlation coefficient.
Table 5. 4




%LDL-I 0.05 - 0.43*
%LDL-1I 0.05 -0 .2
%LDL-III -0.1 0.45*
*p<0.01, CHO, neutral carbohydrate; APG-LDL complex determined by 
turbidity measurement by A U, absorbance unit at 600nm visible wavelength, 
values represent pearsons correlation coefficient.
5.4.3 LDL fractions eluted from affinity chromatography of total LDL on Con-A
Affinity chromatography o f total LDL (d= 1.019-1.063 g/ml), isolated by 
sequential gradient centrifugation, on Con-A was performed by applying 1-3 mg
Chapter 5 Sialic acid, CHO & APG binding 124
of LDL protein to lOmI column o f Con-A (as described in chapter 2, section 
2.3.1). The unbound fraction was eluted by the equilibrating buffer pH 7.2 
which accounted for 5-9% of the total protein applied to the column. The 
weakly bound fraction, eluted by 0.2mol/l a  D-glucopyranoside, and the 
strongly bound fraction, eluted by 0.3mol/l a  D-mannopyranoside accounted for 
40-50% and 43-60% of the total LDL protein applied to the column 
respectively. The reproducibility o f the Con-A affinity chromatography of the 
samples was verified with four determinations of the same sample of LDL and 
the calculated CV was 4.5% (Fig 5.4).
Figure 5.4
The reproducibility of the elution pattern of total LDL on affinity 
chromatography on Con-A Sepharose.
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UB, unbound fraction eluted by equilibrating buffer, a-DG, weakly bound fraction 
eluted by 0.2 mol/l a-D glucopyranoside, a-DM, strongly bound fraction eluted by 
0.3mol/l a-D mannopyranoside; R, regeneration buffer. Four determinations of the 
same LDL sample. The eluted fraction protein was determined by absorbance at 
280nm.
When total LDL, from individuals with different LDL subfraction profile, was 
applied to the Con-A column, the percentage o f weakly bound fraction was
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lower in subjects with LDL-I (n=3) compared to subjects with predominantly 
LDL-III profile (n=3) (p<0.05) (Table5.5). The weakly bound fi-action was 
significantly different from the strongly bound firaction in the same individual in 
subjects with LDL-I (p=0.04), however this significance was lost in the LDL­
III predominant subjects (p=0.22) (Table 5.5). LDL-II elution pattern was not 
significantly different from that o f LDL-I (Table 5.5).
Table 5.5
The unbound, weakly bound and the strongly bound fractions from total 
LDL affinity chromatography on Con-A Sepharose. Comparison between 
group of subjects with different LDL subfraction profile.
Subjects Unbound Weakly bound Strongly bound
G roup-1 (3) 3 % 42% 56 %*
Group- 2 (3) 2 % 45% 53 %*
Group-3 (3) 2 % 48 %î 49 %t
* p<  0.05, between fractions; t  p<0.05, between different group o f subjects; 
unbound, percentage o f unbound fraction eluted by equilibrating buffer; 
weakly bound, percentage o f  weakly bound fraction eluted by 0.2mol/l a  D- 
glucopyranoside; strongly bound, percentage o f  strongly bound fraction eluted 
by 0.3mol/l a  D-mannopyranoside; Group-1, Group-2 and Group-3, subjects 
with predominantly LDL-I, LDL-II and LDL-III subfraction profile 
respectively, number between brackets is the number o f  subjects in each group
Separation o f ^^^I-labelled total LDL with Con-A Sepharose in a tube assay 
showed similar results to that observed with the column afiSnity chromatography 
except, that there was a small percentage (approximately 5%) o f radioactivity 
still remained bound to the Con-A even after elution with 1 mo 1/1 a  D- 
mannopyranoside. This could be either non-specific or a small firaction o f very 
strongly bound LDL remaining on the lectin. Unfortunately we were not able to 
determine the nature of this fraction. The percentage of eluted fractions in the 
tube assay as determined by radioactivity measurement in counts per minute 
(cpm) are shown in (Table 5.6).
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Table 5.6
The percentage of unbound, glucose releasable and mannose releasable 
fractions of ^^ I^-labelled LDL from Con-A Sepharose as measured by cpm 
in non-diseased and CHD subjects.
Subjects Total Unbound weakly bound Strongly
bound
nlOl 100 5 40 46
nl02 100 7 37 48
nl03 100 7 41 53
nl 04 100 6 41 40
nl05 100 5 41 46
n l06 100 6 44 50
n l07 100 5 46 46
n l08 100 5 45 47
mean + SD 100 6 ±  1 42 ±3* I 47 + 4*
CHD 01 100 4 48 44
CHD 02 100 3 49 43
CHD 03 100 2 54 37
CHD 04 100 4 50 42
CHD 05 100 3 47 43
CHD 06 100 8 42 42
CHD 07 100 9 41 48
mean ± SD 100 5 ± 3 47 + 5 43 + 3
*p<O.OS, between normal volunteer and CHD; t  p<0.01 between weakly 
bound and strongly bound fractions in the same group o f  subjects total and 
eluted fractions measured in cpm; the number in the brackets represent the 
percentage o f  eluted fractions; nl, represent normal subjects; CHD, represents 
coronary heart disease patients.
Individual LDL subfractions, isolated by density gradient ultracentrifiagation 
(chapter 2), showed variable elution pattern by affinity chromatography on Con- 
A. LDL-I subfraction bound with greater affinity to the column compared to 
LDL-III subfraction. Table 5.7 shows that the unbound fraction was similar in 
aU the three LDL subfractions, while the percentage of the weakly bound 
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fraction in LDL-I subfraction and the reverse of that was observed in LDL-III 
subfraction (Table 5.7) (Fig 5.5). This pattern suggests that LDL-I subfraction 
contain more high mannose residues compared to LDL-III.
Table 5.7
The percentage of the three eluted fractions from Con-A affinity 
chromatography of individual LDL subfractions isolated by DGUC.
Subjects Unbound Weakly bound Strongly bound
LDL-I 9 34* t 57*
LDL-II 3 39 56
LDL-III 9 51*t 41*
*p<0.01;between LDL-1 & LDL-III, tp<0.01; between weakly bound and 
strongly bound fractions, unbound, percentage o f unbound fraction eluted by 
equilibrating buffer; weakly bound, percentage o f  the fraction eluted by 
0.2mol/l a  D-glucopyranoside; strongly bound, percentage o f  the fraction 
eluted by 0.3mol/l a  D-mannopyranoside; LDL-I, LDL-II and LDL-III, the 
percentage o f  LDL-I, II and III subfraction within total LDL respectively.
Figure 5.5
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UB, unbound fraction eluted by equilibrating buffer, a-DG, weakly bound fraction 
eluted by 0.2 mol/l a-D glucopyranoside, a-DM, strongly bound fraction eluted by
0.3mol/l a-D mannopyranoside; R, regeneration buffer. LDL-I, (A  A )
LDL-II, ( ■-----■ ) LDL-III subfraction (#------ #  )
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5.4.4 APG reactivity of eluted LDL fractions from Con-A
To determine whether the two main eluted fractions from Con-A Sepharose 
afSnity chromatography o f total LDL from subjects with different LDL 
subfraction profile were different in their reactivity towards APG. Weakly 
bound (glucose releasable) and strongly bound (mannose releasable) fractions 
eluted from total LDL o f three group o f subjects with predominantly LDL-I 
(n=3), predominantly LDL-II (n=3) and predominantly LDL-III (n=3) 
subfraction profile were mixed with 2.5jxg CS rich fraction o f APG from 
human aorta and turbidity was measured, by absorbance at 600nm visible 
wavelength, after 30min incubation at 25°C. There was no significant 
differences between the extent o f interaction of the weakly bound fraction 
compared to the strongly bound fraction towards APG. Yet the extent of 
complex formation in both fractions was highest in the subjects with 
predominantly LDL-III compared to the other two as previously noted 
(chapters 3 & 4) (Table 5.8).
Table 5.8
The extant of APG reactivity of the weakly bound and the strongly bound 
fractions eluted from affinity chromatography of total LDL on Con-A 
from three groups subjects with different LDL subfraction profile.
Subjects
APG-LDL complex 




*p<0.01; values represent mean duplicate measurements fo r  APG-LDL 
complex formation as measured by absorbance at 600nm. Group-1, 2 and 3 
were volunteers with predominantly LDL-I, LDL-II and LDL-III subfraction 
profile respectively.
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5.5 Study II
5.5.1 lipids, LDL subfraction profile and sialic acid content
Mean plasma lipid level and LDL subfraction profile for the three groups of 
subjects are described in detail in section 4.4 (Chapter 4). Plasma total 
cholesterol, triglyceride level was significantly higher in group III, with 
predominantly small dense LDLIII, compared to group I and II subjects (Table 
4.2, Chapter 4).
The sialic acid content of IDL2 was positively correlated with plasma LDL 
cholesterol (p<0.05)and negatively correlated with VLDL (p<0.05) and HDL 
cholesterol (P-0.04). LDLA sialic acid was negatively correlated with LDL 
cholesterol (p<0.01) and that o f YLDL2 was positively correlated with total and 
plasma cholesterol (p<0.05 & p<0.01 respectively). There was no significant
correlation between the amount o f sialic acid the other in apoB containing
lipoproteins and the rest of plasma lipid variables (Table 5.9 ).
Table 5.9
Pearson correlation between patients lipid variables and sialic acid content 







T-Chol 0.27 0.42*** 0.20 0.11 -0.16 -0.11
VLDL-C 0.09 -0.18 -0.10 -0.60*** 0.33 0.17
LDL-C 0.09 0.76* 0.32 0.58*** -0.68* -0.12
HDL-C -0.12 -0.15 -0.23 -0.46** 0.07 0.15
TG 0.14 0.13 0.05 0.09 -0.10 -0.15
* p< 0.01; * 04; * * *p< 0. OS; tmol/mol lipoprotein
T-Chol, total cholesterol (mmol/l); VLDL-C, very low density lipoprotein
cholesterol (mmol/l); LDL-C, low density lipoprotein cholesterol (mmol/l);
HDL-C, high density lipoprotein cholesterol (mmol/l); TG, plasma triglyceride
(mmol/l)
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The amount o f siahc acid measured varied between the different Upoprotein 
subfractions isolated by cumulative density gradient ultracentrifugation (Table 
5.10 ). It was highest in the VLDLl and lowest in the LDL-B subfractions 
p<0.0001 in all subjects (Table 5.10) (Fig 5.7). The siahc acid concentration in 
VLDLl was significantly higher compared to VLDL2 (p<0.01) and IDL and 
LDL subfractions (p<0.0001). The later two were not significantly different in 
their siahc acid content (Table 5.10)
Table 5.10
Correlation between the sialic acid content of apoB containing lipoprotein 
subfractions and their reactivity towards APG, as determined by turbidity 
measurement by absorbance at 600nm.
Variable* sialic acid APG-Lipoproteincomplex
correlation
r
VLDLl 119.30 ± 127.2 0.05 ± 0.02 0.02
VLDL2 42.45 ± 16.98 0.08 ± 0.06 0.31
IDLl 20.50 ± 9.91 0.25 ± 0.16 0.26
IDL2 18.91 ± 6.97 0.45 ± 0.19 0.24
LDLA 18.39 ± 4.52 0.42 ± 0.16 0.34
LDLB 18.82 ± 4.81 0.25 ± 0.15 0.14
^VLDLl, very low density lipoprotein S f  60-400; VLDL2, very low density 
lipoprotein S f  20-60; IDLl, intermediate density lipoprotein S f  16-20; IDL2, 
intermediate density lipoprotein S f  12-16; LDLA, low density lipoprotein S f  
8-12; LDLB low density lipoprotein S f  0-8, data represent mean ±  SD 
(standard deviation) fo r  each variable.
In each individual, LDL-A and LDL-B subfractions had similar siahc acid 
contents (mol/mol hpoprotein). However the siahc acid content on the LDL 
fractions was highest in subjects with predominantly LDLI compared to subjects 
with predominantly smaU dense LDLIII, this was not statistically significant and 
was not related to the extent of their interaction with APG (Table 5.11) When 
the siahc acid content in the other hpoprotein subfractions was examined no 
significant differences was found among the three different groups (Table 5.11).
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Table 5. 11
The sialic acid content and APG binding reactivity of apoB containing 
lipoprotein subfractions. Comparison between subjects with 
predominantly LDLI, LDLII and LDLIII subfraction profile.
Variable LDLIX LDLin LDLim
VLDLl
SA/ApoB (mol/mol) 62.92 ± 67.41 89.19 ± 46.38 157.28 ± 168.4
APG-reactivity (AU 0.03 ± 0.01 0.05 ± 0.02 0.05 ± 0.03
VLDL2
SA/ApoB (mol/mol) 34.51 ± 30.92 36.57 ± 4.11 48.91 ± 17.0
APG-reactivity (AU)** 0.04 ± 0.01 0.08 ± 0.04 0.11 ± 0.07
IDLl
SA/ApoB (mol/mol) 16.21 ± 15.10 16.70 ± 2.32 24.42 ± 10.9
APG-reactivity (AU)* 0.10 ± 0.08 0.26 ± 0.09 0.33 ± 0.18
IDL2
SA/ApoB (mol/mol) 12.51 ± 11.40 18.94 ± 2.13 20.73 ± 7.4
APG-reactivity (AU)* 0.24 ± 0.08 0.48 ±. 0.06 0.57 ± 0.20
LDLA
SA/ApoB (moPmol) 19.83 ± 2.74 17.56 ± 2.41 18.64 ± 6.11
APG-reactivity (AU)* 0.24 ± 0.07 0.47 ± 0.07 0.50 ± 0.16
LDLB
SA/ApoB (mol/mol) 22.31 ± 2.73 16.92 ± 1.72 19.09 ± 5.93
APG-reactivity (AU)** 0.13 ± 0.06 0.23 ± 0.1 0.36 ± 0.16
*P<0.0001; ^*p0.003
tLDLI large buoyant; LDLII, intermediate density; LDLIII, small dense low 
density lipoproteins from  Young healthy, normolipidemic and hyperlipidémie 
CHD patients respectively, data represent mean ± S D  (standard deviation) fo r  
each variable.
5.5.2 Sialic acid content and APG binding
The APG binding reactivity o f apoB containing lipoprotein fractions from the 
plasma of these subjects are described in detail in section 4.2 (Chapter 4).
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A similar pattern o f lipoprotein-APG complex formation was observed in all 
individuals (also Fig 4.5, Chapter 4). The mean reactivity for the lipoprotein 
subtractions in the three groups was highest in IDL2 and LDLA followed by 
LDLB and IDLl and the least reactivity was observed in the VLDL subfractions 
(Fig 4.6, Chapter 4). Although sialic acid concentration was highest in VLDLl 
and lowest in LDLB, it was not correlated with the extent o f APG-Lipoprotein 
interaction (Fig 5.6).
Figure 5.6
The amount of sialic acid content and the extent of reactivity of the 
different lipoprotein subfractions towards APG.95 185 -









VLDLl VLDL2 IDL2 LDLBIDLl LDLA
Lipoprotein fractions
The graphs represent mean values for the sialic acid concentration and the 
pattern o f APG-Lipoprotein complex formation in the apoB containing 
lipoproteins in all the subjects.
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There was no significant correlation between the amount o f sialic acid in the 
different apoB containing lipoprotein subfractions and their reactivity with APG 
(Table 5.11) (Figures 5.7 A & B, 5.8 A & B).
Figure 5.7
Correlation between the sialic acid concentration in IDLland IDL2 
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Figure 5.8
C o rre la tio n  b etw een  th e  s ia lic  a c id  co n c e n tr a tio n  in L D L A  a n d  L D L B  
su b fr a c tio n s  an d  th e ir  r e a c tiv ity  to w a r d s  A P G .
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5.6 Study III: Effect of ciprofibrate treatment on the sialic acid content of apoB 
containing lipoproteins and its relation to APG binding reactivity
Treatment with ciprofibrate (lOOmg/day for 8 weeks), in addition to its 
lowering effects on plasma total cholesterol (18%, p=0.039), plasma triglyceride 
(44%, p<0.05) and LDL cholesterol (10%, NS) concentration and the changes 
in the LDL snbfiraction profile (Table 4.6, chapter 4), has resulted in a 
significant decrease in the sialic acid content of the apoB containing lipoprotein 
subtractions (Table 5.12). There was a 45% reduction in VLDLl (p=0.03), a 
46% in VLDL2 (p<0.001), a 46% in IDL l (NS), a 48% m LDLA (NS) and a 






Sialic acid content of apoB containing lipoprotein fractions before and 
after treatment with ciprofibrate




VLDLl 97.4 ± 37.3 53.3 ± 22.8 =0.03
VLDL2 37.9 ± 4.4 19.7 ± 7.6 p<0.001
IDLl 21.3 ± 14.1 11.3 ± 5.2 0.13
IDL2 23.1 ± 11.2 12.0 ± 0.9 0.04
LDLA 16.7 ± 2.3 14.1 ± 2.7 0.09
LDLB 17.9 ± 3.1 13.5 ± 2.9 0.02
"^ciprofibrate treatment lOOmg/day fo r  8 weeks; *sialic acid concentration 
mol/mol apolipoprotein B, Very low density lipoprotein —VLDLl (S f 60-400) 
and VLDL2 (S f20-60), intermediate density lipoprotein = IDLI (S f 16-20) and 
IDL2 (Sf 12-16), low density lipoprotein ^  LDLA (Sf 8-12) and LDLB (S f 0-8). 
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ciprofibrate treatment also decreased the ability of each lipoprotein subfi'action 
to form complexes with APG. IDL l, IDL2 and LDLA reactivity were 
significantly reduced by 54% (p=0.03), 49% (p=0.006) and 40% (p=0.03) 
respectively and that of small dense LDL by 42% but this was not statistically 
significant (Table 4.7, Fig 4.7 chapter 4). There was little or no change in the 
reactivity of the VLDL subfi’actions with APG. This change in sialic acid 
content was not correlated to the change in lipoprotein-APG interaction.
Figure 5.9
Effect of lipid lowering treatment with Ciprofibrate (lOOmg/day for 8 











VLDLl VLDL2 IDLl IDL2 
Lipoprotein fi-actions
LDLA LDLB
The graph represents the median value for each lipoprotein subfi'actions with 
standard error bars in all the subjects, the line is median connect. ■ before 
ciprofibrate, ■ after treatment with ciprofibrate. *p<0.001, ** p<0.05.
5.7 Discussion
A wide variation in the carbohydrate content of glycoconjugates in various 
human LDL preparations has been shown by several investigators (Fless et al 
1986, Marshall et al 1962, Fontaine & Malmendier 1975; 1978, Swaminathan &
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Aladjem 1976, Filipovic et al 1979, Sliireman & Fisher 1979), CHD patients 
have been shown to have lower LDL neutral earbohydrate and sialic acid 
content compared to normal subjects (LaBelle & krauss 1990, Tertov et al 
1993). However the function of the carbohydrate moiety in LDL is not clear. 
In our present study we examined the carbohydrate (neutral and sialic acid) 
content of LDL in relation to the plasma hpid level, LDL subfraction profile and 
the binding reactivity towards arterial wall proteoglycans.
LDL-I subfraction contained more carbohydrate compared to LDL-III 
subfractions in all the subjects, in keeping with the findings by other 
investigators (LaBelle & Krauss 1990). However, the difference in the amount 
o f neutral carbohydrate content of total LDL, which was slightly lower in CHD 
patients compared to normal subjects, was not significant. This was also 
observed by Labelle & Krauss when they correlated the carbohydrate content 
with the peak LDL particle diameter within the subclass pattern A and B 
phenotypes (LaBelle & Krauss 1990).
LDL subfraction profile was strongly determined by the plasma triglyceride 
level (Griffin et al 1994, Tan et al 1995), tliis has been reflected in the 
dyslipidemia syndrome of ALP (Austin et al 1990), in which predominance of 
small dense LDL-III coexists with moderate increase in plasma triglyceride and 
low HDL cholesterol. There was no relationship between the neutral 
carbohydrate content o f total LDL and the presence or absence of ALP. Total 
LDL neutral carbohydrate content correlated neither with the plasma lipid 
levels nor with the LDL subfraction profile. On one hand this might suggest 
that the regulation and distribution of the carbohydrate residues on LDL particle 
might be influenced by factors other than the LDL subfraction profile and on the 
other hand it might be due to comparable particle size diameter, which has not 
been measuied in this study, in both subject groups even though they differ in 
their plasma Hpid levels. The later is supported by the findings o f Labelle and 
Krauss that LDL particle diameter was a more significant predictor o f LDL 
total carbohydrate content than plasma triglyceride (LaBeUe & Krauss 1990). 
The same investigators have shown that subjects with famüial 
hypercholesterolemia have a large LDL particle diameter and their LDL neutral
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carbohydrate and sialic acid content are similar to that o f normal pattern A 
subjects (LaBeUe & Krauss 1990).
Total LDL affinity chromatography on Con-A Sepharose showed a similar 
elution pattern to what has been observed by other investigators (McConathy & 
Alaupovic 1974, TaveUa et al 1991). The percentage o f the weakly bound 
fraction was lower than the percentage o f the strongly bound fraction, in total 
LDL of normal subjects and LDL-I subfraction, compared to the total LDL 
from CHD patients and LDL-III subfractions respectively. This suggest that the 
high mannose residue is greater in LDL-I compared to LDL -III subfractions 
regardless of the amount o f carbohydrate present and because the pattern of 
elution did not correlate with plasma lipid level and the LDL subfraction profile, 
we assume that the carbohydrate content of LDL is not entirely influenced by 
plasma hpid levels.
When we looked at the sialic acid concentration, both LDLA and LDLB 
subfractions were found to have a lower siaUc acid content in patients with 
predominantly LDL-III subfraction compared to normal subjects with 
predominantly LDL-I subfraction profile. This finding was consistent with 
earlier work that reported sialic acid poor (SAP) LDL in CHD patients and 
sialic acid rich (SAR) LDL in normal no-diseased subjects (Tertov et al 1993). 
LabeUe and Krauss had suggested that this difference is due to the lower 
glycolipid content o f LDL in pattern B subjects compared to normal pattern A, 
as there was no difference in the apoB sialic acid content in both groups 
(LaBelle & Krauss 1990). Therefore, we attribute the similar sialic acid 
concentration o f LDLA and LDLB subfractions observed in our study, to the 
similar lipid content of the o f the two subfractions.
Considering the effect of the above mentioned lipid and carbohydrate 
parameters on the interaction of LDL with APG, we found that APG was 
correlated significantly to the plasma lipid levels and LDL subfraction profile in 
the same way as has been reported (Anber et al 1996, Anber et al (in press)) 
and discussed in Chapter 4 & 5. While no significant correlations were foimd 
between the extent of APG-LDL interaction and the amount of neutral 
carbohydrate in total and LDL subfractions. In addition the weakly bound and
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the strongly bound fractions eluted from the Con-A Sepharose affinity 
chromatography column showed a similar binding reactivity towards APG.
The concentration o f sialic acid was highest in VLDL, which decreased 
progressively across the lipoprotein spectrum and was lowest in LDL. If  sialic 
acid concentration was of major importance in the APG-Lipoprotein interaction, 
as was suggested by Camejo (Camejo et al 1985b, Camejo et al 1990), who 
observed that desialation o f LDL by neuraminidase treatment increase in its 
reactivity with APG (Camejo et al 1985b), then one would speculate that the 
extent of lipoprotein binding reactivity towards APG should be highest in LDL 
compared to the other lipoprotein species. However, we found that APG- 
Lipoprotein complex formation was highest in IDL2 and LDLA. The former 
contained more sialic acid compared to the LDL subfractions. Similarly it has 
been shown that lp(a), with a higher content of carbohydrate and notably that of 
sialic acid than LDL apoB, has a greater reactivity towards APG compared to 
LDL (Bihari-Varga a/ 1988). The effect of neuraminidase treatment on LDL 
win be discussed in detail in the next chapter (chapter 6). In addition the lipid 
lowering effect o f ciprofibrate on apoB containing lipoproteins which decreased 
their sialic acid content resulted in a decrease, rather than the expected increase, 
in the ability o f these lipoproteins to interact with APG. Our findings o f the 
reducing effect o f ciprofibrate on APG-lipoprotein interaction supports the 
findings by Wiklund et al (Wiklund et al 1996). All these suggest that 
carbohydrate and sialic acid content o f lipoproteins have little, if any, effect on 
their interaction with APG which might be more conformation related rather 
than charge. It has also been shown that carbohydrate moiety had no role in the 
binding o f apolipoprotein B to the LDL receptor (Shireman and Fisher 1979)
We conclude that the neutral carbohydrate and sialic acid content o f LDL is 
variable and is not clear cut. The concentration of which is not related to the 
extent of APG-Lipoprotein complex formation which is determined to a greater 
extent on plasma triglyceride level and its influence on the LDL subfraction 
profile and other lipoproteins in plasma such as IDL. Finally the conformation 
of lipoprotein subfraction appears to be more important in determining their 
interaction towards APG rather than their carbohydrate concentration. This is 
discussed fully in chapter 6.
Chapter 6
Mechanisms related to APG-Lipoprotein interaction..
6.1 Introduction
In previous chapters we explored the role of plasma lipids and lipoprotein 
carbohydrate content in determining the interaction of apoB containing 
lipoproteins with arterial wall proteoglycans. High plasma triglyceride, low 
HDL cholesterol and predominance of small dense LDL-III, collectively 
described as the dyslipidémie syndrome of atherogenic lipoprotein phenotype 
(ALP) (Austin et al 1990), were shown to be associated with increase APG- 
LDL complex formation (Anber et al 1996). Reactivity was not correlated with 
carbohydrate concentration of the lipoprotein as was originally hypothesised 
(chapter 5).
The question which arises next is “how APG traps lipoproteins and what is the 
nature of this binding process”. The mechanism by which APG interacts with 
lipoprotein has been of a particular focus of research over the past decade. Until 
now there is no comprehensive explanation as to how lipoproteins form 
complexes with extracellular matrix proteoglycans in the arterial intima-media. 
It is believed that this could be a function o f the charge, sialic acid content or 
conformation of apoB (Fig 6.1)
A poB
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Figure 6.1
A schematic diagram illustrating the mechanisms o f  APG~Lipoprotein binding:
1. Charge (positively charged arginine & lysine residues on apoB interacts 
with negative charges on APG)
2. Sialic acid (Confer negative charges on the lipoprotein thereby decreasing 
the net positive charge on the particle surface.
3. ApoB conformation
Proteoglycans are the most negatively charged macromolecules in living tissue 
(Wight 1989). This gives them the property to form complexes with positively 
charged residues on other molecules. Therefore the reaction mechanism of 
LDL and APG was suggested to be an electrostatic binding involving basic 
amino groups on apoB and polyanionic groups of APG (Camejo et al 1988). 
Olsson et al have shown a positively charged amino acid sequence on apoB rich 
in arginine and lysine to be mainly responsible for the interaction of LDL with 
APG (Olsson et al 1993). This has supported earlier work by Vijayagopal et al 
that chemical modification involving lysine and /or arginine residues on apoB 
prevented LDL fi'om forming complexes with APG (Vijayagopal et al 1981). In 
the same study it was also shown that removal of the protein core, 
glycosaminoglycan (GAG) chains and desulphation of proteoglycan also 
inhibited complex formation with LDL, fiirther suggesting the importance of 
charge in the interaction process (Vijayagopal et al 1981).
Since apoB contains sialic acid residues (Swaminathan & Aldjamen 1976, 
Vauhkonen et al 1985) which are negatively charged, it is believed to deter
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LDL from binding to APG (Camejo et al 1985b). In an early study Camejo et
al examined the nature o f neuraminidase treated LDL interaction with APG
(Camejo et al 1985b). They attributed the increase in the ability o f the 
.desialated LDL to interact with APG to the increase in the net positive charge 
of the lipoprotein. The same group o f investigators have suggested that small 
dense LDL, which has been shown to eontain less sialic acid compared to large 
buoyant LDL (Labelle and Krauss 1990), has a greater affinity towards APG 
(Camejo et al 1990). This was concluded after the interesting finding by Hurt- 
Camejo (Hurt-Camejo et al 1990) that when APG was used to fractionate 
LDL, it had a greater preference for small dense LDL . In contrast, Bihari- 
varga et al reported that neuraminidase treatment of LDL did not interfere 
with GAG or chondroitin sulphate binding (Bihari-Varga a/ 1988). In
Î
addition, when we examined the direct relative reactivity, as measured by 
absorbance at 600nm, of different fipoprotein subfractions towards APG, it was 
highest in the IDL2 and LDLA species (chapter 4, Anber et al in press). These 
subfractions contain a higher concentration o f sialic acid compared to small 
dense LDLB (chapter 4). Similarly the reactivity of Lp(a), which also contain 
more sialic acid than LDL, has been shown to be greater compared to the 
reactivity of LDL towards APG (Bihari-Varga et al 1988). All the above 
indicate that the binding process is not entirely charge dependant.
Larger triglyceride rich particles (VLDL and IDL) have been shown to enter the 
arterial intima (Nordestgaard & Nielsen 1994), interact in-vitro with APG 
(Vijayagopal et al 1981, Anber et al in press, chapter 4) and have been isolated 
from atherosclerotic plaque with LDL (Srinivasan et al 1975, Rapp et al 1994) 
They contain apoE as well as apoB, both of which are enriched in 
atherosclerotic lesions, indicating that apoE might play a role in this interaction 
process. It has been suggested that apoE might enhance APG-LDL binding 
(Parks et al 1991, Giaturco & Bradley 1994). Decreasing apoE:apoB ratio of 
LDL by dietary polyunsaturated fat has been shown to decrease its interaction 
with APG (Manning et al 1994). In addition, it has been suggested that apoE 
might act as a bridging molecule between APG and the lipoprotein, possibly 
through heparin binding sites on both apoB and apoE (Saxena et al 1993, Ji et 
al 1993, Wight 1995). Therefore, an increase in the concentration of apoE is
li
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thought to provide additional binding sites for the GAG chains in APG (Wight 
1995). On the other hand, apoE rich HDL has been shown to block lipoprotein 
lipase-induced retention of LDL in the extracellular matrix (Saxena et al 1993). 
This is believed to be due to similar binding sites for apoE and lipoprotein lipase 
on APG (Mulder et al 1993,Wight 1995). Such competition was suggested to 
be one way by which apoE rich-HDL protects against atherosclerosis (Saxena et 
al 1993). Therefore, the role o f apoE in influencing APG-Lipoprotein 
interaction remains controversial.
Data on the influence of chemical composition of the lipoprotein on APG 
binding is inconsistent. LDL with a high ratio of cholesteryl ester to triglyceride 
was shown to have an increased tendency to form insoluble complexes with 
APG (Avila et al 1978). Kostner et al have shown highly significant correlation 
between the content of free cholesterol and of phospholipids with the 
LDL:GAG ratio in the insoluble complex formed (Kostner et al 1985). While 
Wagner et al found no significant influence of the chemical composition o f LDL 
on its binding reactivity towards APG (Wagner et al 1989).
Taking these findings into account, and based on our data, we hypothesise that 
the conformation of apoB might have a key role in this interaction process. 
Evidence in support of this is the suggestion by Wagner et al (Wagner et al 
1989) that surface property of LDL might be responsible for increased number 
of LDL particles bound to APG.
To explore further the mechanism o f the binding process. We undertook a 
series of studies the objective o f which were: 1) to examine the role of sialic 
acid in the reactivity of LDL towards APG, 2) to determine the nature o f this 
interaction in terms of charge and protein structure by examining the effect of 
modified lysine and arginine residues on the ability of LDL to interact with APG 
under near to physiologic conditions, 3) to determine the effect of apoE and 
apoC on the binding process by incubating total LDL with apoE2/3 and 
apoCIII, and finally 4) to determine the chemical composition of the APG 
bound LDL, in the pellet, and the unbound, in the supernatant, and their relation 
to the extent of complex formation.
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6.2 Subjects
A total o f thirty subjects were recruited for various studies. Total LDL from 14 
normal volunteers aged 22-45 years was used for studies I, II, and III, and the 
rest of the subjects (n=16) recruited for the second part of study III, were CHD 
patients aged 45-73 years. These patients were undergoing diagnostic coronary 
angiography in the Department o f Medical Cardiology, Glasgow Royal 
Infirmary. Subjects in the fasting state donated 50ml o f blood which was 
collected by venepuncture using K2EDTA (final concentration 1 mg/ml) as 
anticoagulant. Plasma was harvested at 4°C by low speed centrifugation 
(3000rpm) and aliquots for lipid, lipoprotein measurements and LDL 
subJ&actionation used immediately. Subjects with recent MI (i.e. in the previous 
6 months), renal disease, thyroid disease, diabetes or those taking lipid-lowering 
medications were excluded, as were those with a plasma cholesterol 
concentration of >9.0mmol/l and a plasma triglyceride level of >5.0mmol/l. The 
study was approved by the Research Ethics Committee o f Glasgow Royal 
Infirmary and each volunteer gave written informed consent.
6.2.1 Study I: Role of sialic acid in the mechanism of APG-Lipoprotein
interaction
Since we found no correlation between the sialic acid concentration and APG- 
Lipoprotein complex formation (chapter 5), we incubated total LDL with 
neuraminidase and different ganglio sides to change the sialic acid content on the 
lipoprotein and tested the relative reactivity of this treated LDL vs control LDL. 
Neuraminidase treatment of LDL was performed by incubating total LDL fi-om 
tliree normal subjects, isolated by preparative sequential ultraeentrifiigation at 
densities 1.019-1.063 g/ml, with neuraminidase type VI-A fiom Clostridium 
Perfringens for 25h at 37°C on a roller mixer as described (Camejo et al 1985b) 
(chapter 2).
Total LDL firom another three subjects were incubated with different dilutions 
o f crude, GM3, GMl ganglio side and asialoganglioside (mol/moILDL) (Sigma 
Pharmaceuticals) for 1 hi* at 37°C as described in chapter 2.
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6.2,2 Study II : Effect of LDL modification on APG-LDL binding
To explore further the function o f charge in the mechanism of LDL-APG 
interaction, total LDL isolated from fresh plasma from four volunteers by 
preparative sequential ultraeentrifiigation at densities 1.019-1.063 g/ml was 
subjected to chemical and enzymatic modification. Cyclohexandione 
modification of LDL arginine residues was achieved by the addition o f 1,2 
cyclohexandione and carbamylation o f lysine residues by mixing with potassium 
cyanate as described previously (Weisgraber et al 1978), both reactions reduce 
the net positive charge on LDL apoB. Reductive méthylation of lysine residues 
was performed using sodium borohydrate and the addition o f 40% 
formaldehyde (chapter 2).
6.2.3 Study III : Apolipoprotein E and apolipoprotein C and APG binding
Factors tested in this study were apoE, apoCIII and heparin. Total LDL 
isolated from the plasma o f 8 subjects (normal volunteers) were incubated with 
different dilutions of apoE2, apoE3 and apoCIII for Ih  at 37°C as described in 
chapter 2.
Total LDL from 16 CHD patients was examined to determine the effect of 
heparin on APG-LDL interaction. Each patient donated two 50 ml samples of 
blood, collected in to EDTA tubes, one before and the other immediately after 
cardiac angiogram. Heparin (1000-2000 lU, according to the patients BMI) 
was flushed down the femoral artery into the inferior venacava during the 
catheterisation procedure. Therefore plasma obtained after the angiogram was 
mixed with heparin. LDL isolated from the first sample (without heparin) was 
termed as native LDL and from the second sample, heparinised LDL.
Chapter 6 mechanisms related to APG-Lipoprotein interaction 146
6.3 APG-Lipoprotein complex formation
The binding assay has been described in detail in chapter 2. In all the studies a 
blank and a test was performed on each sample to detect non-specific LDL 
precipitation.
Control samples were exposed to the same buffers (without the addition of the 
enzymes and apoproteins listed in Table 6.2) and conditions as the modified 
LDL samples. The ability o f these enzymes and apoproteins to form complexes 
with APG was tested by incubating them with 2.5 pg CS-rich APG under the 
same conditions o f the binding assay but without the addition of LDL (chapter 
2).
6.4 Statistical analysis
Statistical analysis and manipulations were performed using the PC version 
o f MINITAB Release 10 for Windows (Minitab Inc., PA), associations 
between variables were tested by calculating the pearson correlation 
coeffecient. The significance of association between pairs of variables was 
determined by linear regression.
6.5 Subjects characteristics
The subjects characteristics are shown in Table 6.1. Normal volunteers had 
significantly higher HDL cholesterol and a lower plasma triglyceride level 
than CHD patients (Table 6.1). They also had a predominantly LDL-II in 
their subfiraction profile eompared to the LDL-III in the CHD patients.








T-Cholesterol 4.6 ± 0.9 5.8 ± 1.5
VLDL-Cholesterol 0.5 ± 0.2 0.7 ± 0.4
LDL-Cholesterol 3.4 ± 0.7 3.8 ± 1.4
HDL-Cholesterol 1.2 ± 0.5 1.0 ± 0.3*
Triglyceride 1.0 ± 0.3 1.6 ± 0.8*
*p<0.01, CHD, coronary heart disease patients; n, represent number o f  
subjects.
Results
6.6.1 Neuraminidase treatment of LDL and APG binding
Incubation of total LDL, (d= 1.019-1.063 g/ml) with agarose bound 
neuraminidase for 25h released up to 37%, and incubation with the free enzyme 
released up to 50%, of the sialic acid content o f the lipoprotein (Table 6.2). 
This resulted in a 54% and a 176% increase respectively in the binding 
reactivity o f the LDL compared to the control sample (Table 6.2). No insoluble 
complex formation was detected between neuraminidase and APG (Table 6.2).
6.6.2 The effect of LDL incubation with ganglioside on APG binding
The reactivity of total LDL was perturbed following incubation with different 
ganglio sides to increase the amount o f carbohydrate on apoB. GM3 ganglioside 
from plasma resulted in only 12 % reduction in the binding reactivity (Fig 6.2a). 
Increasing concentrations of crude ganglioside from brain, decreased the 
reactivity o f LDL towards APG and near abolition of the reactants at 
40mol/mol LDL (Fig 6.2b). GMl ganglio sides had no effect on binding while 
asialo-GMl increased the binding interaction by 10% (Fig 6,3a and b, 
respectively) (Table 6.2). When APG was mixed with ganglio sides without 
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Table 6. 2
The extent of APG-LDL complex formation. Comparison between control 
and modified LDL.
Variable APG-LDL complex APG complex
Test (% change) * control (without LDL)f
Neuraminidase 0.389 (+76) 0.221 (100) 0.005
GM3-ganglioside 0.397 (-12) 0.446 (100) 0.006
Crude-ganglioside 0.055 (-93) 0.602 (100) 0.003
GM l-ganglioside 0.490 (0) 0.490 (100) 0.004
Asialo-ganglioside 0.520 (+10) 0.490 (100) 0.005
ApoE2 0.049 (-92) 0.600 (100) 0.003
ApoE3 0.048 (-91) 0.470 (100) 0.004
ApoCIII 0.470 (-23) 0.606 (100) 0.003
Lp(a) 0.778 (+29) 0.602 (100) 0.666
Heparin 0.271 (-21) 0.385 (100) -
Cyclohexandione 0.005 (-99.2) 0.580 (100) -
Carbamylation 0.006 (-99.2) 0.580 (100) -
Reductive méthylation 0.006 (-99.2) 0.580 (100) -
* % change V5 control; f  the extent o f  insoluble complex formation, as 
measured by absorbance at 600nm, was determined by incubating different 
amounts (discussed in the appropriate section) o f  the enzymes and lipoproteins 
listed with 2.5pg CS-rich APG (in the absence o f LDL in the binding mixture) 
at 25X1 fo r  30 min. The extent o f  APG-LDL complex formation was 
determined by adding 2.5pg CS-rich APG to O.lmg LDL protein and 
absorbance was measured at 600nm; the values in the brackets represent the 
percentage increase or decrease in the binding reactivity after modification.
a
%
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Figure 6.2
The extent of APG-LDL complex formation in the presence of different 
dilutions of GM3 ganglioside from plasma and crude gangliosides from 













Glycolipid added mol/mol LDL
The graph represents the extent o f  APG-LDL complex formation in three 
different subjects in the presence o f gangliosides. Total LDL was incubated, 
fo r  60min at with 0-40 mol gangliosides/mol LDL (final apoB
concentration 0.1 mg/ml), 2.5pg APG was added and the extent o f  complex 
formation was measured by absorbance at 600nm after 30min incubation at 
25X1. A) GM3 ganglioside from plasma, B) crude ganglioside from brain
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Figure 6. 3
The extent of APG-LDL complex formation in the presence of different 
dilutions of G M land asialo-G M l gangliosides in three subjects.
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Glycolipid added mol/mol LDL
The graph represents the extent o f  APG-LDL complex formation in three 
different subjects in the presence o f gangliosides. A) GMl ganglioside, 
B)Asialo-GMl ganglioside. Total LDL was incubated, fo r  60min at 37X1, with 
0-40 mol ganglioside/mol LDL (final apoB concentration 0.1 mg/ml), 2.5pg  
APG was added and the extent o f  complex formation was measured by 
absorbance at 600nm after SOmin incubation at 25 XI.
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6.6.3 Chemical modification of LDL and APG binding
Total LDL isolated from the plasma of normal volunteers by sequential gradient 
ultracentrifugation was subjected to a number of enzymatic and chemical 
modifications. The extent o f complex formation between the modified LDL 
compared to the native and neuraminidase treated LDL with APG is shown in 
Table 6.2. A blank and a test was performed on each sample to detect non­
specific LDL precipitation. Modification o f lysine and arginine residues by 
carbamylation and cyclohexandione treatment respectively, reduced the net 
positive charge o f LDL on agarose electrophoresis (Fig 6.4) and abolished the 
ability of the LDL to form complexes with APG ( Table 6.2, Fig 6.5). Reductive 
méthylation which did not alter the charge on LDL was also effective in 
blocking completely the binding reactivity of LDL with APG (Table 6. 2).
Figure 6. 4
Chemical modification of LDL and effect on APG-LDL complex 
formation.
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The extent o f charge modification on the native total, chemically modified and 
neuraminidase treated LDL samples was tested by agarose electrophoresis 
(Figure 6.5).
Figure 6. 5
The diagram represents agarose electrophoresis of native and modified 
total LDL to determine charge modification.
+
A B C D  E F G H I J K
ww# Hiiiü
A, native total LDL; (B-K) modified total LDL as follows: B, reductive 
méthylation; C, cyclohexandione treatment; D, carbamylation; E, 
neuraminidase treatment; F, incubation with crude ganglioside from the 
brain; G, incubation with GM l ganglioside; H, incubation with asialo GMl 
ganglioside; I, incubation with GM3 ganglioside from plasma; J, incubation 
with apoE2; K, incubation with apoE3.
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6.6.4 Effect of apoE and apoCIII on APG-LDL interaction
Apolipoprotein E2 and E3 had similar effect on the binding reactivity of total 
LDL towards APG. Apolipoprotein CIII had little effect in blocking the ability 
o f LDL to interact with APG (Fig 6 .6 ). The extent o f complex formation was 
reduced by 23% at Imol apoCIII /mol LDL (Table 6.2). Interestingly, the 
extent of complex formation decreased as the concentration of apoE (E2 & E3) 
increased in the binding mixture and was almost completely blocked at Imol 
apoE/mol LDL (Fig 6.7 A & B). There was no insoluble complex formation 
between APG and apoE2, apoE3 or apoCIII (Table 6.2).
Figure 6.6
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Apolipoprotein CIII (moFmol LDL)
The graph represents mean values fo r  the extent o f  APG-LDL complex 
formation, in the presence o f  apoCIII, in three different subjects. The bars 
represent standard error. O.lmg LDL was incubated with 0-1 mol apoCIII/mol 
LDL and mixed with 2.5pg APG. Absorbance was measured at 600nm after 
20min incubation at 25 XI.
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Figure 6. 7













Apolipoprotein E (mol/mol LDL)
The graph represents mean values fo r  APG-LDL complex formation in the 
presence ofapoES (A) and apoE2 (B). 0.1 mg LDL incubated with apoE (0- 
Imol/molLDL) was mixed with 2.5pg APG and turbidity was measured by 
absorbance at 600nm.
Chapter 6 mechanisms related to APG-Lipoprotein interaction 155
Heparinisation during the procedure of cardiac catheterisation was significantly 
eflfective in reducing the reactivity o f total LDL towards APG by 21 % (p< 
0.05 ) (Table 6. 2). This was observed in all the patients (Fig 6.8).
Figure 6. 8
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The graph represents the extent of total LDL reactivity towards APG in each 
patient before and after catheterisation. ■  initial LDL (unheparinised), □  
heparinised LDL after catheterisation.
6.6.5 Compositional analysis of apoB containing lipoproteins and binding 
interaction with APG.
The compositional analysis of the precipitated and the unreacted firactions irom 
the apoB containing lipoproteins are shown in Table 6.3. Free cholesterol and 
protein were similar in the precipitated fraction and the supernatant in aU 
lipoproteins (Table 6,3), while lipoprotein mass in the precipitate was lower 
compared to the supernatant (Table 6.3). The precipitate in the VLDL 
subfractions contained higher esterified cholesterol (EC) and lower triglyceride 
(TG) compared to the unreacted fraction while the precipitated LDL 
subfractions were TG-rich and EC poor (Table 6.3). This suggest that the 
lipoprotein particles which are more prone to be trapped by the APG appear to 
be TG-poor remnant particles in the TGRL spectrum and TG-rich LDL particles 
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6,7 Discussion
Variability in APG-Lipoprotein interaction has been shown in several studies. 
This has been attributed partly to variability in APG itself (Wagner et al 1986, 
Alves & Mourao 1988, Cardoso & Mourao 1994, Sambandam 1991) and partly 
to variation in lipoprotein components (Linden et al 1989, Srinivasan et al 
1984, Anber et al 1996, Bihari-Varga et al 1988, Vijayagopal et al 1981, 
Wagner et al 1989). In this study we focused on factors affecting hpoprotein, 
and used a single APG preparation which was fully characterised as described 
in chapter 3. Different mechanisms which have been implicated to play a role in 
this interaction process were tested. The effect of neuraminidase treatment of 
LDL on its reactivity with APG (Table 6.2), in keeping with the findings by 
Camejo (Camejo et al 1985b) supports the sialic acid hypothesis in which the 
higher reactivity of small dense LDL towards APG was attributed to its lower 
sialic content which increases the net positive charge of the lipoprotein particle 
(Camejo et al 1985b). It also supports our earlier findings (Anber et al 1996) 
that LDL from subjects exhibiting an ALP with a predominance of small dense 
LDL-III (chapter 3) is more reactive towards APG. In contrast, the higher 
reactivity of the IDL2 fraction, among the apoB containing lipoproteins, with a 
higher sialic acid content (Anber et al (inpress) chapter 5) towards APG goes 
against the above mentioned hypothesis. This is further questioned due to the 
variability in the APG-LDL interaction after LDL incubation with different 
gangliosides. Increasing concentrations of crude gangliosides was most effective 
in reducing the ability of LDL to interact with APG (Fig 6.2b). However this 
ganglioside was fi'om brain and not plasma. GM3 gangliosides from plasma was 
effective in diminishing LDL reactivity towards APG by only 12% (Table 6.2a), 
Wliile GMl and asialo GMl did not have a significant effect on the binding 
process (Fig 6.3 a & b). This variability in effect may be due to either lack of 
binding of certain gangliosides to LDL or the fact that it is not the crude overall 
charge on the lipoprotein that is important but critical domains that may interact 
in only certain circumstances with ganglioside. For example, GM3 has been 
shown to interact with LDL resulting in conformational changes mainly, a 
rearrangement o f LDL surface phospholipid (Mikliilenko et al 1991). We
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suggest that sialic acid on lipid is important for exposing or hiding free amino 
groups on the lipoprotein rather than simply affecting its net charge.
Our findings on LDL modification, in keeping with earlier reports (Vijayagopal 
et al 1981) suppose the contention that arginine and lysine residues on apoB are 
essential for APG-Lipoprotein interaction. This further supports the observation 
by Olsson et al, that positively charged aminoacid residues rich within a specific 
domain on apoB m LDL, are critically important in the binding process (Olsson 
et al 1993). On the other hand we foimd that reductive méthylation o f LDL, 
which changes the protein structure o f apoB without affecting the net charge on 
the particle, was also effective in blocking APG-LDL interaction. It is worth 
noting that reductive méthylation was reported by Mahley et al not to affect
heparin (analogous to heparan sulphate) binding of LDL and HDL (Mahley et al 
1979). However, marked differences in the ability o f heparin and chondroitm 
sulphate proteoglycan to form soluble or insoluble complexes with LDL have 
been reported (Vijayagopal et al 1983). This is supported by the fact that HDL 
does not bind to CS-PG (Camejo et al 1980b), yet it binds to heparin (Mahley 
et al 1979). Taken all these together, suggest that although overall charge and 
sialic acid content o f the lipoprotein may contribute to some extent to the 
regulation o f binding, it can not be frilly responsible for controlling o f the 
lipoprotein-APG interaction.
Interestingly, modification of the lipoprotein by reductive méthylation has been 
shovm earlier to be effective in abolishing the receptor activity of both LDL and 
HDL (Mahley et al 1979), which suggests that the mechanism of APG binding 
might be similar to receptor binding. If  that was the case, then it is reasonable 
to presume that the high reactivity o f IDL2 towards APG (chapter 4) would be 
due to a high content of apoE in this lipoprotein, which also mediates receptor 
binding activity. An increase in apoE concentration o f LDL-I in CHD patients 
has been shown to be related to increase receptor activity of this lipoprotein 
compared to small dense LDL (Campos et al 1996). However we found that 
the addition o f increasing amounts o f both apoE2 and apoE3, to total LDL in 
different subjects decreased the ability of the lipoprotein to interact with APG.
The concentrations of apoE used in this study did not affect the net charge on 
LDL particle, as tested by gel electrophoresis. In addition, apoCIII did not have
s
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a significant blocking effect on APG-LDL interaction, yet it has been shown to 
inhibit receptor mediated cellular uptake of lipoproteins (Windier et al 1980) 
Thus, conformational changes on apoB, which might be influenced by apoE, is a 
more likely explanation for rendering the lipoprotein particle not susceptible to 
APG binding. This might indicate one way by which apoE protects against 
atherosclerosis.
Our data on the compositional analysis, o f the precipitated and unreacted 
fractions o f different apoB containing lipoproteins is in keeping by the findings 
by other investigators (Avila et al 1978) that particles which are CE-enriched 
show a greater affinity to APG . In our study, the APG-reacted fractions in 
VLDL were relatively enriched in CE. This indicated that VLDL remnant 
particles were more reactive towards APG. Since it is recognised that a 
subpopulation o f VLDL which contain no apoE exists in human plasma (Evans 
et al 1989 ) it is reasonable to postulate that the CE-enriched VLDL remnants 
might be apoE poor with impaired receptor mediated removal from plasma. CE- 
enriched VLDL are also thought to be unable to complete the VLDL to LDL 
conversion process (Oschry et al 1985). This may result in an increased 
residence time in circulation and subsequent filtration o f these particles into the 
arterial wall leading to their entrapment by APG. On the other hand, the 
reacted fractions m the denser lipoprotein species were relatively TG-enriched 
(Table 6.3). Several investigators have reported decreased interaction of TG- 
enriched LDL with LDL receptor (Chait et al 1984, Aviram et al 1988, 
Kinoshita et al 1990, Galaeno et al 1993). This was attributed to 
conformational changes m apoB induced by TG with altered expression o f free 
amino groups (Aviram et al 1988, Galaeno et al 1993). TG induced 
conformational change may increase expression o f the domains critical in APG 
binding.
These observations suggest that the mechanism of interaction between APG and 
lipoprotein is not straight forward, and that multiple factors are responsible for 
controlling the process. The predominance of small dense LDL and raised 
plasma triglyceride are important determinants (Anber et al 1996). It is 
associated with an increased concentration of other lipoprotein subfractions 
important in the binding process i.e. IDL. Conformation and surface property
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of the lipoprotein appears to be of major importance in the binding mechanism. 
I f  the sialic acid content of the lipoprotein has an effect on binding, it appears to 
be through hiding or revealing different epitopes on apoB which are important 
in the interaction rather than through a change m overall charge. The blocking 
effect o f apoE on the binding process fiirther provides evidence that the 
mechanism is conformation related rather than dependant on charge.
Chapter 7
Effect of EPO on plasma lipids and LDL subfractions 
and their susceptibility to oxidative modification in 
NIDDMs...
7.1 Introduction
Diabetes is a major contributor to cardiovascular morbidity and mortality and an 
independent factor with 2-3 fold increase in risk of atherosclerosis (Kannel & 
McGee 1979). Undoubtedly diabetic individuals are predisposed to premature 
coronary heart disease for a number of reasons. Acceleration of atherosclerosis 
in diabetics has been linked to the long term control o f blood glucose and to 
lipid abnormalities (Albrink et al 1963, Santen et al 1972). The incidence of 
fasting hyperlipidemia in diabetes is 30-40% (New et al 1963, Hays 1972). Non 
insulin dependant diabetics (NIDDM) have raised plasma triglyceride and low 
levels o f HDL cholesterol (Kennedy et al 1978, Howard et al 1978, Simpson et 
al 1979, Lopes-Virella et al 1977). Although non-insulin dependent diabetes 
mellitus (NIDDM) patients exhibit normal LDL cholesterol, there is an 
increased tendency to oxidise, glycosylate ( Hunt et al 1990, Lyons 1991) and 
glycate (Tames et al 1992) the lipoprotein. The syndrome of an atherogenic 
lipoprotein phenotype (ALP) which has been associated with a 3-fold increase 
in risk of coronary heart disease (CHD), is generally considered to be the 
characteristic dyslipidemia associated with the insulin resistance syndrome 
(Reaven et al 1993a).
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The mechanisms linking small, dense LDL with atherogenesis may be explained 
by several theories. One o f which is its prolonged residence time in circulation, 
owing to its slow removal by cellular LDL receptors (Caslake et al 1992), thus 
enhancing its infiltration into the arterial wall. In addition, small, dense LDL 
has been shown to be more susceptible to in-vitro copper catalysed oxidative 
modification (DeGraff 1991), a prerequisite step for the deposition of LDL 
cholesterol and foam cell formation in the atherosclerotic plaque. Increased 
LDL copper catalysed oxidative modification in patients with ALP (Austin et al 
1988) and diabetics might be partly explained by their low HDL level (Lopes- 
Virella et al 1977, Kennedy et al 1978, Howard et al 1978, Simpson et al 1979). 
This is supported by the significantly lower serum paroxonase activity in 
NIDDMs (MacNess et al 1991) which has been reported to be responsible for 
the antioxidant properties o f HDL (MacNess et al 1993). In a study, 
monitoring peroxidative stress in LDL surface and core compartment, using 
oxidation labile Fluorescent probe, Tribble et al have attributed the enhanced 
susceptibility o f small, dense LDL to oxidative stress to its surface monolayer 
(Tribble et al 1995). Furthermore, diabetics ar e prone to infection and increased 
superoxide production by activated monocytes which may increase lipoprotein 
oxidation (Hiramatsu & Arimori 1988). The increased activity of sorbitol 
pathway in these patients leads to increased consumption o f NAPDH which is 
essential for the regeneration of antioxidants (Barnett et al 1986). Increasing 
amounts of glycated lipoprotein has been found in the serum of diabetics which 
is thought to render the lipoprotein more susceptible to oxidation (Lyon et al 
1986). Hicks et al (Hicks et al 1988) have shown that both glucose and 
glycosylated collagen can catalyse the peroxidation of linoleic acid (LA) and 
arachidordc acid (AA) in-vitro. A similar process might occur in-vivo which 
might enhance lipid peroxidation in diabetes. The process of oxidative 
modification o f LDL appears to be dependent on the peroxidative 
decomposition o f polyusaturated fatty acids (PUFA), releasing reactive 
fi'agments such as malonyldialdehyde (MDA), some o f which form covalent 
bonds with LDL apoB, which may in turn cause fi'agmentation o f the 
apolipoprotein B (Palinski et al 1989, Yia-Herttuala et al 1989, Steinbrecher
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1987, Hoff et al 1989). This modified LDL is not recognised by the LDL 
receptor and it is taken up by alternative, scavenger receptors to be rapidly 
internalised by macrophages leading to cholesteryl ester accumulation and foam 
cell formation (Parathasarathy et al 1987, Sparrow et al 1989). Therefore the 
fatty acid composition o f LDL is thought to be an important determinant of 
oxidative susceptibility.
LA (C l8:2, n-6 is an essential fatty acid found in many vegetable oils) and more 
importantly its metabolites gamma linolenic acid (GLA) (C l8:3, n-6) and 
dihommolinolenic acid (DGLA) (C20:3, n-6) and arachidonic acid (AA) (C20:4, 
n-6) may influence the pathogenesis o f CHD by affecting the traditional set of 
coronary risk factors (Horrobin & Huang 1987) namely plasma lipoprotein 
levels, haemostasis and diabetes. Diets rich in LA and GLA have been shown 
to lower plasma total cholesterol, LDL cholesterol, apolipoprotein B (Ishikawa 
et al 1989) and plasma triglyceride (Chaintruil et al 1984). The TG-lowering 
effects o f n-6 PUFA has been suggested to be due to a decrease in hepatic 
VLDL production (Chait et al 1974, Nestel & Barter 1971, Cortese et al 1983). 
Since VLDL is the precursor o f much o f the circulating LDL, it might explain 
the decrease in LDL with LA-enriched diet. These effects have been suggested 
to depend on the quantity and quality o f PUFA supplied by the diet (Chaintruil 
et al 1984). Evening Primrose Oil (EPO), a natural vegetable oil extracted fi"om 
the seeds o f the evening primrose (Oenethera species) has been shown to have a 
higher hpid-lowering capacity than sunflower oil. Both o f which contain linoleic 
acid as their principal component in common with other vegetable oils 
(Chaintruil et al 1984, Ishikawa et al 1989), but EPO is unique in containing 
about 9% gammalinolenic acid. The later is believed to be more potent in lipid 
lowering compared to the former. In addition GLA has been shown to induce 
an increase in HDL (Fragoso & Skinner 1992). Therefore, it can be speculated 
that the influence of dietary n-6 PUFA in EPO on the distribution o f LDL 
subclass pattern will reflect its capacity to reduce the concentration of 
triglyceride rich lipoproteins which might increase the susceptibility o f LDL to 
oxidation . However, its direct influence on discrete LDL subclasses has yet to 
be elucidated.
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Therefore, we hypothesise that supplementation o f LA in the form of EPO with 
GLA present might by lowering triglyceride rich lipoproteins beneficially affect 
the LDL subfiraction profile and also be protective against atherosclerosis.
The aims and objectives of our study were to examine 1) the effects o f EPO 
supplementation on LDL oxidisabifity in a subgroup o f NIDDM expressing an 
ALP, 2) to elucidate the ability o f EPO to modify components o f an ALP, 
namely, lowering plasma TG, redistribution of LDL subclass pattern and 
increasing HDL cholesterol, in these patients and finally 3) to examine 
relationships between changes in ALP status and oxidative susceptibility.
7.2 Study design
The trial was conducted in 2 phases over 24 months. The first phase o f which 
was double bhnd, parallel, placebo controlled for 12 months with the patients 
randomised to receive active or placebo therapy. The next 12 months was a 
single blind phase and all patients were on active therapy.
The dose was 12 capsules/day o f either active EPO (500mgx6 bd) or placebo 
capsules. The capsules were identical in appearance (and taste if swallowed 
intact). They were packaged and individually labelled for each patient. 
Treatment was ahocated by a computer program using block randomisation by 
Scotia Pharmaceuticals. All unused capsules and the completed capsule packs 
were returned to Scotia Pharmaceuticals
Active therapy: oral Efamol EPO (evening primrose oil) 500 mg with 10
mg vitamin- E in a soft gelatine capsule, containing as active ingredient 40mg 
GLA. Total dose of GLA= 500mg/day
Placebo: oral liquid parafiSn 500 mg with 10 mg vitamin E in a soft
gelatine capsule.
7 .3  Subjects
A total o f 28 subjects were selected from those attending the diabetic clinic at 
the Southern General Hospital. All donated 50ml of blood after an overnight
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(12h) fast. Fasting blood was collected by venepuncture using K2EDTA (final 
concentration 1 mg/ml) as an anticoagulant for immediate transport ( on the 
same day) on wet ice to the Institute o f Biochemistry, Glasgow Royal Infirmary. 
Plasma was separated at 4°C by low speed centrifugation (3000rpm) and 
aliquots for lipid, lipoprotein measurements and LDL subfractionation used 
immediately.
Patients compliance and control o f diabetes were monitored by completion of 
diary card, measurement o f plasma essential fatty acids, measurement of 
glycosylated haemoglobin (HbAl) and fructosamine level in plasma.
Inclusion criteria
i) Patients with idiopathic non-insulin dependent (type II) diabetes melhtus 
(who met the WHO criteria at the time of diagnosis).
ii) Patients o f either sex aged between 18-70 years, who have given written 
informed consent.
iii) patients in whom control of diabetes has been stable for at least 6 
months prior to recruitment, i.e. no acute metabolic decompensation, for 
example a hypoglycemic event requiring intervention by a second party 
or hyperglycemic event requiring hospitalisation, or a change in type of 
therapy for diabetes.
Exclusion criteria
i) Patients with acute febrile illness.
Ü) active hepatic disease, renal failure ( creatinine above 200pmol/l) or
other intercurrent disease
iii) Patients receiving experimental drugs (other than the study capsules).
iv) Patients who are pregnant or trying to conceive.
v) Patients on lipid lowering medications.
Adverse events
No serious risks are known to accompany the ingestion of EPO. Patients may 
complain of mild gastrointestinal upset, e.g. flatulence, loosening of stools or
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mild nausea rarely these are sufficiently troublesome to cause the patient to stop 
treatment.
7.4 Statistical analysis
Statistical analysis and manipulations were performed using the PC version 
o f MINITAB Release 10 for Windows (Minitab Inc., PA). The distribution 
of all variables was assessed by normality plots gnd the ones which were not 
normally distributed were normalised by appropriate transformations. 
Plasma triglyceride was normalised by log transformation, small, dense 
LDLIII concentration within total LDL was normalised by square root 
transformation. Pearson’s correlation coefficient, simple regression, 2 sample 
t-test and one way analysis of variance (ANOVA) were used to assess the 
relationship between variables.
7.5 Patients characteristics
The patients age, sex, body mass index (BMI), current illnesses, other than non- 
insulin dependent diabetes, and medications are listed in Table 7.1. 
Anthropometric indices, systolic and diastolic blood pressure o f both groups 
(active and placebo) are shown m Table 7.2.
Age, weight, BMI, systolic and diastolic blood pressure were similar between 
the two groups (active and placebo) (Table 7.2). They had also similar levels of 
total, LDL and VLDL cholesterol, apoAI and apoB concentration in plasma 
(Table 7.4). Patients who were on active treatment had a lower HDL 
cholesterol (p<0.02) and cholesteroI/HDL ratio (p=0.008) and a higher plasma 
triglyceride level, though the latter did not reach statistical significance.
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Table 7.1
Patients characteristics at the initial visit.
Subjects Sex Age BMI Clinical
diagnosis*
Medications
EPO 01 M 66 33.1 D&O,  Fybogei, senna
EPO 02 F 58 26.6
EPO 03 M 60 30.3 D & O
EPO 04 F 64 24.6 D
EPO 05 M 51 25.6 D
EPO 06 M 48 34.0 D & O
EPO 07 M 64 27.1 tBP D&O,  Adalat
EPO 08 M 52 25.2 D
EPO 09 M 62 25.6 D & O
EPO 10 M 60 30.7 D & O
EPO 11 M 48 D & O
EPO 12 F 71 25.0 MI 9/93 D&O,  Istin
EPO 13 M 55 23.5 D & O
EPO 14 M 66 27.6 Angina, MI, tS P Insulin, Digoxin, 
Hoidaruroa
Aspirin,
EPO 15 M 59 26.2 IHD D & O ,  Isosorbide 
Diltiazam
dinitrate.
EPO 16 M 41 22.8 tBP Insulin, Tenormin
EPO 17 M 60 20.3 Angina, HF, tBP D, Digoxin, Tenormin, 
Captopril
Wrfarin,
EPO 18 F 55 26.2 tBP D&O,  Adalat
EPO 19 M 69 33.1 tBP D, Nifidipine











D & O ,  Adalat, ventolin 
Colofac
inhaler.
Clinical diagnosis other than NIDDM; BMI, body mass index; D&O, diet 
and oral hypoglycemics; IHD, ischemic heart disease; BP, blood pressure 
mmHg; MI, myocardial infarction; HE, heart failure.
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Table 7.2
Anthropometric indices, plasma lipids, lipoproteins, LDL subfraction 
profile, blood glucose, HbAl and Fructosamine level in both study groups
Variable Active fi=^ 14 Placebo n~ 8
Age 57.5 ± 8.7 57.7 ± 8.4
Weight (kg) 77.5 ± 12.1 76.2 ± 15.7
BMI 27.3 ± 4.0 27.1 ± 3.9
BP systolic (mmHg) 138.7 ± 25.1 140 ± 9.3
BP diastolic (mmHg) 87.0 ±12.8 85.6 ± 11.8
BMI, body mass index; BP, blood pressure
The lower plasma triglyceride level in the placebo group was reflected in their 
baseline LDL subtraction profile, with a higher LDL-I and a lower LDL-III 
percentage within total LDL compared to the active treatment group (Table 
7.3) but this was not statistically significant.
Table 7.3
Plasma LDL subfraction profiles of the two groups of patients at the end 
of the first year of the trial.
Variable Active n=14 
Baseline 12 months
Placebo n ~ 8
Baseline 12 
months
%LDL-I 1 6 + 9 16 ± 9 22 ± 9 1 8 ± 8
%LDL-II 46 ±17 45 ± 9 53 ±10 55 ± 9
%LDL-III 31 ±17 38 ±14 26 ±17 27 ±10
%LDL~l LDL-II, LDL-III, the percentage o f large, intermediate and small dense LDL 
within total LDL; active, treatment with 500mgxl2 EPO +10mg Vit.E/day; 
placebo, treatment with liquid paraffin capsules 500mg + 10 mg vit. E/day.
Correlation coefficient between the mean percentage of the LDL subfi’actions 
and the lipid and other parameters showed that small dense LDL-III to be 
positively associated with plasma triglyceride (log transformed data) (p<0.001), 
plasma apoB concentration (p<0.05), plasma glucose level (p<0.05) and
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cholesterol/HDL ratio (p<0.01) and negatively associated with HDL cholesterol 
concentration (p<0.04) and HDLz subfraction mass (p<0.05).
Plasma triglyceride was positively related to blood glucose (r= 0.42, p<0.05), 
BMI (r= 0.46, p= 0.03) and apoB concentration (r= 0.75, p<0.0001). The 
latter was positively correlated with total cholesterol ( r -  0.52, p= 0.02), weight 
o f the patients in kg (r= 0.42, p<0.05), BMI (r= 0.47, p= 0.04) and 
cholesterol/HDL ratio ( r -  0.75, p<0.0001).
The mean blood glucose values and glycosylated haemoglobin percentages 
shown in Table 7.4, indicate that the patients of both groups exhibited a 
satisfactory diabetic control at the start o f the trial. Fructosamine level was 
used to monitor the long term control o f diabetes.
Table 7.4
Indices of diabetic control in both groups before the start of the trial.
Variable Active n-14 Placebo n=8
Glucose mmoFl 8.7 ± 1.9 8.8 ± 3.8
Total HbAl (%) 8.2 ± 1.8 8.3 ± 1.2
Fructosamine jumol/1 328.7 ± 45.0 300.1 ± 44.5
Total HbAl, the percentage o f glycosylated haemoglobin; Glucose; fasting blood 
glucose level mmol/l, Fructosamine; used to monitor the long term control of 
diabetes
7.6 Effect of EPO treatment on patients anthropometric indices, lipids and 
lipoproteins
No significant changes were observed in total, LDL and HDL cholesterol after 
treatment with 500mg EPOx 12/day for 12months, and there were no 
differences between the active treatment and placebo group of patients (Table
7.5).
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Plasma triglyceride showed a tendency to increase in the active treatment group 
(by 24%) compared to the placebo group (Table 7.5). Although this was not 
statistically significant. HDL2 and HDL3 mass was reduced at the end o f the first 
year both in the active (by 12% and 23% respectively) and placebo group (by 28% 
and 25% respectively) (Table 7.5). There were no changes in the other lipid 
parameters in either group (active and placebo) at the end o f the first yeai' (Table
7.5)
The control of blood pressure in all the patients was satisfactory through out the 
24 months o f the trial period (Table 7.6). The mean percentages of glycosylated 
haemoglobin (%HbAl), used to monitor diabetic control, at the initial visit, at 12- 
months and 24-months sample were similar and indicated reasonable control of 
diabetes (Table 7.6). However blood glucose measurement was significantly 
higher at 12 months and 24 months compared with the initial visit (p<0.05) (Table
7.6).
Table 7.6
Blood pressure, blood glucose and glycosylated haemoglobin measurements 
during the trial period.
Variable baseline 1 st year 2 nd  year
B-glucose 8.8 ± 2.6 10.9 ± 4.2* 10.8 ± 3.9*
% HbAl 8.2 ± 1.5 8.9 ± 1.7 9.2 + 1.9
BP systolic 139.2 ± 20.5 142.7 ± 20.8 144.3 ± 15.5
BP diastohc 86.5 ± 12.2 85.6 ± 12.6 86.7 ± 10.4
^p<0.05
B-glucose, blood glucose mg/dl; %HbAl, the percentage o f glycosylated haemoglobin; 
BP systolic, systolic blood pressure measured in mmHg; BP diastolic, diastolic blood 
pressure measured in mmHg.
During the second year of the trial, all patients were on active EPO treatment. At 
the end of which there were no significant changes in the plasma total cholesterol, 
LDL cholesterol, VLDL and HDL cholesterol (Table 7.7). There was a 24% 
decrease in plasma triglyceride and a 17% decrease in plasma Lp(a) but these did 
not reach statistical significance. Although, there were no changes in HDL-
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cholesterol and apoAI, a significant increase in the HDL2 and HDL3 subfiaction 
mass was observed (p<0.05 and p<0.0001 respectively) (Table 7.7), in keeping 
with findings by Fragoso & Skinner (Fragoso & Skinner 1992).
Table 7.7
Effect of EPO on lipid and lipoprotein variables in the second phase of the 
trial.




Total cholesterol mmoFl 6.1 ± 1.0 6.0 ± 1.3
LDL cholesterol mmoFl 3.9 ± 0.9 3.9 ± 0.9
VLDL cholesterol mmoFl 1.0 ± 0.6 0.9 ± 1.0
HDL cholesterol mmoFl 1.1 ± 0.3 1.1 ± 0.3
Triglyceride mmoFl 2.5 ± 1.5 1.9 ± 0.8
Chol/HDL ratio 5.5 ± 1.3 5.6 ± 2.1
HDLz mass mg/dl 29.5 ± 21.9 51.1 ± 35.2**
HDL] mass mg/dl 189.3 ± 50.8 266.3 ± 60.9*
Lp(a) mg/dl 34.8 ± 44.5 28.9 ± 35.1
ApoAI mg/dl 1.3 ± 0.2 1.2 ± 0.2
ApoB mg/ml 1.3 ± 0.3 1.3 ± 0.3
% LDL-I 16.3 ± 8.7 15.3 ± 7.7
% LDL-II 47.5 ± 11.7 49.2 ± 15.5
% LDL-III 36.2 ± 16.1 31.1 ± 16,6
* P<0.0001; ** P=0.002; Lp(a), lipoprotein (a); % LDL-I, %LDL-II and %LDL- 
III, are percentages o f  low density lipoprotein-I, II and III subfractions within 
total LDL
Compositional analysis of total LDL and the effect o f EPO during the second 
phase of the trial, i.e. when all the patients were on active EPO treatment are 
shown in Table 7.8. There were no significant variations between the two years 
samples except, in the percentage of LDL-phospholipid which was reduced 
significantly by 29% (p=0.002) (Table 7.8).
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Table 7.8
comparison between the compositional analysis of the LDL samples at the 
end of and 2"** year of the trial
Variable 1 2  months 24 months
n=22 n=22
% protein 24.9 ± 5.7 27.5 ± 2.9
% F-Chol 13.1 ± 2.6 14.5 ± 6.0
% E-Chol 33.9 ± 4.8 35.9 ± 6.7
% Triglyceride 7.4 ± 2.7 7.5 ± 2.1
% Phospholipid 20.7 ± 2.6 14.8 ± 7.8**
Protein/Choi ratio 0.8 + 0.3 0.8 + 0.2
** P=0.002; %FChol, the percentage o f free cholesterol; %E-Chol, the
percentage o f  esterified cholesterol; Protein/Chol, protein/ cholesterol ratio
7.7 Effect of EPO on LDL oxidation
The susceptibility of LDL to oxidative modification was tested by incubation (0.2 
mg apo LDL/2ml) at 37°C in the presence of copper ions following the method 
described by Cominacini et al (Cominacini et al 1991) (chapter 2, section 2.5). 
The fluorescence curve fi*om each individual patient was determined by measuring 
emission rate at 430nm (excitation at 350) at time intervals (fig 7.1) using Perkin- 
Elmer Ls-50 spectrophotofluorimeter. The excitation and emission slits were both 
maintained at 5nm. During measurement the instrument drift o f sensitivity was 
checked by measuring the fluorescence intensity of a quality control sample of 
quinine sulphate (Chapter 2, section 2.5) and the instrument was adjusted 
accordingly before reading the samples. The initial fluorescence was read at Oh 
and thereafter every hour for the first 4-hours, then at 24h (Fig 7.1 A). The 
development of fluorescence was “biphasic” and thus subdivided into an inhibitory 
and propagatory phases. The inhibitory phase fluorescence development rate (IP- 
FDR), was calculated by dividing the fluorescence development rate (FDR) 
between 0-2h by time (t), and the propagatory phase fluorescence development
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rate (PP-FDR) was calculated by dividing the FDR between 2-4h by time (Fig 
7. IB).
Figure 7.1
Fluorescence intensity curve and FDR. 
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Ti m e (h)
A, represents fluorescence curve determined by fluorescence measurement at 430 
emission, 350 excitation (F430). (h), relative fluorescence at 430 between 0-2h; (d)
relative fluorescence unit at 430 between 2-4h. B, determination of the IP-FDR and PP- 
FDR.. IP-FDR = b (F4 3 o)/a(t in h), -PP-FDR = d (F4 3o)/c(t in h).
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The mean fluorescence rate for both patient groups (active and placebo) is shown 
in Table 7.9. There were no significant differences between the fluorescence 
intensity, as measured by relative fluorescence units, at hourly intervals and at 24h 
between the active EPO treatment group and the placebo group (Table 7.9, Fig 
7.2) at the initial visit.
Table 7. 9
Relative fluorescence at different time intervals in the active EPO treatment 
and the placebo group of patients.
Patients Fluorescence (relative Fluorescence Units) *
n = 2 2 Oh Ih 2 h 3h 4h 24h
Placebo 22.6 ±4.6 22.4 ±6.8 25.0 ±6.7 30.6 ±19.5 41.0 ±18.4 70.7 ±26.8
Active 23.4 ±15.1 27.5 ±15.3 31.8 ±18.9 39.1 ±22.8 49.1 ±28.9 97.0 ±49.8
* Relative Fluorescence Units measured by measuring emission rate at 430nm 
and excitation at 350
Figure 7.2











IP-FDR (F430/t), inhibition period fluorescence development rate, PP-FDR 
(F430/t), propagation period fluorescence development rate. 0 - 0  , active;
, placebo.
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Treatment with EPO enhanced the rate o f oxidation significantly in the active 
treatment group by 40-50% (p<0.001) (Fig 7.3). Patients who were on placebo 
treatment showed a significant increase in the IP-FDR (P<0.01) and PP-FDR 
(p<0.001) during the second phase of the trial i.e. after treatment with EPO (Table 
7.10, Fig 7.4).
Table 7.10
Fluorescence development rate in both groups of patients after active EPO 
treatment.
FDR Patients
Placebo Treatment Active —> Active
n=8 n=I4
IP-FDR 13.7 ±6.2  28.5 ±15.4** 20.1 ± 16 33.2 ±20.1*
PP-FDR 28.7 ± 13.2 58.5 ±9.7* 27.7 ±7 .6  55.8 ±21.4*
*p<0.001; **p<0.01; IP-FDR; PP-FDR,DP-FDR, Inhibitory phase; propagatory 
phase and degradation phase fluorescence development rate respectively 
measured in relative fluorescent units at 430/hr (Rel. F43o/hr).
Figure 7.3
Mean fluorescence rate for the active group after treatment with EPO at the 
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IP-FDR, inhibition period fluorescence development rate, PP-FDR, propagation 
period fluorescence development rat^. #  Before and S  after EPO 
supplementation P<0.001 and p<0.01 fo r  IP-FDR and PP-FDR respectively.
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Figure 7.4
Mean fluorescence rate for the placebo group after treatment with EPO at 
the end of the trial (24months).
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IP-FDR, inhibition period fluorescence development rate, PP-FDR, propagation 
period fluorescence development rate. 0  before and  #  after treatment with
EPO.
During the second year of the trial all the patients were on active EPO treatment. 
The mean rate of oxidation (± standard deviation ) at hourly measurements and 
FDR for all the patients at the end of the first and second year o f the trial are 
shown in Table 7.11. There was a significant increase in both the fluorescence 
intensity, as measured by relative fluorescence units and FDR (IP-FDR and PP- 
FDR), in the second year compared to the first year samples (Table 7.11, Fig 7.5).
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Table 7.11
Patients mean fluorescence emission rate and fluorescence development rate 
during phase II of the trial.
12 months 24 months
Oh 23.1 ± 12.0 24.7 ± 3.2
Ih 25.6 ± 12.8 33.9 ± 13.0***
2h 29.2 ± 15.5 40.4 ± 9.2**
3h 38.5 ± 21.1 57.9 ± 11.2**
4h 46.0 ± 25.2 77.0 ± 18.6*
24h 87.0 ± 43.7 118.6 ± 15.3**
FDR 0-2 17.7 ± 13.3 28.0 ± 9.7**
FDR 2-4 31.4 ± 18.2 56.8 ± 17.8*
*P<0.0001, **P<0.01, ***P<0.05
Figure 7.5
Effect of EPO supplementation on IP-FDR and PP-FDR in all the patients at 
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IP-FDR, inhibition period fluorescence development rate, PP-FDR, propagation 
period fluorescence development ratç. # , Baseline and #  , after EPO 
supplementation fo r  24 months in all the patients. P<O.OJ and p<0.001 fo r  IP- 
FDR and PP-FDR respectively.
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7. 8 Determinants of LDL oxidation
IP-FDR (0-2h), was negatively correlated with the percentage of LDL-I (NS) 
within total LDL and positively correlated with apolipoprotein B concentration in 
plasma (p= 0.03) and the percentage of glycosylated haemoglobin (%HbAl, 
?<0.05) (Table 7.12). PP-FDR (2-4h) was positively correlated with the 
percentage of small dense LDL-III within total LDL (p<0.05), plasma triglyceride 
level (p<0.05), apoB concentration in plasma (p - 0.02), blood glucose level and 
%HbAl measurement in plasma (Table 7.12). However, the correlation between 
PP-FDR and blood glucose level and glycosylated haemoglobin (%HbAl) did not 
reach statistical significance. There were no significant correlation with HDL and 
LDL cholesterol levels (Table 7.12).
Table 7.12
Correlation between inhibition and propagation fluorescence development 
rates and lipid and lipoprotein variables
Variable IP-FDR PP-FDR
Total-C mmol/l 0.16 0.33
VLDL-C mmoFl 0.07 0.31
LDL-C mmoFl 0.1 0.17
HDL-C mmoFl 0.15 0.07
Triglyceride mmoFl 0.11 0.43»*
Apo B mg/ml 0.46* 0.50*
Glucose mg/dl 0.22 0.33
%HbAl 0.40*» 0.35
% LDL-I -0.26 - 0.50*
% LDL-II -0.08 -0.19
% LDL-III 0.19 0.40**
^p=0.02, Total-C, plasma total cholesterol; VLDL-C, LDL-C and
HDL-C, plasma very low density, low density and high density lipoprotein 
cholesterol level respectively; ApoB, plasma apolipoprotein B-100 concentration; 
%HbAl, the percentage o f  glycosylated haemoglobin in plasma; % LDL-I, 
%LDL-II and %LDL-III, are percentages o f  low density lipoprotein~I, I I  and III 
subfractions within total LDL
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The relationship between IP-FDR (0-2h) and PP-FDR (2-4h) and compositional 
analysis of total LDL, after treatment with EPO, is shown in table 7.13. IP-FDR 
showed a positive correlation with the percentage of LDL-esterified cholesterol 
and the PP-FDR was correlated positively with the percentage of LDL- triglyceride 
and LDL-phospholipid and negatively with the percentage o f LDL-protein and 
esterified cholesterol (Table 7.13). There was no correlation between the extent of 
oxidation and the other compositional parameters in LDL.
Table 7.13
Correlation between the compositional analysis of total LDL and IP-FDR and 
PP-FDR at the end of the second year
Variable IP-FDR PP-FDR
% Protein -0 .07 -0.35
% FC -0.16 0.02
% EC 0.30 -0.22
% TG -0.19 0.35
% PL -0.07 0.22
P/C ratio -0.11 -0.08
% FC, percentage o f  LDL free cholesterol; % EC, percentage o f  LDL esterified 
cholesterol; % TG, percentage o f  LDL triglyceride; % PL; percentage o f  LDL 
phospholipid; P/C ratio, protein/ cholesterol ratio
1 .9  Discussion
The need to lower plasma lipid levels in management of CHD is well documented. 
In general, dietary recommendations have been designed to decrease total dietary 
fat intake and to replace dietary saturated fats with polyunsaturated fats (National 
cholesterol education program 1988; 1994). The identification of triglyceride as 
the major underlying determinant of an ALP, suggest that this lipid should be a 
target for dietary fatty acid modifications as a means o f correcting lipoprotein 
abnormalities seen in an ALP, The triglyceride lowering effect of n-3 PUFA have
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been given little attention because o f its mininial effect on HDL and their 
potentially adverse effect on raising LDL cholesterol and enhancing LDL oxidation 
(Suzukawa et al 1995). The latter has been shown to occur also with dietary 
supplements enriched with linoleic acid (Reaven et al 1993b). However, the 
replacements of saturates with LA (n-6, PUFA) has been shown in most studies to 
reverse nearly all the effects of saturated fatty acids on lipids and lipoproteins. In 
the present study we have examined the effect of EPO on lipids, lipoproteins and 
LDL subfraction profile and LDL oxidative modification in NIDDM patients.
In contrast, to the findings o f other investigators (Ishikawa et al 1989, Chaintruil et 
al 1984), our study showed that EPO had no effect on plasma total LDL and HDL 
cholesterol and apolipoprotein B concentration. This could be due to two factors, 
firstly, most of the studies performed were either on animals or non-diabetic 
patients. The lipid lowering effects o f LA might be through its conversion to its 
metabolites by sequential desaturation and elongation steps. This is supported by 
several studies performed both in animals and human which have reported GLA 
and AA to be more potent, as lipid-lowering agent, compared to LA (Chaintruil et 
al 1984). The first step o f conversion of LA to GLA, regulated by the enzyme 
delta-6-desaturase, is defective in diabetic patients and experimental animals (Jones 
et al 1986, Mercuri et al 1966). Therefore diabetic patients might be more resistant 
to the lipid-lowering effect o f LA than normal subjects. Secondly, EPO 
supplementation containing 500mg GLA, the dosage which was used in this study, 
has been shown to have no significant change in lipid parameters compared to 2g 
GLA/day (Chaintruil et al 1984). In this case our finding is in keeping with the 
results observed by Chaintreuil et al. In addition, the patients examined in our 
study were not hospitalised and were not monitored for their dietary intake, as it 
was done by other groups (Reaven et al 1993b, Chaintruil et al 1984) during the i
trial period. Therefore, the increase in triglyceride observed in the first year is i
more likely to be due to inappropriate or lipid raising dietary habits, than the effect 
o f EPO. However, plasma triglyceride showed a tendency to decrease after EPO 
supplementation for the second year. This might be due to the longer term effect i
of EPO rather than the dosage, as SOOmg EPO supplementation has been shown to 
have no acute effects (Chaintruil et al 1984). This could also account for the 
significant increase in the HDL2 and HDL3 subfractions at the end of the second i
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year of the trial, i.e. when all the patients were on active EPO treatment, compared 
to the first year. This suggestion supported by the findings o f Fragoso & Skinner 
though they used a higher concentration of GLA (70%) in the dietary 
supplementations o f their experimental animals (Fragoso & Skinner 1992). With 
regards to the effects of EPO on LDL subtraction profile, the absence o f any 
change in the LDL subfi'actions would mainly reflect a lack o f influence of EPO on 
plasma triglyceride, which has been shown to be a major determinant of the LDL 
sufraction profile (Griffin et al 1994). These findings indicate that EPO 
supplementation at 500mg/day has no significant effect on the modification o f ALP 
Therefore, a higher concentration o f GLA in EPO preparations is needed to exert 
beneficial effect in terms o f lipid lowering especially in diabetics.
The increased in-vitro copper catalysed LDL oxidation after EPO supplementation 
observed in this study is in keeping with the findings by other investigators (Reaven 
et al 1993b, de Graaf et al 1991). The likely explanation o f this is the absence o f a 
significant modification of the components of ALP, discussed above, by EPO 
supplementation and the persistence predominance of small dense LDL in these 
patients. In addition, inhibition o f the 6-desaturation o f LA, in diabetics and 
hyperlipidémie patients, might be responsible for its accumulation in LDL 
rendering it more susceptible to oxidation, as was reported by Reaven et al 
(Reaven et al 1993b). Unfortunately we did not measure the LDL fatty acid 
composition after EPO supplementation. Furthermore, these patients have low 
plasma HDL cholesterol level which has been reported to confer a low antioxidant 
activity (MacNess et al 1991).
The positive association between the extent of LDL oxidation, as measured by the 
rate o f fluorescent development (FDR), and the percentage of small dense LDL 
found in our study, is in agreement with the increased susceptibility of small dense 
LDL to oxidative modification observed by others (DeGraaf 1991, Tribble et al 
1992). Reaven et al, has suggested that increased susceptibility of small dense 
LDL to oxidation was linked to the preferential enrichment of this subfi'action with 
linoleic acid (Reaven et al 1993b). This has supported earlier work by DeGraaf, 
which attributed the increased susceptibility of small dense LDL was partly due to 
higher ratios of arachidonic acid (AA), a metabolite o f linoleic acid, to vitamin E 
(an antioxidant) levels (DeGraaf 1991). Our observation of the positive
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correlation between plasma triglyceride and LDL oxidation supports the findings 
by Hiramatsu and Arimori that monocytes hom  diabetic patients with 
hypertriglyceridemia exhibited increased superoxide production and that this 
response was determined to a greater extent by hypertriglycridemia than by the 
presence o f diabetes (Hiramatsu & Arimori 1988). This is in keeping with the role 
of triglyceride as the major determinant o f ALP and further provides evidence of 
the positive association between ALP and CHD. On the other hand, we have 
found a positive correlation between the PP-FDR and blood glucose level. The 
latter was higher at the end of the second year compared to the initial visit. This 
might be yet another suggestion as to why these NTDDM patients exhibit an 
increase in LDL oxidation.
We conclude that EPO supplementation at 500mg /day does not affect lipid and 
lipoprotein concentration in plasma. It does increase LDL oxidation as has bpen 
reported previously possibly due to enrichment of LDL with LA. The increase in 





Modern models o f atherogenesis place apoB containing lipoproteins in an 
etiological role. Despite the progress that has been made in elucidating the 
underlying mechanism of atherogenesis no single cogent hypothesis has been 
described that accounts for all clinical, epidemiologic and laboratory 
observations. However, two well documented mechanisms, APG-Lipoprotein 
interaction and lipoprotein oxidative modification, are beheved to have a central 
role in the initiation and advancement of the disease process. The role o f the 
two mechanisms in lesion development suppose to be dependant upon rate and 
nature of apoB containing lipoproteins generated through delipidation of 
secreted VLDL from liver. This is modulated through genetic and 
environmental factors as a result o f which heterogeneous particles different in 
structure and function are produced within each lipoprotein class. Factors 
determining the make-up of these particles have important implications for their 
potential atherogenicity which we have addressed throughout this work.
8.2 Determinants of APG-LDL interaction
Several theories have been described to explain the atherogenic process. A 
schematic representation of the atherosclerotic lesion development on the basis 
o f current knowledge and concepts is illustrated in Fig 8.1.
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APG- Lipoprotein interactions under near to physiological ionic concentration 
and temperature were investigated to simulate the in-vivo process (Chapter 4). 
Attention was focused on the binding o f a chondroitin sulphate rich 
proteoglycan fraction isolated from human aorta, since it binds most avidly to 
LDL.
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F ig u re  8.1
Schematic diagram illustrating mechanisms and theories related to 
atherosclerotic lesion development. Increased concentration o f  lipids and 
lipoproteins confer a 1) "Cholesterol Load" on the vascular endothelial 
surface leading to: endothelial dysfunction together with the (2) "Response to 
Injury” hypothesis increases endothelial permeability leading to the influx o f  
lipoproteins into the arterial wall (3) "Lipid Infiltration theory”, within the 
arterial wall as a (4)"Response to Retention hypothesis the lipoproteins are 
trapped by extracellular matrix components particularly APG, this is charge 
related and dependant on the conformation o f  the lipoprotein particle, a 
consequence o f  which is (5) lipoprotein "oxidative modification”, which is 
enhanced in small dense LDL, subsequently these modified lipoproteins are 
taken up by macrophages leading to lipid accumulation and deposition 
characteristic o f  atherosclerotic lesions
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An important observation in the present study was the positive association 
between the extent of APG-LDL reactivity and the percentage of small dense 
LDL-III subfraction within total LDL supporting the suggestion provided by 
Camejo et al (Camejo et al 1993a) that CS-PG interaction favours small, dense 
LDL. An even greater reactivity was associated with the concentration of 
small dense LDL above lOOmg/dl (Fig 3.21). Furthermore, plasma TG was 
positively associated and HDL cholesterol was inversely related to the extent of 
APG- Lipoprotein interaction. When we examined the direct reactivity of 
different apoB containing lipoprotein subtraction including small dense LDL, a 
pattern of reactivity which was similar in each individual was observed with 
IDL2 and LDLA Sf 8-16 being the most reactive species (Fig 4.5). However, 
the magnitude of this pattern was highest in subjects with a predominance of 
small dense LDL. Since VLDL represents the major precursor of LDL, this 
provides evidence that a predominance of small dense LDL in circulation is 
associated with the presence of potentially more atherogenic apoB containing 
lipoproteins, such as IDL, which are produced during the delipidation cascade 
of VLDL to LDL. The effect of triglyceride on the modulation of LDL 
subtraction has been shown to be mediated through large TG-rich VLDLl 
particles. These particles are suggested to be a major determinant of 
remodelling of LDL to smaller dense particles (Patsch et al 1984, Tan et al 
1995) by mechanisms that involve the donation of TG in exchange for CE in 
the process of neutral lipid exchange. This results in the production of IDL and 
VLDL remnant particles with a prolonged residence time in plasma which 
promote their infiltration to the arterial wall and subsequent entrapment by 
APG. In addition, they undergo further delipidation by the action of hepatic 
lipase enzyme resulting in the production of small LDL.
The different APG-LDL reactivity between male and female could be 
attributed to the difference in lipid and lipoprotein levels in those two sex 
groups. The high reactivity of IDL from male subjects towards APG compared 
to female subjects is due to the high level of small dense LDL-III which is 
more prevalent in male patients as well as their lower HDL cholesterol level. 
This could partly explain the high incidence of CHD rates in men compared to 
women below the age of 60years.
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8.2.1 Carbohydrate on LDL
The LDL-I subfraction contained more neutral carbohydrate compared to small 
dense LDL-III (Table 5.2). This was also observed by subfractionation of LDL 
by affinity chromatography on Con-A (Table 5.5) which we attributed to the 
liigh mannose structure of LDL-I compared to LDL-III. The lack o f any 
association between the extent of APG-LDL interaction and the lipoproteins 
neutral carbohydrate and sialic acid concentration indicate that the “anti 
atherogenic” effects, if any, o f these carbohydrate residues are not related to 
their reactivity towards APG. This is supported by the sialic acid lowering 
effect o f ciprofrbrate on the lipoprotein which also reduced its ability to interact 
with APG as opposed to increasing it. It is worth noting, that neither neutral 
carbohydrate nor sialic acid content o f the lipoprotein were related to the 
plasma lipid levels which suggest that the carbohydrate content of the 
lipoprotein is a fimction of particle size rather than abnormalities in lipoprotein 
metabolism.
8.2.2 Lipid lowering treatment
The rate and nature o f LDL generated from VLDL can be perturbed 
pharmacologically, as we have shown by lipid lowering treatment with 
ciprofrbrate. The reduction o f plasma triglyceride in the form of VLDLl after 8 
weeks treatment was possibly due to decreased hepatic secretion (Gaw & 
Shepherd 1991). This was reflected in the change in the LDL subfraction 
profile from small dense LDL to a more buoyant LDL-I profile. We imphcated 
this in the reduced reactivity o f aU apoB containing lipoproteins towards apoB 
which feU in concert after treatment (Fig 4.7). This is another favourable effect 
o f treatment with ciprofrbrate. It is worth noting that ciprofrbrate treatment was 
more effective in reducing the number of APG-reactive circulating apoB 
particles in the LDL species compared to IDL (Fig 4.8).
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8.3 Mechanisms related to APG-Lipoprotein interaction
The mechanism o f APG-Lipoprotein reactivity is complex. Several factors are 
implicated in mediating this interaction process. Like receptor mediated uptake 
o f LDL particles the mechanism is charge related involving lysine and arginine 
residues on apoB which is indicated by the reduced reactivity of charge 
modified LDL towards APG. However, we believe that APG-Lipoprotein 
interaction is different fi*om receptor mediated pathways. This can be explained 
by the significant effect of apoE2 and apoE3 (which act as a ligand for receptor 
mediated uptake) on reducing the reactivity o f LDL towards APG rather than 
increasing it. This could be either due to the effect o f apoE in inducing 
conformational changes on apoB since no charge modification was observed as 
tested by gel electrophoresis, or that the apoE is competing with the lipoprotein 
for proteoglycan binding sites. The latter possibility is a little remote since no 
insoluble complexes were formed between APG and apoE (Table 6.2). In 
addition apoCIII did not have any effect on the binding process.
The controversy over the effect o f sialic acid on APG-Lipoprotein interaction 
was resolved in this work. Although the interaction is a function of charge, the 
net charge o f the lipoprotein particle, particularly through the effect o f sialic 
acid has little contribution in controlling the APG-lipoprotein interaction. 
Despite the higher reactivity of neuraminidase treated LDL towards APG, the 
sialic acid concentration o f the apoB containing lipoproteins was not associated 
with the extent o f APG-Lipoprotein complex formation. In addition, incubation 
with GM3 gangliosides had little effect in reducing the ability o f the lipoprotein 
towards APG. Our data suggest that conformation is pivotal in determining the 
interaction process by exposing positively charged fiee amino groups on critical 
domains on apoB particle to mediate the interaction process. This is supported 
by several findings. First, modification of apoB by reductive méthylation which 
affects the protein structure was effective in blocking the interaction process. 
Second, we believe that the blocking effect of apoE is more conformation 
related (mentioned above). Finally, we implicate conformational changes
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induced by TG enrichment of the precipitated fraction in the denser lipoprotein 
species for their reactivity towards APG.
8.4 LDL oxidative modification
The second main aim of this work was to illustrate the effect of EPO (n-6 
PUFA) on LDL subfraction profile and in relation to its oxidative modification 
in a group of NIDDM patients. An ALP was the characteristic feature in these 
patients as it has been shown before (Reaven et al 1993a). In keeping with the 
finding by other investigators (Reaven et al 1993b), we found an increased in- 
vitro copper catalysed LDL oxidation on EPO supplementation. We attribute 
this to a predominance o f small dense LDL within the total LDL of these 
patients (Table 7.3) which was positively correlated with PP-FDR. In addition 
increased LDL oxidative modification might be due to enrichment o f small 
dense LDL with linoleic acid as reported by others (Reaven et al 1993b) and 
low HDL level found m NIDDM with low antioxidant activity. Our observation 
on the positive correlation between plasma triglyceride and LDL oxidation is in 
keeping with the most recent report on the link between ALP and enhanced 
LDL oxidation (Tribble 1995).
The lack of any effect o f EPO supplementation on modifying lipid abnormalities 
iu these patients is mainly due to the lower dose which we have used m the 
study.
8.5 ALP and atherosclerotic lesion formation
A most contentious issue which we addressed in this work is the dyslipidémie 
syndrome of an ALP because o f its strong association with CHD and its 
importance in modulating apoB containing lipoproteins particularly that of LDL 
subfraction profile discussed above. It is evident now that an ALP confer 
changes on apoB containing lipoproteins rendering them more atherogenic. 
Therefore it is reasonable to summarise the role of an ALP in lesion 
development through APG-Lipoprotein interaction and its link to oxidative 
modification in the schematic diagram below.
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Natts lane Billingshurst, West Sussex RH14 9EY, UK. 
Denley orbital mixer.
Dynatech Laboratories Ltd
Daux Road, Billingshurst, West Sussex R H l4 95J, UK,. 
mr5000 microtitre plate reader
Jenway UK
Jenway, Dunmow, Essex, England CM6 3LD. 
Jenway 3020 pH meter
Appendix 
Suppliers of Reagents, Equipment and Software.
Aldrich Chemical Company
A division o f  the Sigma-Aldrich Company Ltd
The Old Birickyard, New Road, Gillingham, Dorset, SP8 4XT, England 
D-Mannose
Amersham International pic
Amersham Place, Little Chalfont, Amersham, Bucks. HP7 9NA, UK. 
Na['"'l]
Beckman Instruments, Spinco Division
Beckman Instruments (UK) Ltd Analytical Sales and Service Operation 
Progress Road, Sands Industrial Estate, High Wycombe, Bucks. HP 12 4JL, UK.
L8-60M ultracentrifiige L8-70 ultracentrifiige
Prep UV Scanner AnF rotor J
SW 40 rotor Ti 60 rotor
Ultra-Clear™ centrifiige tubes Ti 50.4 rotor
Polycarbonate centrifuge bottles and caps Spinkote
Silicone vacuum grease Tube slicer
Bio-Rad Laboratories Ltd
Bio-Rad House, Mary lands Avenue, Hemel Hempstead, Herts. HP27TD,UK.




1 Microsoft Way, Redmond, WA, USA.
MS Word Version 4.0
M S E
Fisons Instruments, Sussex Manor Park, GatwickRd, Crawley, Sussex, RHI0 2QQ, UK. 
Mistral 4L refrigerated centrifuge.
Paar Scientific Ltd
594 Kington Road, Raynes Park, London SW20 8DN, UK 
Digital densitometer DMA 35
Perkin Elmer Ltd.
Maxwell Rd., Beaconsfield, Buckinghamshire, HP9 IQA. 
Perkin Elmer LS ~ 50 Fluorimeter.
Pharmacia
Pharmacia Ltd, Pharmacia LKB Biotechnology Division, Midsummer Boulevard Central, 
Milton Keynes, Bucks. MK9 3HP, UK 
Sephadex G-25(PD10 columns)
Sanofi “ Winthrop
Onslow St, Guilford, Surrey, GUI 4YS, UK 
Ciprofibrate
Scotia Pharmaceuticals Ltd
Scotia House, Castle Business Park, Stirling, FK9 4TZ, Scotland 
Efamol (Evening Erimrose 0Ü, EPO)
Sigma
Sigma Chemical Co. Ltd, Fancy Road, Poole, Dorset B H I7 7TG, UK
Iodine monochloride (ICI) Dithiothreitol (DTT)
T rishydroxymethyIaminomethane(TRl S) T etramethylurea(TMU)
Spectrapor
Orme Technology, PO Box 3, Stakehill Industrial Park, Middleton, Manchester, M24 
2RH,UK
Dialysis tubing
Technicon ( Ireland) Ltd.
Swords Co. Dublin, Eire.
12 channel Peristaltic pump
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Glossary
a -D G ....................................................................... a - D-methyl glucopyranoside
a-D M ....................................................................... a-D-methyl mannopyranoside
A LP   atherogenic lipoprotein phenotype




BSA bovine serum albumin
C H D .......................................................................................coronary heart disease
C H O ..........................................................................................neutral carbohydrate
CM........................................................................................................... chylomicron
Con-A ................................................................................................ concanavalin-A
CS-PG chondroitin sulphate proteoglycan
C V  coefficient of variation
d .........................................................................................................................density
D a ......................................................................................................................Dalton
EDTA .............................................................ethylene diamine tetra-acetie acetate
E P O ........................................................................................... evening primrose oil
F D R ........................................................................ fluorescence development rate
FH............................................................................. familial hypercholesterolaemia
Gdn-HCL guanidine hydrochloride
GLA......................................................................................   gamma linolenic aeid
HDL  ........................................................................ high density lipoprotein
H L  hepatic lipase
HMG C oA  hydroxy methyl glutaryl coenzyme A
ID E......................................................................... intermediate density lipoprotein
IP-FDR....................................... inhibition period fluorescence development rate
1RS.................................................................................insulin resistance syndrome
L A ........................................................................................................... linoleic acid
LD L low density lipoprotein
Lp(a)......................    lipoprotein (a)
LPL.................................................................................................. lipoprotein lipase
N ID D M ...................................................................non insulin dependent diabetes
PBS phosphate buffered saline
PP-FDR................................. propagation period fluorescence development rate
QS......................................................................................................quinine sulphate
SD.................................................................................................. standard deviation
SD S.................................................................................... sodium dodecyl sulphate
TC total cholesterol
T G ........................................................................................................... triglyceride
VLD L very low density lipoprotein
GLASGOW ^^jVERSHt
